

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**SCHEDULE 14A**

**PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

---

Filed by the Registrant       Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

**BIOGEN INC.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
  - Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
    - 1) Title of each class of securities to which transaction applies: \_\_\_\_\_
    - 2) Aggregate number of securities to which transaction applies: \_\_\_\_\_
    - 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): \_\_\_\_\_
    - 4) Proposed maximum aggregate value of transaction: \_\_\_\_\_
    - 5) Total fee paid: \_\_\_\_\_
  - Fee paid previously with preliminary materials.
  - Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    - 1) Amount Previously Paid: \_\_\_\_\_
    - 2) Form, Schedule or Registration Statement No.: \_\_\_\_\_
    - 3) Filing Party: \_\_\_\_\_
    - 4) Date Filed: \_\_\_\_\_
- 
-



————— NOTICE OF —————  
2021 Annual Meeting of  
Stockholders and Proxy Statement

***Wednesday, June 2, 2021***

***9:00 a.m. Eastern Time***

**To be held online at**

**[www.virtualshareholdermeeting.com/BIIB2021](http://www.virtualshareholdermeeting.com/BIIB2021)**

PRELIMINARY PROXY STATEMENT—SUBJECT TO COMPLETION  
DATED APRIL 9, 2021



## Letter from our Chairman

April , 2021

### *To My Fellow Stockholders:*

On behalf of the Board of Directors, I want to thank you for your investment in Biogen and for the confidence you place in this Board to oversee your interests in our company. For more than 40 years, Biogen has played a key role in advancing the field of biotechnology as we work to address some of the most complex diseases. Today, as we continue to face the challenges posed by the global COVID-19 pandemic, the importance of developing and assuring access to therapies for patients in need is more evident than ever.

As I reflect on 2020 and consider the challenges we faced, both as a society and in our business, I am reminded of the importance of our mission – we are pioneers in neuroscience. We care deeply about making a difference, and we are passionate about our commitment to patients, our employees, the environment, the communities where we live and work and you, our stockholders. Our employees work every day knowing that thousands of people worldwide count on Biogen and our therapies to make a meaningful difference in their lives. But we don't stop there. We work to have an impact beyond our medicines as we strive to improve patient health outcomes, address social and environmental challenges, cultivate a workplace that enables our employees to thrive, support local communities and inspire future generations of scientists. I am thankful for the drive and dedication of our employees and how they rose to meet the challenges of 2020.

In response to the COVID-19 pandemic, the Biogen Foundation donated \$12.0 million to support COVID-19 relief efforts, assisting 82 organizations across 35 countries. The donations were focused on expanding testing options, easing the strain on medical systems and supporting access to necessities like food.

We are committed to Diversity, Equity and Inclusion (DE&I) across all aspects of our organization – from hiring, promotion and development practices, to clinical research and trials, to patient advocacy that helps us better serve our African American, Black, Latinx and other minority communities. We believe that having a diverse, equitable and inclusive workplace allows us to empower our global workforce, foster innovation and achieve better business results. In 2020 we enhanced our DE&I strategy and outlined actionable steps to deepen our commitment and build upon our strong foundation. This plan includes a four-part initiative to build our talent and leadership pipeline, improve health outcomes for the African American, Black, Latinx and other minority communities in the disease areas we treat and expand sourcing with minority-owned businesses.

We have a longstanding commitment to addressing key environmental and sustainability impacts and we aspire to be a catalyst for positive change. In September 2020 we launched Healthy Climate, Healthy Lives™, a \$250.0 million, 20-year initiative to eliminate fossil fuels across our operations and collaborate with renowned institutions with the aim to improve health, especially for the world's most vulnerable populations. We are the first *Fortune 500* company to commit to become fossil fuel free across our operations by 2040.

Our Board takes its role in protecting the interest of our fellow stockholders and overseeing our long-term business strategy very seriously. We believe that good corporate governance and high ethical standards are key to our success. We are accountable to you, our stockholders, and remain committed to investing time with you to

## [Table of Contents](#)

increase transparency and better understand your perspectives. During 2020 independent members of our Board met with several stockholders to discuss a variety of topics, including business strategy, capital allocation, corporate governance, executive compensation and our environmental, social and governance initiatives. We look forward to continuing these dialogues in 2021 and beyond.

Our Board believes ensuring diverse perspectives, including a mix of skills, experience and backgrounds, is key to representing the interests of stockholders effectively. This year we have nominated two new candidates to stand for election as directors at our 2021 annual meeting of stockholders.

We had a productive and successful 2020 despite the challenges we faced – including the entry of multiple TECFIDERA generic entrants in the U.S. market, in addition to the challenges we faced relating to the COVID-19 pandemic. As I write to you, we have submitted regulatory filings for aducanumab, the investigational treatment for early Alzheimer's disease we are developing in collaboration with Eisai Co., Ltd., in the U.S., the European Union (E.U.) and Japan and we are ready to launch aducanumab in the U.S. If approved, aducanumab would become the first therapy to meaningfully change the course of Alzheimer's disease.

We are proud of all of our other accomplishments in 2020, including:

- Generating revenue of \$13.4 billion for the year while maintaining leadership in our core businesses in multiple sclerosis (MS) and spinal muscular atrophy.
- Submission of regulatory filings for:
  - SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, in the U.S. and the E.U., which we are developing in collaboration with Samsung Bioepis Co., Ltd.; and
  - VUMERITY (diroximel fumarate; DRF) in the E.U.
- The addition or advancement of 12 clinical programs to our pipeline, in areas such as MS, amyotrophic lateral sclerosis, Parkinson's disease and other movement disorders, depression and biosimilars.
- The European Commission's approval of a new intramuscular injection route of administration for PLEGRIDY (peginterferon beta-1a) for the treatment of relapsing-remitting MS.
- Our collaborations with:
  - Sangamo Therapeutics, Inc. to develop and commercialize gene regulation therapies for the potential treatment of Alzheimer's, Parkinson's, neuromuscular and other neurological diseases;
  - Denali Therapeutics Inc. to co-develop and co-commercialize therapies for the potential treatment of Parkinson's disease and neurodegenerative diseases; and
  - Sage Therapeutics, Inc. to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.
- The approximately €2.4 billion of healthcare savings in Europe that we estimate was contributed by our three anti-tumor necrosis factor biosimilars.
- Being named the number one biotechnology company on the Dow Jones Sustainability World Index for the fifth time and being recognized as a corporate sustainability leader with the Gold Class Sustainability Award from RobecoSAM.
- Our use of green chemistry processes and techniques to reduce our waste and energy consumption.
- Our perfect score of 100% on the Human Rights Campaign's Corporate Equality Index (a national benchmarking tool on corporate policies and practices pertinent to LGBTQ employees) for the seventh consecutive year and our perfect score of 100% on the Disability Equality Index for the third consecutive year.
- The engagement of more than 57,000 students in hands-on learning to inspire their passion for science since the inception of Biogen's Community Labs in 2002 with priority focus on underrepresented students.

---

[Table of Contents](#)

On behalf of the Board, I am pleased to invite you to attend our 2021 annual meeting of stockholders, which will be held on Wednesday, June 2, 2021, beginning at 9:00 a.m. Eastern Time. Due to the ongoing COVID-19 pandemic and to support the health and well-being of our employees and stockholders, this year's annual meeting will be held in a virtual meeting format only. You may attend the meeting virtually via the Internet at [www.virtualshareholdermeeting.com/BIIB2021](http://www.virtualshareholdermeeting.com/BIIB2021), where you will be able to view the meeting, vote online and submit questions. You will need the 16-digit control number included on your Notice of Internet Availability of Proxy Materials or your proxy card or voting instruction form to attend the annual meeting virtually via the Internet. We plan to evaluate the format of future annual meetings following this public health crisis.

The following notice of our annual meeting of stockholders contains details of the business to be conducted at the meeting. Only stockholders of record at the close of business on April 9, 2021, will be entitled to notice of, and to vote at, the annual meeting.

It is an honor to serve as your Chairman and, on behalf of the Board of Directors, I thank you for your continued support and investment in Biogen.

**Very truly yours,**



STELIOS PAPADOPOULOS, Ph.D.

*Chairman of the Board*

On behalf of the Board of Directors of Biogen Inc.

PRELIMINARY PROXY STATEMENT—SUBJECT TO COMPLETION  
DATED APRIL 9, 2021



## Notice of 2021 Annual Meeting of Stockholders

- Date:** Wednesday, June 2, 2021
- Time:** 9:00 a.m. Eastern Time
- Place:** Online only at [www.virtualshareholdermeeting.com/BIB2021](http://www.virtualshareholdermeeting.com/BIB2021)
- Record Date:** April 9, 2021. Only Biogen stockholders of record at the close of business on the record date are entitled to receive notice of, and vote at, the annual meeting.
- Items of Business:**
1. To elect the 13 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2022 annual meeting of stockholders and their successors are duly elected and qualified.
  2. To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
  3. To hold an advisory vote on executive compensation.
  4. To approve an amendment to Biogen's Amended and Restated Certificate of Incorporation, as amended, to add a federal forum selection provision.
  5. To act on a stockholder proposal, if properly presented at the meeting, requesting that Biogen prepare a report on Biogen's lobbying activities.
  6. To act on a stockholder proposal, if properly presented at the meeting, requesting that Biogen prepare a report on Biogen's gender pay gap.
  7. To transact such other business as may be properly brought before the annual meeting and any adjournments or postponements.
- Virtual Meeting:** To participate in the annual meeting virtually via the Internet, please visit [www.virtualshareholdermeeting.com/BIB2021](http://www.virtualshareholdermeeting.com/BIB2021). You will need the 16-digit control number included on your Notice of Internet Availability of Proxy Materials or your proxy card or voting instruction form that accompanied your proxy materials. Stockholders will be able to vote and submit questions during the annual meeting.
- You will not be able to attend the annual meeting in person.**
- Voting:** **Your vote is extremely important regardless of the number of shares you own. Whether or not you expect to attend the annual meeting online, we urge you to vote as promptly as possible by telephone or Internet or by signing, dating and returning a printed proxy card or voting instruction form, as applicable. If you attend the annual meeting online, you may vote your shares during the annual meeting virtually via the Internet even if you previously voted your proxy. Please vote as soon as possible to ensure that your shares will be represented and counted at the annual meeting.**

**Important Notice Regarding the Availability of Proxy Materials for Annual Meeting of Stockholders  
To Be Held on June 2, 2021:**

The Notice of 2021 Annual Meeting of Stockholders, Proxy Statement and 2020 Annual Report on Form 10-K are available at the following website: [www.proxyvote.com](http://www.proxyvote.com).

By Order of Our Board of Directors,

A handwritten signature in black ink that reads "Susan H. Alexander".

SUSAN H. ALEXANDER,  
Secretary

225 Binney Street  
Cambridge, Massachusetts 02142  
April , 2021

**This Notice and Proxy Statement are first being sent to stockholders on or about April , 2021.  
Our 2020 Annual Report on Form 10-K is being sent with this Notice and Proxy Statement.**

# Proxy Statement Table of Contents

<a href="#">Proxy Statement Summary</a>		iv
1	<a href="#">General Information About the Meeting</a>	1
2	<a href="#">Corporate Governance at Biogen</a>	<a href="#">Corporate Governance Practices</a> 7 <a href="#">Director Independence</a> 7 <a href="#">Nominating Processes</a> 8 <a href="#">Annual Elections and Majority Voting</a> 9 <a href="#">Director Qualifications, Standards and Diversity</a> 9
3	<a href="#">Board of Directors</a>	<a href="#">Proposal 1 – Election of Directors</a> 11 <a href="#">Committees and Meetings</a> 19 <a href="#">Director Compensation</a> 20 <a href="#">2020 Changes to Director Compensation</a> 20 <a href="#">Retainers and Expenses</a> 20 <a href="#">Equity Awards</a> 21 <a href="#">10b5-1 Trading Plans</a> 21 <a href="#">Non-Employee Director Stock Ownership Guidelines</a> 21 <a href="#">2020 Director Compensation</a> 22 <a href="#">Director Equity Outstanding at 2020 Fiscal Year-End</a> 23 <a href="#">Board Risk Oversight</a> 23 <a href="#">Compensation Risk Assessment</a> 24
4	<a href="#">Stock Ownership</a>	26
5	<a href="#">Audit Committee Matters</a>	<a href="#">Proposal 2 – Ratification of the Selection of Our Independent Registered Public Accounting Firm</a> 28 <a href="#">Audit Committee Report</a> 29 <a href="#">Audit and Other Fees</a> 30 <a href="#">Policy on Pre-Approval of Audit and Non-Audit Services</a> 30

# Proxy Statement Table of Contents (continued)

<h1>6</h1>	<u><a href="#">Executive Compensation Matters</a></u>	<u><a href="#">Proposal 3 – Advisory Vote on Executive Compensation</a></u>	31
		<u><a href="#">Compensation Discussion and Analysis</a></u>	32
		<u><a href="#">Executive Summary</a></u>	32
		<u><a href="#">2020 Executive Compensation Programs and Pay-for-Performance Alignment</a></u>	37
		<u><a href="#">Roles and Responsibilities</a></u>	38
		<u><a href="#">Executive Compensation Philosophy and Objectives</a></u>	39
		<u><a href="#">External Market Competitiveness and Peer Group</a></u>	40
		<u><a href="#">Compensation Elements</a></u>	41
		<u><a href="#">Compensation Mix</a></u>	41
		<u><a href="#">Performance Goals and Target Setting Process</a></u>	41
		<u><a href="#">2020 Hiring and Transition-Related Compensation Decisions</a></u>	43
		<u><a href="#">2020 Base Salary</a></u>	43
		<u><a href="#">2020 Performance-Based Plans and Goal Setting</a></u>	43
		<u><a href="#">Long-Term Incentives</a></u>	49
		<u><a href="#">Total Target Direct Compensation and Realizable Pay</a></u>	55
		<u><a href="#">Retirement Plans</a></u>	55
		<u><a href="#">Other Benefits</a></u>	55
		<u><a href="#">Post-Termination Compensation and Benefits</a></u>	56
		<u><a href="#">Stock Ownership Guidelines</a></u>	56
		<u><a href="#">Recoupment of Compensation</a></u>	56
		<u><a href="#">Insider Trading, Hedging and Pledging Policy Prohibitions</a></u>	57
		<u><a href="#">Tax-Deductibility of Compensation</a></u>	57
		<u><a href="#">Compensation Committee Report</a></u>	57
<u><a href="#">Summary Compensation Table</a></u>	58		
<u><a href="#">2020 Grants of Plan-Based Awards</a></u>	60		
<u><a href="#">Outstanding Equity Awards at 2020 Fiscal Year-End</a></u>	61		
<u><a href="#">2020 Option Exercises and Stock Vested</a></u>	62		
<u><a href="#">2020 Non-Qualified Deferred Compensation</a></u>	63		
<u><a href="#">Potential Payments Upon Termination or Change in Control</a></u>	64		
<u><a href="#">CEO Pay Ratio</a></u>	67		
<h1>7</h1>	<u><a href="#">Other Management Proposal</a></u>	<u><a href="#">Proposal 4 – Approve an Amendment to Biogen’s Amended and Restated Certificate of Incorporation, as Amended, to Add a Federal Forum Selection Provision</a></u>	68
<h1>8</h1>	<u><a href="#">Stockholder Proposals</a></u>	<u><a href="#">Proposal 5 – Stockholder Proposal Requesting a Report on Biogen’s Lobbying Activities</a></u>	70
		<u><a href="#">Proposal 6 – Stockholder Proposal Requesting a Report on Biogen’s Gender Pay Gap</a></u>	72

## Proxy Statement Table of Contents (continued)

<b>9</b>	<b><a href="#">Additional Information</a></b>	<a href="#">Certain Relationships and Related Person Transactions</a>	74
		<a href="#">Equity Compensation Plan Information</a>	75
		<a href="#">Miscellaneous</a>	76
		<a href="#">Stockholder Proposals</a>	76
		<a href="#">Other Stockholder Communications</a>	76
		<a href="#">Incorporation by Reference</a>	76
		<a href="#">Copies of Annual Meeting Materials</a>	76
		<a href="#">Manner and Cost of Proxy Solicitation</a>	76
<hr/>			
	<a href="#">Appendix A — GAAP to Non-GAAP Reconciliation</a>	<b>A-1</b>	
	<a href="#">Appendix B — Certificate of Amendment of Amended and Restated Certificate of Incorporation, as amended</a>	<b>B-1</b>	

# Proxy Statement Summary

This summary highlights important information you will find in this Proxy Statement. As it is only a summary, please review the complete Proxy Statement before you vote.

## Annual Meeting Information

<b>DATE:</b>	Wednesday, June 2, 2021
<b>TIME:</b>	9:00 a.m. Eastern Time
<b>LOCATION:</b>	Online only at <a href="http://www.virtualshareholdermeeting.com/BIIB2021">www.virtualshareholdermeeting.com/BIIB2021</a>
<b>RECORD DATE:</b>	<b>You will not be able to attend the annual meeting in person.</b> April 9, 2021

## Voting Matters and Vote Recommendation

Voting Matter	Board Recommendation	Page Number for more detail
Item 1—Election of Directors	FOR each nominee	11
Item 2—Ratification of the Selection of our Independent Registered Public Accounting Firm	FOR	28
Item 3—Advisory Vote on Executive Compensation	FOR	31
Item 4—Approval of an Amendment to Our Amended and Restated Certificate of Incorporation, as Amended, to Add a Federal Forum Selection Provision	FOR	68
Item 5—Stockholder Proposal Requesting a Report on Our Lobbying Activities	AGAINST	70
Item 6—Stockholder Proposal Requesting a Report on Our Gender Pay Gap	AGAINST	72

## How to Vote

### Vote Right Away Through Advance Voting Methods

#### Vote by Internet Using Your Computer



Go to [www.proxyvote.com](http://www.proxyvote.com) and enter the 16-digit control number provided on your proxy card or voting instruction form.

#### Vote by Telephone



Call 800-690-6903 or the number on your proxy card or voting instruction form. You will need the 16-digit control number provided on your proxy card or voting instruction form.

#### Vote by Mail



Complete, sign and date the proxy card or voting instruction form and mail it in the accompanying pre-addressed envelope.

### Vote During Meeting

#### Vote During the Meeting




See Part 1 - "General Information About the Meeting" for details on how to vote during the Annual Meeting.

# Proxy Statement Summary (continued)

## Highlights of 2020 Company Performance

We are a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. For additional information, please see our 2020 Annual Report on Form 10-K.



### 2020 Operating Performance Highlights

- Full year total revenue of \$13.4 billion.
- Submission of regulatory filings for:
  - aducanumab, the investigational treatment for early Alzheimer's disease we are developing in collaboration with Eisai Co., Ltd. (Eisai), in the U.S., the European Union (E.U.) and Japan;
  - SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, in the U.S. and the E.U., which we are developing in collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics); and
  - VUMERITY (diroximel fumarate; DRF) in the E.U.
- The addition or advancement of 12 clinical programs to our pipeline, including in MS, ALS, Parkinson's disease and other movement disorders, depression and biosimilars.
- The European Commission's approval of a new intramuscular injection route of administration for PLEGRIDY (peginterferon beta-1a) for the treatment of relapsing-remitting MS.
- Our collaborations with:
  - Sangamo Therapeutics, Inc. (Sangamo) to develop and commercialize gene regulation therapies for the potential treatment of Alzheimer's, Parkinson's, neuromuscular and other neurological diseases;
  - Denali Therapeutics Inc. (Denali) to co-develop and co-commercialize therapies for the potential treatment of Parkinson's disease and neurodegenerative diseases; and
  - Sage Therapeutics, Inc. (Sage) to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.

## Proxy Statement Summary (continued)

- We continued to expand our biosimilars business, with over approximately 240,000 patients on our three anti-tumor necrosis factor (TNF) biosimilars in Europe as of December 31, 2020. We estimate that our anti-TNF biosimilars contributed approximately €2.4 billion of healthcare savings in 2020 across Europe.
- Named the number one biotechnology company on the Dow Jones Sustainability World Index for the fifth time.
- Repurchased approximately 22.4 million shares of our common stock at a total cost of approximately \$6.7 billion.

### Our Values

#### Biogen Elements

Much like the periodic table of elements documents the building blocks of the universe around us, the **Biogen Elements** give shape to our company's culture and are embedded into all our people processes, including performance management, rewards and recognition, goal setting and development programs and activities. The Biogen Elements drive the behaviors, actions and decisions required to achieve our strategy and promote a unified approach to our individual jobs – strengthening our mission, informing our leadership, expanding our impact and fueling our growth.



As we remain focused on discovering, developing and delivering worldwide innovative therapies, we remain **customer focused**. We keep patients, payers and physicians front and center in our daily work and collaborate to solve critical scientific and business challenges. In doing so, we foster an **inclusive** community, both internally and externally. We work in partnership to break down siloes and encourage diverse perspectives and backgrounds at all levels.

A **pioneering** spirit permeates our work. We challenge the status quo and experiment to create new possibilities. We are not afraid to take calculated risks and learn from failure. We are resilient and **agile**, adapting in response to internal changes and external disruptors, and developing solutions quickly to take advantage of emerging opportunities.

As pioneers and leaders, we hold ourselves **accountable** for our work and results. We honor our commitments and we never compromise our integrity. We sustain an **ethical** environment of trust, honesty and transparency while ensuring appropriate confidentiality.

#### Climate and Health

We have a longstanding commitment to addressing key environmental and sustainability impacts and we aspire to be a catalyst for positive change. We have adopted strong corporate responsibility policies and work to reduce the operational impact on the environment resulting from our business, including carbon emissions and water use, and by increasing the environmental and social performance of our supply chain.

In September 2020 we announced **Healthy Climate, Healthy Lives**, a \$250.0 million, 20-year initiative to eliminate fossil fuels across our operations and collaborate with renowned institutions with the aim to improve health, especially for the world's most vulnerable populations. We are the first *Fortune 500* company to commit to become fossil fuel free across our operations by 2040.

As part of this commitment, we utilize a science-based approach, demonstrated by establishing a climate target consistent with reductions required to keep warming to 1.5°C. Our Science Based Targets Initiative-approved commitment is to reduce absolute scopes 1 and 2 greenhouse gas emissions 55% by 2032 and 100% by 2040 from a 2019 base year. To achieve this goal, we embrace sustainable drug development, including green chemistry and reduced packaging, as an opportunity to improve our operations.

# Proxy Statement Summary (continued)

Our 2020 accomplishments include:

- Launched Healthy Climate, Healthy Lives, an initiative that goes beyond net zero emissions with a goal of realizing zero emissions from our global operations by 2040.
- Named the Biotechnology Industry Leader on the Dow Jones Sustainability World Index for the fifth time.
- Recognized as a corporate sustainability leader with the Gold Class Sustainability Award from RobecoSAM.
- Reduced total potable water usage by 10% and non-hazardous waste generated by 35%, each as compared to 2019.
- Demonstrated our commitment by signing America Is All In and joining the World Business Council on Sustainable Development, the United Nations Global Compact, the World Economic Forum Alliance of CEO Climate Leaders, the EV100 (committing to a 100% electric vehicle fleet by 2025), Ceres BICEP, Biopharma Sustainability Roundtable and the Pharmaceutical Environmental Group, among others.

## Diversity, Equity and Inclusion

We believe that prejudice, racism and intolerance are unacceptable and that different perspectives and all forms of diversity make us stronger and help us succeed as a business. We are committed to Diversity, Equity and Inclusion (DE&I) across all aspects of our organization, including hiring, promotion, compensation and development practices. As of December 31, 2020, 28% of Biogen's director-level and above positions were held by ethnic or racial minorities in the U.S. Our policies and practices are global, but the laws in many countries outside the U.S. do not permit us to collect ethnic or racial data on our employees. Globally, 48% of Biogen's positions at director-level and above were held by women.

In 2020 we enhanced our DE&I strategy and outlined actionable steps to deepen our commitment and build upon a strong foundation. This four-part strategy aims to:

- Build a diverse talent and leadership pipeline
- Build awareness and capability on how to drive DE&I throughout our organization
- Help improve health outcomes in the disease areas we treat
- Promote economic empowerment

We plan to create even greater awareness and capability in our organization through leadership accountability and transparency. To establish and progress this strategy, we rely on a cross-company governing body of employees known as the Diversity, Equity & Inclusion Strategic Council.

We aim to increase diversity\* in U.S. manager positions and above by 30% by the end of 2021. We have and will continue to disclose our EEO-1 (Equal Employment Opportunity) data as part of our effort to foster greater transparency.

We are honored to be recognized as a company of choice. We scored 100% on the 2020 Disability Equality Index, which measures our policies and practices related to disability inclusion, for the third consecutive year. Additionally, for the seventh consecutive year, we were recognized as a Best Place to Work for LGBTQ Equality by the Human Rights Campaign, scoring 100% on their Corporate Equality Index.

\* Percent of U.S. manager positions and above held by Black, African American and Latinx employees as well as Asian employees where underrepresented.

## Philosophy on Pay Equity

We are committed to ensuring that our employees receive equal pay for equal work. We establish components and ranges of compensation based on market and benchmark data. Within this context, we strive to pay all employees equitably within a reasonable range, taking into consideration factors such as role, function, market data, internal equity, job location, relevant experience and individual, business unit and company performance. In addition, we are committed to providing flexible benefits designed to allow our diverse global workforce to have reward opportunities that meet their varied needs so that they are inspired to perform their best on behalf of patients and stockholders each day.

## Proxy Statement Summary (continued)

We have multiple initiatives to recognize, interrupt and prevent bias in hiring, performance management and compensation decisions and we provide resources to further develop managers and leaders to help them make equitable decisions about pay.

We regularly review our compensation practices and analyze the equity of compensation decisions, for individual employees and our workforce as a whole. If we identify employees with pay gaps, we review and take appropriate action to ensure fidelity between our stated philosophy and actions.

To better understand our pay equity performance, we completed a global analysis in 2020, which was conducted by an external consultant who helped us analyze comparable roles to evaluate whether gender impacted compensation at Biogen. In the U.S., where the law permits the collection of race data, we also included race in the analysis, consistent with our commitment to racial equity. Overall, 85% of our global workforce was included in at least one analysis. Individuals not included in the analysis were either single-incumbent roles or in homogenous groups (by gender or by race), and therefore did not need to be analyzed.

We analyzed our employees' pay relative to race, gender, geography, responsibilities, level, performance and a wide range of other criteria. The pay equity analysis showed that the compensation of 99.7% of those analyzed was equitable. For the remaining 0.3% (17 employees) we made appropriate adjustments. The robust analysis confirmed that fairness and equity are embedded in our compensation practices around the globe.

We will continue to regularly review our compensation philosophy, ensure employees understand the total compensation practices and provide training for managers and leaders to prevent bias during hiring, compensation decisions and performance management.

### Community Engagement

Our employees are not only passionate about how their work at Biogen may help improve lives, they are also engaged across a broad range of activities to be a positive presence wherever we operate. Our newly refreshed **Care Deeply Every Day** program – an ongoing volunteer program through the whole year – provides every Biogen employee with eight hours of volunteer time for in-person and virtual volunteer opportunities. In 2020 347 employees from 8 countries logged 4,370 hours volunteering at different service projects, mostly virtual, in the communities where we live and work.

Many Biogen employees also participate in Employee Resource Networks, employee-led groups engaged in activities around a common interest. A newly created group, ourIMPACT, is focused on furthering our Healthy Climate, Healthy Lives initiative within Biogen and in our employees' everyday home life. This group tackles issues such as reducing waste in the workplace through reuse programs, improving energy use in laboratories and bringing healthier and more climate-friendly meals into Biogen's cafeterias.

Our **Community Labs**, with locations at our headquarters in Cambridge, Massachusetts, which opened in 2002, and in Research Triangle Park, North Carolina, which opened in 2014, is the longest-running, hands-on corporate science lab in the nation, serving as the model for a growing number of similar initiatives in the biotech community. At our Community Labs, local middle and high school students can engage in hands-on biotechnology experiments and interact with scientists and other biotech professionals in a state-of-the-art laboratory classroom. Since its inception, our Community Labs have engaged more than 57,000 students in hands-on learning to inspire their passion for science with priority focus on underrepresented students.

In 2020, as a result of the ongoing COVID-19 pandemic, we brought our Community Lab science learning program together with the Lemelson-MIT Program at the Massachusetts Institute of Technology (MIT) to launch the new online **Biogen-MIT Biotech in Action: Virtual Summer Lab**. This virtual lab offered 400 Massachusetts and North Carolina high school students a first-hand experience in biotechnology and provided the opportunity to learn directly from, and be mentored by, leading scientists at Biogen and MIT. Most of the students were from low-income households and groups historically underrepresented in science, technology, engineering and math (STEM).

## Proxy Statement Summary (continued)

---

We also worked with many leading institutions to bring scientific content and engaging experiences to students through an online hub called the Virtual Community Lab. Here students, parents and teachers around the world can access and experience free online resources, including tutorial videos of science experiments that can be done at home, plus other educational materials.

### The Biogen Foundation

The Biogen Foundation is focused on two core areas: science education and strengthening our communities by supporting essential human services for children and their families in the communities in which we work and live.

The Biogen Foundation is deeply committed to sparking a passion for science and discovery, supporting effective science education initiatives and strengthening efforts to make science education and science careers accessible to diverse populations. Most of all, we want young people to know that through science they have the ability to change the world. To realize this goal, the Biogen Foundation principally supports nonprofit organizations that focus on four areas: providing access to hands-on science education, teacher development in science, college readiness and support and basic social needs (child hunger, poverty and social mobility).

Through December 31, 2020, the Biogen Foundation donated \$18.9 million to organizations around the world. This included \$12.0 million in grants to 82 organizations across 35 countries to support COVID-19 relief to expand testing options, ease the strain on medical systems and support access to necessities like food.

The Biogen Foundation also supported ongoing programs in science education and nutrition, and matched Biogen employee gifts to nonprofit organizations, up to \$25,000 per employee, per year. From the \$18.9 million donated by the Biogen Foundation in 2020, the employee matching gift program contributed \$2.5 million to causes ranging from disease research to camps for children with serious illnesses to disaster relief efforts.

### Our Pricing Principles

As a pioneer in neuroscience, we have the opportunity and responsibility to bring potentially transformative treatments to patients. Our patients remain at the center of everything we do as a company. We recognize that access and the price of our medicines are of concern to our patients, providers, payers and policy makers. We work collaboratively to help ensure that patients are not denied access to life-changing therapies and are guided by the following principles:

- **Value to Patients:** We assess the value our therapies bring to patients, including clinical outcomes, improvements in daily living and quality of life, and the impact on unmet needs. We believe the prices of our medicines reflect their unique advancements in improving patient health.
- **Present and Future Benefit to Society:** In the near term, our benefit to society includes supporting people living with serious neurological and neurodegenerative diseases while also reducing overall healthcare system costs. In the longer-term, we respect the social contract that allows free pricing of innovation followed by swift entry of biosimilars/generics after loss of exclusivity, which makes room for the next wave of innovation.
- **Fulfilling our Commitment to Innovation:** Continued innovation is our growth strategy. We rely on the sale of our medicines to drive our ongoing research and clinical trials for new medicines in areas of high unmet medical need.
- **Evolution toward Value Based Care:** We believe in holistic value frameworks, with benefits to patients, providers and society. We seek value-based agreements and partnerships which maximize the benefit of our therapies.
- **Affordability & Sustainability:** It is the shared responsibility of all healthcare stakeholders to find solutions that ensure patients can afford new innovations. Biogen partners with healthcare systems so patients can access our medicines in a sustainable way. And we remain flexible to enable affordability for patients across economic circumstances.

A copy of our Pricing Principles is posted on our website, [www.biogen.com](http://www.biogen.com), under the "Guiding Principles" subsection of the "Who We Are" section of the website.



## Proxy Statement Summary (continued)

---

We regularly review our pricing strategy and prioritize patient access to our therapies. We have a value-based contracting program designed to align the price of our therapies to the value our therapies deliver to patients. We also work with regulators, clinical researchers, ethicists, physicians and patient advocacy organizations and communities, among others, to determine how best to address requests for access to our investigational therapies in a manner that is consistent with our patient-focused values and compliant with regulatory standards and protocols. In appropriate situations, patients may have access to investigational therapies through Early Access Programs, single patient access or emergency use based on humanitarian or compassionate grounds.

We believe biosimilar products benefit patients and help reduce the costs of healthcare systems. We estimate that the anti-TNF biosimilars we sell provided healthcare savings of approximately €2.4 billion in 2020 in the markets where they are sold.

### Year in Review Corporate Responsibility Report

For more information on our commitment to addressing environmental, social and governance aspects across our business, please see our report, [Year in Review: Our Commitment to Corporate Responsibility](#), which is posted on our website, [www.biogen.com](http://www.biogen.com), under the “Corporate Responsibility” section of the website. We believe these efforts reflect the best interests of our employees, our patients, our stockholders and various other stakeholders, including the communities in which we operate and serve.

Furthermore, we are committed to transparent and clear disclosure of our policies and performance on a broad array of issues. Our Year in Review meets the Global Reporting Initiative framework and aligns with the Sustainability Accounting Standards Board, the Task Force on Climate-Related Financial Disclosures, the United Nations Global Compact and Sustainable Development Goals.



# Proxy Statement Summary (continued)

## Corporate Governance Matters

We are committed to the highest standards of ethics, business integrity and corporate governance, which we believe will ensure that our company is managed for the long-term benefit of our stockholders. Our governance practices are designed to establish and preserve accountability of our Board of Directors and management, provide a structure that allows our Board to set objectives and monitor performance, ensure the efficient use and accountability of resources and enhance stockholder value. Please see Part 2 – “Corporate Governance at Biogen” for more information.

### Corporate Governance Highlights

Board and Board Committees	
Number of Independent Director Nominees/Total Number of Director Nominees	12/13
Number of Female Director Nominees/Total Number of Director Nominees	3/13
Number of Director Nominees of International Origin/Total Number of Director Nominees	4/13
Number of Diverse Director Nominees/Total Number of Director Nominees	5/13
Average Age of Directors Standing for Election (as of April 9, 2021)	64
All Board Committees Consist of Independent Directors	Yes
Risk Oversight by Full Board and Committees	Yes
Active Board Oversight of Enterprise Risk Management	Yes
Separate Independent Chairman and CEO	Yes
Regular Executive Sessions of Independent Directors	Yes
Annual Anonymous Board and Committee Self-Evaluations	Yes
Annual Independent Director Evaluation of CEO	Yes
Mandatory Retirement Age for Directors (75 years old)	Yes
Director Education and Orientation	Yes
Annual Equity Grant to Directors	Yes
Director Stockholder Engagement Initiative	Yes
Stockholder Rights, Accountability and Other Governance Practices	
Annual Election of All Directors	Yes
Majority Voting for Directors and Resignation Policy	Yes
One-Share, One-Vote Policy	Yes
Proxy Access Bylaw (3% ownership, 3 years, nominees for up to 25% of our Board)	Yes
Annual Advisory Stockholder Vote on Executive Compensation	Yes
Stockholder Ability to Call Special Meetings (25% Threshold)	Yes
Stockholder Ability to Act by Written Consent	Yes
Anti-Overboarding Policy Limiting the Number of Other Public Company Boards on which our Directors May Serve (four for Non-Employee Directors and one for the CEO)	Yes
Stock Ownership Guidelines for Directors and Executives	Yes
Prohibition from Hedging and Pledging Securities or Otherwise Engaging in Derivative Transactions	Yes
Compensation Recoupment in Equity and Annual Bonus Plans	Yes
Comprehensive Code of Business Conduct and Corporate Governance Principles	Yes
Related Person Transaction Policy and Conflicts of Interest and Outside Activities Policy with Oversight by the Corporate Governance Committee	Yes
Active Board Engagement in Succession Planning of Executive Officers	Yes
Absence of a Stockholder Rights Plan (referred to as “Poison Pill”)	Yes
Strong Commitment to Diversity, Environmental and Sustainability Matters	Yes
Board Oversight and Disclosure on Website Related to Corporate Political Contributions and Expenditures	Yes

# Proxy Statement Summary (continued)

## Director Stockholder Engagement Initiative

We value the views of our stockholders and other stakeholders, and we solicit input throughout the year. During 2020 independent members of our Board of Directors met with several stockholders to discuss a variety of issues, including business strategy, capital allocation, corporate governance, executive compensation and our environmental, social and governance initiatives.

## Our Director Nominees

### Proposal 1 — Election of Directors

You are being asked to vote on the election of the following 13 nominees for director. All directors are elected annually by the affirmative vote of a majority of votes cast. Detailed information about each director's background, skill sets and areas of expertise can be found beginning on page 11.

Name, Occupation and Experience	Age*	Independent	Committee Memberships*			Other Public Boards
			AC	C&MDC**	CGC	
<b>Alexander J. Denner, Ph.D.</b> Founding Partner and Chief Investment Officer, Sarissa Capital Management LP	51	Yes				2
<b>Caroline D. Dorsa</b> Retired Executive Vice President and Chief Financial Officer, Public Service Enterprise Group Incorporated	61	Yes	 			2
<b>Maria C. Freire, Ph.D.</b> President and Executive Director, Foundation for the National Institutes of Health	66	Yes				2
<b>William A. Hawkins</b> Senior Advisor, EW Healthcare Partners	67	Yes				3
<b>William D. Jones</b> President and Chief Executive Officer, CityLink Investment Corp.	65	Yes				1
<b>Nancy L. Leaming</b> Retired Chief Executive Officer and President, Tufts Health Plan	73	Yes				—
<b>Jesus B. Mantas</b> Senior Managing Partner, IBM Global Services	52	Yes				—
<b>Richard C. Mulligan, Ph.D.</b> Mallinckrodt Professor of Genetics, Emeritus, Harvard Medical School and Head of SanaX and Executive Vice Chairman, Sana Biotechnology, Inc.	66	Yes				1
<b>Stelios Papadopoulos, Ph.D.</b> Chairman, Biogen Inc., Chairman, Exelixis, Inc., Chairman, Regulus Therapeutics Inc. and Chairman Eucrates Biomedical Acquisition Corp.	72	Yes				3
<b>Brian S. Posner</b> Private Investor and Founder and Managing Partner, Point Rider Group LLC	59	Yes				2
<b>Eric K. Rowinsky, M.D.</b> President and Executive Chairman, RGenix, Inc.	64	Yes				3
<b>Stephen A. Sherwin, M.D.</b> Clinical Professor of Medicine, University of California, San Francisco and Advisor to Life Sciences Companies	72	Yes				1
<b>Michel Vounatsos</b> Chief Executive Officer, Biogen Inc.	59	No				1

\* Age and Committee memberships are as of April 9, 2021. Dr. Freire and Mr. Jones are each new director nominees standing for election to our Board of Directors at the Annual Meeting.

\*\* Robert W. Pangia is the Chair of our Compensation and Management Development Committee. Mr. Pangia is retiring from our Board of Directors, effective as of the Annual Meeting.

AC: Audit Committee

C&MDC: Compensation and Management Development Committee

CGC: Corporate Governance Committee

Chair: 

Member: 

Financial Expert: 

# Proxy Statement Summary (continued)

## Our Auditors

### Proposal 2 – Ratification of Independent Registered Public Accounting Firm

You are being asked to vote to ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2021. Detailed information about this proposal can be found beginning on page 28.

## Executive Compensation Matters

### Proposal 3 – Advisory Vote on Executive Compensation

Our Board of Directors recommends that stockholders vote to approve, on an advisory basis, the compensation paid to the Company's named executive officers (NEOs) as described in this Proxy Statement (the "say-on-pay" vote). Detailed information about the compensation paid and awarded to our NEOs can be found beginning on page 31.

Our executive compensation programs embody a pay-for-performance philosophy that supports our business strategy and aligns executive interests with those of our stockholders. Highlights of our executive compensation programs for 2020 and our executive compensation best practices follow.

#### Pay-for-Performance

Short- and long-term incentive compensation rewards financial, strategic and operational performance and the accomplishment of pre-established goals that are set to support our annual and/or long-range plans.

Approximately 91% of the target compensation for Michel Vounatsos, our CEO, was performance-based and at-risk in 2020, creating strong alignment with the interests of our stockholders.

Approximately 85% of the target compensation for our currently-employed NEOs (other than our CEO) was performance-based and at-risk in 2020, creating strong alignment with the interests of our stockholders.

#### Other Executive Compensation Best Practices

We provide competitive total pay opportunities designed to attract, retain and motivate our executives, after consideration of many factors, including comparative data from a carefully selected peer group and the broader market in which we compete for talent.

An independent compensation consultant assists the Compensation and Management Development Committee in evaluating and setting executive and non-employee director compensation.

We believe that our compensation programs do not encourage unnecessary and excessive risk taking, and risk assessments are conducted annually.

Payments under our annual bonus plan are performance-based and capped.

Long-term incentive awards are generally performance-based and subject to multi-year vesting periods that are designed to reward long-term performance.

While stock option awards are not currently part of our compensation programs, if granted, they would be granted at fair market value; we do not backdate or reprice stock option awards.

We maintain robust stock ownership guidelines for executive officers and directors.

Compensation may be recouped/clawed back under our equity and annual bonus plans.

A double-trigger is required for accelerated equity vesting upon change in control.

In June 2009 we adopted a policy to eliminate excise tax gross ups for newly-hired executives and in March 2020 our two executives that remained eligible for this benefit voluntarily waived their rights to this benefit. Therefore, no executive officer is eligible to receive excise tax gross ups.

We do not offer additional special perquisites to our executive officers that are not offered to our broad employee base or senior management populations.

## Proxy Statement Summary (continued)

### Other Management Proposal

#### **Proposal 4 — Approve an Amendment to Our Amended and Restated Certificate of Incorporation, as Amended, to Add a Federal Forum Selection Provision**

Our Board of Directors recommends that stockholders vote to approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to add a federal forum selection provision. Detailed information about this proposal can be found beginning on page 68.

### Stockholder Proposals

#### **Proposal 5 — Stockholder Proposal Requesting a Report on Our Lobbying Activities**

Our Board of Directors recommends that stockholders vote against a stockholder proposal requesting a report on our lobbying activities. Detailed information about this proposal can be found beginning on page 70.

#### **Proposal 6 — Stockholder Proposal Requesting a Report on Our Gender Pay Gap**

Our Board of Directors recommends that stockholders vote against a stockholder proposal requesting a report on our gender pay gap. Detailed information about this proposal can be found beginning on page 72.

### Note about Forward-Looking Statements

This Proxy Statement contains forward-looking statements, including statements relating to: our strategy and plans; potential of our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials and data readouts and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings and approvals and the timing thereof; the potential benefits, safety and efficacy of our products and investigational therapies; and the anticipated benefits and potential of investments, collaborations and business development activities. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” “would” and other words and terms of similar meaning. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including the risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). These statements are based on our current beliefs and expectations and speak only as of the date of this Proxy Statement. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

### Note regarding Trademarks

PLEGRIDY®, SPINRAZA®, TECFIDERA®, TYSABRI®, VUMERITY® and ZINBRYTA® are registered trademarks of Biogen. Healthy Climate, Healthy Lives™ is a trademark of Biogen. LUCENTIS®, EYLEA® and other trademarks referenced in this Proxy Statement are the property of their respective owners.

# 1 General Information About the Meeting

**Biogen Inc.**  
225 Binney Street  
Cambridge, Massachusetts 02142

The Board of Directors of Biogen Inc. is soliciting your proxy to vote at our 2021 annual meeting of stockholders (Annual Meeting) to be held at 9:00 a.m. Eastern Time on Wednesday, June 2, 2021, for the purposes summarized in the accompanying Notice of 2021 Annual Meeting of Stockholders. Our 2020 Annual Report on Form 10-K is also available with this Proxy Statement.

References in this Proxy Statement to “Biogen” or the “Company,” “we,” “us” and “our” refer to Biogen Inc.

<b><i>What is the purpose of the Annual Meeting?</i></b>	At the Annual Meeting, stockholders will vote upon the matters that are summarized in the formal meeting notice. This Proxy Statement contains important information for you to consider when deciding how to vote on the matters before the Annual Meeting.
<b><i>Can I attend the Annual Meeting?</i></b>	We will be hosting the Annual Meeting virtually via the Internet.  Any stockholder can listen to and participate in the Annual Meeting live via the Internet at <a href="http://www.virtualshareholdermeeting.com/BIIB2021">www.virtualshareholdermeeting.com/BIIB2021</a> . Stockholders may vote and submit questions while connected to the Annual Meeting via the Internet. You will need the 16-digit control number included on your Notice of Internet Availability of Proxy Materials or your proxy card or voting instruction form in order to be able to vote your shares or submit questions via the Internet during the Annual Meeting.  You will not be able to attend the Annual Meeting in person.
<b><i>What do I need in order to be able to participate in the Annual Meeting virtually via the Internet?</i></b>	You will need the 16-digit control number included on your Notice of Internet Availability of Proxy Materials or your proxy card or voting instruction form in order to be able to vote your shares or submit questions via the Internet during the Annual Meeting. If you do not have your 16-digit control number, you will be able to listen to the meeting only — you will not be able to vote or submit questions during the meeting.
<b><i>Who can vote?</i></b>	Each share of our common stock that you own as of the close of business on the record date of April 9, 2021 (Record Date) entitles you to one vote on each matter to be voted upon at the Annual Meeting. As of the Record Date, [●] shares of our common stock were outstanding and entitled to vote. We are making this Proxy Statement and other Annual Meeting materials available on the Internet at <a href="http://www.proxyvote.com">www.proxyvote.com</a> or, upon request, by sending printed versions of these materials on or about April , 2021, to all stockholders of record as of the Record Date. For ten days before the Annual Meeting, a list of stockholders entitled to vote will be available for inspection at our offices located at 225 Binney Street, Cambridge, Massachusetts 02142 and will also be available for examination during the Annual Meeting at <a href="http://www.virtualshareholdermeeting.com/BIIB2021">www.virtualshareholdermeeting.com/BIIB2021</a> . If you would like to review the list, please call our Investor Relations department at (781) 464-2442.

# 1 General Information About the Meeting (continued)

<p><i>What am I voting on at the Annual Meeting?</i></p>	<p>Stockholders will be asked to vote on the following items at the Annual Meeting:</p> <ul style="list-style-type: none"><li>• The election to our Board of Directors of the 13 director nominees (Proposal 1);</li><li>• The ratification of the selection of PricewaterhouseCoopers LLP (PwC) as our independent registered public accounting firm for the fiscal year ending December 31, 2021 (Proposal 2);</li><li>• The advisory vote on executive compensation (Proposal 3);</li><li>• The approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended, to add a federal forum selection provision (Proposal 4);</li><li>• To consider and vote on a stockholder proposal requesting a report on our lobbying activities, if properly presented (Proposal 5);</li><li>• To consider and vote on a stockholder proposal requesting a report on our gender pay gap, if properly presented (Proposal 6); and</li><li>• The transaction of such other business as may be properly brought before the meeting and any adjournments or postponements.</li></ul>
<p><i>What is the recommendation of our Board of Directors on each of the matters scheduled to be voted on at the Annual Meeting?</i></p>	<p>Our Board of Directors recommends that you vote:</p> <ul style="list-style-type: none"><li>• <b>“FOR”</b> each of the director nominees (Proposal 1);</li><li>• <b>“FOR”</b> the ratification of the selection of PwC as our independent registered public accounting firm for the fiscal year ending December 31, 2021 (Proposal 2);</li><li>• On an advisory basis, <b>“FOR”</b> the approval of our executive compensation (Proposal 3);</li><li>• <b>“FOR”</b> the approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended, to add a federal forum selection provision (Proposal 4);</li><li>• <b>“AGAINST”</b> the approval of a stockholder proposal requesting a report on our lobbying activities, if properly presented (Proposal 5); and</li><li>• <b>“AGAINST”</b> the approval of a stockholder proposal requesting a report on our gender pay gap, if properly presented (Proposal 6).</li></ul>
<p><i>How do proxies work?</i></p>	<p>Our Board of Directors is asking for your proxy authorizing the individuals named as proxies to vote your shares at the Annual Meeting in the manner you direct. You may abstain from voting on any matter. If you submit your proxy without specifying your voting instructions, we will vote your shares on the matters scheduled to be voted on at the Annual Meeting in accordance with our Board of Directors’ recommendations described above. As to any other matter that may properly come before the Annual Meeting or any adjournment or postponement, the individuals named as proxies will vote your shares at the Annual Meeting in accordance with their best judgment.</p> <p>Shares represented by valid proxies received in time for the Annual Meeting and not revoked before the Annual Meeting will be voted at the Annual Meeting. You can revoke your proxy and change your vote in the manner described below (under the heading “Can I revoke or change my vote after I submit my proxy?”). If your shares are held through a bank, broker or other nominee, please follow the instructions that you were provided by your bank, broker or other nominee.</p>



# 1 General Information About the Meeting (continued)

## *How do I vote and what are the voting deadlines?*

**Stockholders of Record.** If you are a stockholder of record, there are several ways for you to vote your shares.

-  **By Internet.** You may vote at [www.proxyvote.com](http://www.proxyvote.com), 24 hours a day, seven days a week. You will need the 16-digit control number included on your Notice of Internet Availability of Proxy Materials or, if you received a printed copy of the proxy materials, on your proxy card. Votes submitted through [www.proxyvote.com](http://www.proxyvote.com) must be received by 11:59 p.m. Eastern Time on June 1, 2021.
-  **By Telephone.** You may vote using a touch-tone telephone by calling **1-800-690-6903**, 24 hours a day, seven days a week. You will need the 16-digit control number included on your Notice of Internet Availability of Proxy Materials or, if you received a printed copy of the proxy materials, on your proxy card. Votes submitted by telephone must be received by 11:59 p.m. Eastern Time on June 1, 2021.
-  **By Mail.** If you received printed proxy materials, you may submit your vote by completing, signing and dating each proxy card received and returning it in the prepaid envelope. Sign your name exactly as it appears on the proxy card. Proxy cards submitted by mail must be received no later than June 1, 2021, to be voted at the Annual Meeting.
-  **During the Annual Meeting.** You may vote during the Annual Meeting by going to [www.virtualshareholdermeeting.com/BIIB2021](http://www.virtualshareholdermeeting.com/BIIB2021). You will need the 16-digit control number included on your Notice of Internet Availability of Proxy Materials or, if you received a printed copy of the proxy materials, on your proxy card to be able to vote during the Annual Meeting.

If you vote via the Internet or by telephone before the Annual Meeting, your electronic vote authorizes the named proxies in the same manner as if you signed, dated and returned your proxy card. **If you vote via the Internet or by telephone before the Annual Meeting, do not return your proxy card.**

**Beneficial Owners.** *If your shares are held in a brokerage account in your broker's name, then you are the beneficial owner of shares held in "street name."* If you are a beneficial owner of your shares, you should have received a Notice of Internet Availability of Proxy Materials or voting instructions from the bank, broker or other nominee holding your shares. You should follow the instructions in the Notice of Internet Availability of Proxy Materials or voting instructions provided by your bank, broker or other nominee in order to instruct your bank, broker or other nominee on how to vote your shares. The availability of telephone and Internet voting will depend on the voting process of the bank, broker or other nominee. **Shares held beneficially may not be voted during the Annual Meeting; instead a beneficial holder must instruct their bank, broker or other nominee in advance of the Annual Meeting.**

# 1 General Information About the Meeting (continued)

**Can I revoke or change my vote after I submit my proxy?**

**Stockholders of Record.** If you are a stockholder of record, you may revoke or change your vote at any time before the final vote at the Annual Meeting by:

- signing and returning a new proxy card with a later date, to be received no later than June 1, 2021;
- submitting a later-dated vote by telephone or via the Internet — only your latest telephone or Internet proxy received by 11:59 p.m. Eastern Time on June 1, 2021, will be counted;
- participating in the Annual Meeting virtually via the Internet and voting again; or
- delivering a written revocation to our Secretary at Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142, to be received no later than June 1, 2021.

Only your latest vote, in whatever form, will be counted.

**Beneficial Owners.** If you are a beneficial owner of your shares, you must contact the bank, broker or other nominee holding your shares and follow their instructions for revoking or changing your vote.

**Will my shares be counted if I do not vote?**

**Stockholders of Record.** If you are the stockholder of record and you do not vote before the Annual Meeting by proxy card, telephone or via the Internet, or during the Annual Meeting virtually via the Internet, your shares will not be voted at the Annual Meeting.

**Beneficial Owners.** If you are the beneficial owner of shares, your bank, broker or other nominee, as the record holder of the shares, is required to vote those shares in accordance with your instructions. If no voting instructions are provided, these record holders can vote your shares only on discretionary, or routine, matters and not on non-discretionary, or non-routine, matters. Uninstructed shares whose votes cannot be counted on non-routine matters result in what are commonly referred to as “broker non-votes.”

The proposal to ratify the selection of our independent registered public accounting firm is a routine matter and the other proposals are non-routine matters. If you do not give your broker voting instructions, your broker (1) will be entitled to vote your shares on the proposal to ratify the selection of our independent registered public accounting firm and (2) will not be entitled to vote your shares on the other proposals. We urge you to provide instructions to your bank, broker or other nominee so that your votes may be counted on all of these important matters.

You should vote your shares by telephone or by Internet according to the instructions provided by your bank, broker or other nominee or by signing, dating and returning a printed voting instruction form to your bank, broker or other nominee to ensure that your shares are voted on your behalf.

**How many shares must be present to hold the Annual Meeting?**

A majority of our issued and outstanding shares of common stock as of the Record Date must be present at the Annual Meeting to hold the Annual Meeting and conduct business. This is called a quorum. Shares voted in the manner described above (under the heading “How do I vote and what are the voting deadlines?”) will be counted as present at the Annual Meeting. Shares that are present and entitled to vote on one or more of the matters to be voted upon are counted as present for establishing a quorum. If a quorum is not present, we expect that the Annual Meeting will be adjourned until we obtain a quorum.

# 1 General Information About the Meeting (continued)

## *What vote is required to approve each proposal and how are votes counted?*

- **Proposal 1: Election of Directors:** Directors are elected by a majority vote of the votes cast in uncontested elections — that is, a director will be elected if more votes are cast for that director’s election than against that director — and by a plurality of votes cast in contested elections — that is, the directors receiving the highest number of “For” votes will be elected. Abstentions and broker non-votes, if any, are not counted for purposes of electing directors and will have no effect on the results of this vote.
- **Proposal 2: Ratification of the Selection of our Independent Registered Public Accounting Firm:** The affirmative vote of a majority of shares present in person or represented by proxy and having voting power at the Annual Meeting is required to ratify the selection of PwC as our independent registered public accounting firm for the fiscal year ending December 31, 2021. Abstentions will have the effect of votes against this proposal. Brokers generally have discretionary authority to vote on the ratification of the selection of our independent registered public accounting firm, thus we do not expect any broker non-votes on this proposal.
- **Proposal 3: Advisory Vote on Executive Compensation:** Because this proposal asks for a non-binding, advisory vote, there is no “required vote” that would constitute approval. We value the opinions expressed by our stockholders in this advisory vote, and the Compensation and Management Development Committee of our Board of Directors (sometimes referred to in this Proxy Statement as our “C&MD Committee”), which is responsible for overseeing and administering our executive compensation programs, will consider the outcome of this vote when designing our compensation programs and making future compensation decisions for our named executive officers. Abstentions and broker non-votes, if any, will not have any effect on the results of those deliberations.
- **Proposal 4: Approval of an Amendment to our Amended and Restated Certificate of Incorporation, as Amended, to Add a Federal Forum Selection Provision:** The affirmative vote of a majority of shares issued and outstanding and entitled to vote on the proposal is required to approve the amendment to our Amended and Restated Certificate of Incorporation, as amended, to add a federal forum selection provision. Abstentions and broker non-votes will have the effect of votes against this proposal.
- **Proposal 5: Stockholder Proposal: Requesting a Report on our Lobbying Activities:** Because this proposal asks for a non-binding vote, there is no “required vote” that would constitute approval. We value the opinions expressed by our stockholders in this non-binding vote, and the outcome of this vote may cause our Board of Directors to reevaluate its recommendation concerning this proposal. Abstentions and broker non-votes, if any, will not have any effect on that determination.
- **Proposal 6: Stockholder Proposal: Requesting a Report on our Gender Pay Gap:** Because this proposal asks for a non-binding vote, there is no “required vote” that would constitute approval. We value the opinions expressed by our stockholders in this non-binding vote, and the outcome of this vote may cause our Board of Directors to reevaluate its recommendation concerning this proposal. Abstentions and broker non-votes, if any, will not have any effect on that determination.



# 1 General Information About the Meeting (continued)

<b><i>Are there other matters to be voted on at the Annual Meeting?</i></b>	We do not know of any other matters that may come before the Annual Meeting. If any other matters are properly presented at the Annual Meeting, your proxy authorizes the individuals named as proxies to vote, or otherwise act, in accordance with their best judgment.
<b><i>Why did I receive a one-page notice in the mail regarding the Internet availability of proxy materials instead of a full set of proxy materials?</i></b>	We have elected to provide access to our proxy materials on the Internet, consistent with the rules of the SEC. Accordingly, in most instances we are mailing a Notice of Internet Availability of Proxy Materials to our stockholders. You can access our proxy materials on the website referred to in the Notice of Internet Availability of Proxy Materials or you may request printed versions of our proxy materials for the Annual Meeting. In addition, you may request to receive proxy materials in printed form by mail or electronically by email on an ongoing basis.
<b><i>What does it mean if I receive more than one notice regarding the Internet availability of proxy materials or more than one set of printed proxy materials?</i></b>	If you hold your shares in more than one account, you may receive a separate Notice of Internet Availability of Proxy Materials or a separate set of printed proxy materials, including a separate proxy card or voting instruction form, for each account. To ensure that all of your shares are voted, please vote by telephone or by Internet or sign, date and return a proxy card or voting instruction form for each account.
<b><i>Where do I find the voting results of the Annual Meeting?</i></b>	We will publish the voting results of the Annual Meeting in a Current Report on Form 8-K filed with the SEC within four business days after the end of the Annual Meeting. You may request a copy of this Form 8-K by contacting Investor Relations, Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142, (781) 464-2442. You will also be able to find a copy of this Form 8-K on the Internet through the SEC's electronic data system, called EDGAR, at <a href="http://www.sec.gov">www.sec.gov</a> or on our website, <a href="http://www.biogen.com">www.biogen.com</a> , under the "Financials" subsection of the "Investors" section of the website.
<b><i>Who should I call if I have any questions?</i></b>	If you have any questions or require any assistance with voting your shares, please contact the bank, broker or other nominee holding your shares, or our Investor Relations department at (781) 464-2442.
<b><i>Who do I contact if I experience technical difficulties trying to access or during the Annual Meeting?</i></b>	If you have technical difficulties when accessing the Annual Meeting, there will be technicians available to assist you. If you encounter any technical difficulties accessing the virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the Annual Meeting log-in page.



# 2 Corporate Governance at Biogen

## Corporate Governance Practices

We are committed to the highest standards of ethics, business integrity and corporate governance, which we believe will ensure that our company is managed for the long-term benefit of our stockholders. Our governance practices are designed to establish and preserve accountability of our Board of Directors and management, provide a structure that allows our Board to set objectives and monitor performance, ensure the efficient use and accountability of resources and enhance stockholder value. A description of our corporate governance highlights is set forth in the “Proxy Statement Summary” above.

We believe that our Board of Directors’ primary functions are to appoint, evaluate and hold accountable management, oversee key strategic, operational and compliance risks and ensure optimal capital allocation such that long-term stockholder value is maximized.

We believe part of effective corporate governance includes active engagement with our stockholders. We value the views of our stockholders and other stakeholders, and we communicate with them regularly and solicit input on a number of topics such as business strategy, capital allocation, corporate governance, executive compensation and our environmental, social and governance initiatives.

- **Director Stockholder Engagement Initiative.** Our Corporate Governance Committee leads our Board of Directors’ efforts on director stockholder engagement and directs discussions with stockholders to the appropriate Board and committee members. During 2020 independent members of our Board of Directors met with several stockholders to discuss a variety of issues, including business strategy, capital allocation, corporate governance, executive compensation and our environmental, social and governance initiatives. We remain committed to investing time with our stockholders to increase transparency and better understand our stockholder base and their perspectives.
- **Corporate Responsibility.** Our passion for developing medicines that make a meaningful difference in patients’ lives is reflected in our commitment to corporate social responsibility and stewardship, including environmental sustainability, diversity, equity and inclusion, STEM education and other key initiatives. Our Year in Review: Our Commitment to Corporate Responsibility is posted on our website, [www.biogen.com](http://www.biogen.com), under the “Corporate Responsibility” section of the website. We believe these efforts reflect the best interests of our patients, stakeholders and the communities in which we operate and

serve. Our citizenship and sustainability commitments and performance have been recognized over the years, including the most recent acknowledgements noted in the executive summary section under “Compensation Discussion and Analysis” below.

## Director Independence

### Board of Directors

All of our directors and nominees for director, other than Michel Vounatsos, our Chief Executive Officer, satisfy the independence requirements of The Nasdaq Stock Market (Nasdaq).

### Committees

- All members of the committees of our Board of Directors are independent directors, as defined by Nasdaq rules.
- All members of our Audit Committee meet the additional SEC and Nasdaq independence and experience requirements applicable specifically to audit committee members.
- All members of our C&MD Committee are non-employee directors within the meaning of the rules under Section 16 of the Securities Exchange Act of 1934, as amended (Exchange Act), and our Board of Directors has affirmatively determined that the members of our C&MD Committee satisfy the additional Nasdaq independence requirements specifically applicable to compensation committee members.

### Leadership Structure

We separate the roles of Chairman of the Board of Directors and Chief Executive Officer. Stelios Papadopoulos, an independent director, is the Chairman of our Board. Among other responsibilities, our Chairman:

- presides at meetings of our Board of Directors, executive sessions of our independent directors and our annual meetings of stockholders;
- reviews and assists in setting the agenda and schedule for our Board of Directors meetings in collaboration with our Chief Executive Officer;
- advises the committee chairs in fulfilling their responsibilities to our Board of Directors;
- recommends to our Board of Directors the retention of any advisors who report directly to our Board of Directors;

## 2 Corporate Governance at Biogen (continued)

- serves as a liaison for stockholder communications with our Board of Directors;
- leads the process of evaluating our Chief Executive Officer; and
- discharges such other responsibilities as our Board of Directors may assign from time to time.

We believe that having an independent Chairman promotes a greater role for the independent directors in the oversight of the Company, including oversight of material risks facing the Company, encourages active participation by the independent directors in the work of our Board of Directors, enhances our Board of Directors' role of representing stockholders' interests and improves our Board of Directors' ability to supervise and evaluate our Chief Executive Officer and other executive officers. Further, separation of the Chairman and Chief Executive Officer roles allows our Chief Executive Officer to focus on operating and managing Biogen while leveraging our independent Chairman's experience and perspectives.

### Nominating Processes

Our Corporate Governance Committee is responsible for identifying individuals qualified to become members of our Board of Directors and reviewing candidates recommended by stockholders. Stockholders may recommend nominees for consideration by our Corporate Governance Committee by submitting the names and supporting information to our Secretary, Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142. Any such recommendation should include at a minimum the name(s) and address(es) of the stockholder(s) making the recommendation and appropriate biographical information for the proposed nominee(s). Candidates who are recommended by stockholders will be considered in the same manner as candidates from other sources. For all potential candidates, our Corporate Governance Committee will consider all factors it deems relevant, including at a minimum those listed below in the subsection entitled "Director Qualifications, Standards and Diversity." Director nominations are recommended by our Corporate Governance Committee to our Board of Directors and must be approved by a majority of independent directors.

In addition, our Fourth Amended and Restated Bylaws (Bylaws) contain provisions that address the process by which a stockholder may nominate an individual to stand for election to our Board of Directors at an annual meeting of stockholders.

- *Stockholder Nominations Not for Inclusion in Company's Proxy Statement.* Our Bylaws permit stockholders to

nominate directors for consideration at an annual meeting. To nominate a director for consideration at an annual meeting, a nominating stockholder must provide the information required by our Bylaws and give timely notice of the nomination to our Secretary in accordance with our Bylaws, and each nominee must meet the qualifications required by our Bylaws. To nominate a director for consideration at next year's annual meeting, stockholders must provide the notice required by our Bylaws no later than March 4, 2022, and no earlier than February 2, 2022. However, if the date of the 2022 annual meeting of stockholders is more than 30 days before or more than 60 days after the anniversary of the Annual Meeting, stockholders must provide the notice required by our Bylaws not earlier than the close of business on the 120<sup>th</sup> day before the 2022 annual meeting of stockholders and not later than the close of business on the later of (1) the 90<sup>th</sup> day prior to the 2022 annual meeting of stockholders and (2) the 10<sup>th</sup> day following the day on which public announcement of the date of the 2022 annual meeting of stockholders is first made.

- *Stockholder Nominations Under Proxy Access Bylaw.* In addition, our Bylaws provide that, under certain circumstances, a stockholder or group of stockholders may include director candidates that they have nominated in our annual meeting proxy statement. These proxy access provisions of our Bylaws provide, among other things, that a stockholder or group of up to 20 stockholders seeking to include director candidates in our annual meeting proxy statement must own 3% or more of our outstanding common stock continuously for at least the previous 3 years.

The number of stockholder-nominated candidates appearing in any annual meeting proxy statement can equal up to 25% of the number of directors then serving on our Board of Directors. If 25% is not a whole number, the maximum number of stockholder-nominated candidates would be the closest whole number below 25%, subject to a minimum of one. A nominee will be counted in determining whether the 25% maximum has been reached if the nominee was included in the proxy materials as a Board-nominated candidate, if we have received notice that such nominee has been nominated by a stockholder pursuant to our Bylaws, the nominee was submitted under the proxy access procedures and later withdrawn or the nominee was nominated in any of our three preceding annual meetings and is being recommended by our Board of Directors for reelection.

The nominating stockholder or group of stockholders also must deliver the information required by our Bylaws,

## 2 Corporate Governance at Biogen (continued)

and each nominee must meet the qualifications required by our Bylaws.

Requests to include stockholder-nominated candidates in our proxy materials for next year's annual meeting must be received by our Secretary no earlier than November 24, 2021, and no later than December 24, 2021. However, if the 2022 annual meeting of stockholders is called for more than 30 days earlier or later than the anniversary of the Annual Meeting, requests to include stockholder-nominated candidates in our proxy materials for the 2022 annual meeting of stockholders must be received not later than (1) the 10<sup>th</sup> day after public announcement of the date of the 2022 annual meeting of stockholders or (2) the 60<sup>th</sup> day prior to the date we file our proxy statement in connection with the 2022 annual meeting of stockholders.

### Annual Elections and Majority Voting

Our directors are elected annually to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified. Our directors must be elected by a majority of votes cast in uncontested elections (meaning any election for which the number of directors nominated does not exceed the number of directors to be elected at such meeting), and by a plurality of votes cast in contested elections (meaning any election for which the number of directors nominated exceeds the number of directors to be elected at such meeting, regardless of whether such nominees were proposed by the Company or by stockholders). In addition, following their appointment or election by stockholders to our Board of Directors, directors must submit an irrevocable resignation that will be effective upon (1) the failure to receive the required number of votes for reelection at the next annual meeting of stockholders at which they face reelection and (2) acceptance of such resignation by our Board of Directors. If an incumbent director fails to receive the number of votes required for reelection, our Board of Directors (excluding the director in question) will, within 90 days after certification of the election results, decide whether to accept the director's resignation taking into account such factors as it deems relevant. Such factors may include the stated reasons why stockholders voted against such director's reelection, the qualifications of the director and whether accepting the resignation would cause us to fail to meet any applicable listing standards or would violate state law. Our Board of Directors will promptly disclose its decision in a filing with the SEC.

### Director Qualifications, Standards and Diversity

- **Board Composition.** Our Board of Directors is committed to ensuring that it is well-equipped to oversee the Company's business and effectively represent the interests of stockholders. Our Board of Directors regularly reviews its composition to ensure it includes directors with the experience, skills and diversity necessary for effective, independent Board oversight. Towards this end, our Board of Directors initiated a process to add new directors with capabilities that would be beneficial to the Company and stockholders. As a result of this process, we have nominated two new director candidates to stand for election at the Annual Meeting. Our Board of Directors will continue to seek to add new directors to our Board, focusing on skills, experience and diversity.
- **General Qualifications and Standards.** Our Corporate Governance Principles provide that directors should possess the highest personal and professional ethics and integrity, understand and be aligned with our core values and be committed to representing the long-term interests of our stockholders. Our directors must also be inquisitive and objective and have practical wisdom and mature judgment.
- **Diversity.** Our Board of Directors believes that diverse experience and personal diversity, including gender, national origin and ethnic and racial diversity, is a benefit to our Board of Directors as a whole and is key to representing the interests of stockholders effectively. In accordance with our Corporate Governance Principles, we endeavor to have a Board of Directors that collectively represents diverse experience at strategic and policy-making levels in business, government, education, healthcare, science and technology and the international arena, and collectively has knowledge and expertise in the functional areas of accounting and finance, risk management and compliance, strategic and business planning, corporate governance, human resources, marketing and commercial and research and development. Consistent with our Corporate Governance Principles, in selecting nominees to our Board of Directors, our Corporate Governance Committee considers the diversity of skills and experience that a potential nominee possesses and the extent to which such diversity would enhance the perspective, background, knowledge and experience of our Board of Directors as a whole.
- **Director Term and Resignation.** Our Board of Directors does not believe that arbitrary term limits on directors' service are appropriate, nor does it believe that directors should expect to be re-nominated. Our Corporate

## 2 Corporate Governance at Biogen (continued)

Governance Principles provide that directors should offer their resignation in the event of any significant change in personal circumstances, including a significant change in principal job responsibilities or any circumstances that may adversely affect their ability to effectively carry out their duties and responsibilities or in the case of a significant conflict of interest that cannot otherwise be resolved. Our directors are also expected to offer their resignation to our Board of Directors effective at the annual meeting of stockholders in the year of their 75<sup>th</sup> birthday.

- *Board and Committee Evaluations.* Regular evaluations are an important determinant for continued tenure, and, to that end, our Board of Directors and its committees perform a self-evaluation on an annual basis that is intended to determine whether our Board, its committees

and each member of our Board of Directors are functioning effectively, and to provide our Board with an opportunity to reflect upon and improve processes and effectiveness. Our Corporate Governance Committee oversees the evaluations and reports the results to our Board of Directors, which considers the results and ways in which Board processes and effectiveness may be enhanced.

- *Director Orientation and Continuing Education.* We provide orientation for new directors and provide directors with materials or briefing sessions on subjects that we believe will assist them in discharging their duties. We also make director education program information available to directors on a regular basis and encourage directors to attend director education programs and reimburse the costs of attending such programs.



# 3 Board of Directors

## Proposal 1 – Election of Directors

We are asking our stockholders to elect the 13 director nominees listed below to serve a one-year term extending until our 2022 annual meeting of stockholders and until their successors are duly elected and qualified, unless they resign or are removed:

Alexander J. Denner  
Caroline D. Dorsa  
Maria C. Freire  
William A. Hawkins  
William D. Jones

Nancy L. Leaming  
Jesus B. Mantas  
Richard C. Mulligan  
Stelios Papadopoulos

Brian S. Posner  
Eric K. Rowinsky  
Stephen A. Sherwin  
Michel Vounatsos

Our Board of Directors has nominated these 13 individuals based on its carefully considered judgment that the experience, qualifications, attributes and skills of our nominees qualify them to serve on our Board of Directors. As described in detail below, our nominees have considerable professional and business expertise. We know of no reason why any nominee would be unable to accept nomination or election.

If any nominee is unable to serve on our Board of Directors, the shares represented by your proxy will be voted for the election of such other person as may be nominated by our Board of Directors. In addition, in compliance with all applicable state and federal laws and regulations, we will file an amended proxy statement and proxy card that, as applicable, (1) identifies the alternate nominee(s), (2) discloses that such nominees have consented to being named in the revised proxy statement and to serve if elected and (3) includes the disclosure required by Item 7 of Schedule 14A with respect to such nominees. All nominees have consented to be named in this Proxy Statement and to serve if elected.

### Director Skills and Qualifications

The Corporate Governance Committee believes that the 13 director nominees collectively have the skills, experience, diversity and character to execute the Board's responsibilities. The following is a summary of those qualifications:

	Alexander J. Denner	Caroline D. Dorsa	Maria C. Freire	William A. Hawkins	William D. Jones	Nancy L. Leaming	Jesus B. Mantas	Richard C. Mulligan	Stelios Papadopoulos	Brian S. Posner	Eric K. Rowinsky	Stephen A. Sherwin	Michel Vounatsos
<b>Attributes, Experience and Skills</b>													
General Management Experience	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Financial Experience	✓	✓	✓	✓	✓	✓	✓		✓	✓		✓	✓
Audit Committee Financial Expertise	✓	✓	✓	✓		✓				✓		✓	✓
Mergers & Acquisitions Experience	✓	✓		✓	✓	✓	✓		✓	✓	✓	✓	✓
Scientific Research Experience	✓		✓				✓	✓	✓		✓	✓	
Drug Development Experience	✓		✓					✓	✓		✓	✓	✓
Commercial Experience	✓	✓		✓	✓	✓	✓	✓	✓				✓
International Business Experience		✓	✓	✓			✓						✓
Public Policy Experience		✓	✓	✓	✓	✓	✓					✓	✓
Operations Experience	✓	✓		✓	✓	✓	✓	✓		✓	✓	✓	✓
Environmental, Social, Governance (ESG) Experience	✓		✓	✓	✓		✓		✓	✓	✓	✓	✓
Diversity		✓	✓		✓	✓	✓						
Other Public Company Board Service	✓	✓	✓	✓	✓	✓		✓	✓	✓	✓	✓	✓



# 3 Board of Directors (continued)

## Our Nominees for Director

(Information is as of April 9, 2021)

### Alexander J. Denner, Ph.D.



**Director Since:** 2009  
**Age:** 51  
**Biogen Board Committee:**  
– Corporate Governance (Chair)

#### Experience

Dr. Denner is a founding partner and Chief Investment Officer of Sarissa Capital Management LP, a registered investment advisor, which he founded in 2012. Sarissa Capital focuses on improving the strategies of companies to enhance stockholder value. From 2006 to 2011 Dr. Denner served as a Senior Managing Director at Icahn Capital L.P. Prior to that, he served as a portfolio manager at Viking Global Investors, a private investment fund, and Morgan Stanley Investment Management, a global asset management firm. Dr. Denner also serves as Chairman and CEO of Sarissa Capital Acquisition Corp, a special purpose acquisition company, and as a director of Ironwood Pharmaceuticals, Inc., a healthcare company.

#### Qualifications

Dr. Denner has significant experience overseeing the operations and research and development of healthcare companies and evaluating corporate governance matters. He also has extensive experience as an investor, particularly with respect to healthcare companies, and possesses broad healthcare industry knowledge.

#### Other Current Public Company Boards

- Ironwood Pharmaceuticals, Inc.
- Sarissa Capital Acquisition Corp. (Chair)

#### Former Public Company Directorships Held in the Past Five Years

- Ariad Pharmaceuticals, Inc. (Chair)
- Bioverativ Inc.
- The Medicines Company (Chair)

### Caroline D. Dorsa



**Director Since:** 2010  
**Age:** 61  
**Biogen Board Committee:**  
– Audit (Chair)

#### Experience

Ms. Dorsa served as the Executive Vice President and Chief Financial Officer of Public Service Enterprise Group Incorporated, a diversified energy company, from April 2009 until her retirement in October 2015, and served on its Board of Directors from February 2003 to April 2009. From February 2008 to April 2009 she served as Senior Vice President, Global Human Health, Strategy and Integration at Merck & Co., Inc., a pharmaceutical company. From November 2007 to January 2008 Ms. Dorsa served as Senior Vice President and Chief Financial Officer of Gilead Sciences, Inc., a life sciences company. From February 2007 to November 2007 she served as Senior Vice President and Chief Financial Officer of Avaya, Inc., a telecommunications company. From 1987 to January 2007 Ms. Dorsa held various financial and operational positions at Merck & Co., Inc., including Vice President and Treasurer, Executive Director of U.S. Customer Marketing and Executive Director of U.S. Pricing and Strategic Planning. Ms. Dorsa also serves as a director of Illumina, Inc., a life sciences company, and Intellia Therapeutics, Inc., a biotechnology company.

#### Qualifications

Ms. Dorsa has significant financial and accounting expertise and a deep knowledge of the pharmaceutical industry. Her strategic perspective on the industry is particularly valuable to our Board of Directors as it oversees our growth initiatives and reviews both internal development projects and external opportunities.

#### Other Current Public Company Boards\*

- Illumina, Inc.
- Intellia Therapeutics, Inc.

#### Former Public Company Directorships Held in the Past Five Years

- Goldman Sachs Investment Funds

\* Ms. Dorsa is standing for election to the Board of Directors of Duke Energy Corporation, an electric power holding company, at its 2021 annual meeting of stockholders to be held on May 6, 2021.



# 3 Board of Directors (continued)

## Maria C. Freire, Ph.D.



**Director Since:** New Nominee  
**Age:** 66  
**Biogen Board Committee:**  
 – New Nominee

### Experience

Since November 2012 Dr. Freire has served as President and Executive Director and as a member of the board of directors of the Foundation for the National Institutes of Health. From March 2008 to November 2012 she served as President and as a member of the board of directors of the Albert and Mary Lasker Foundation. Prior to joining the Lasker Foundation, Dr. Freire served as President and Chief Executive Officer of the Global Alliance for TB Drug Development from 2001 to 2008 and Director of the Office of Technology Transfer at the National Institutes of Health from 1995 to 2001. Dr. Freire also serves as a director of Alexandria Real Estate Equities, Inc., a publicly held urban office real estate investment trust uniquely focused on collaborative life science and technology campuses, and Exelixis, Inc., a drug discovery and development company. She has served on the boards of numerous national and international organizations, including the Science Board of the U.S. Food and Drug Administration, the World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health and the United Nations Secretary General's High Level Panel on Access to Medicines. Dr. Freire is also a member of the National Academy of Medicine and the Council on Foreign Relations, and she is the recipient of numerous awards, including a 2017 Gold Stevie Award for "Woman of the Year," the U.S. Department of Health and Human Services Secretary's Award for Distinguished Service, the Arthur S. Fleming Award and the Bayh-Dole Award. Dr. Freire holds a Ph.D. in Biophysics from the University of Virginia and a B.S. from the Universidad Peruana Cayetano Heredia in Lima, Peru.

### Qualifications

Dr. Freire has significant knowledge and experience with respect to medical research, the pharmaceutical industry and government healthcare policymaking. Dr. Freire's strong public policy and government experience also provides vital insights to our Board of Directors about significant issues affecting the highly regulated life sciences industry.

### Other Current Public Company Boards

- Alexandria Real Estate Equities, Inc.
- Exelixis, Inc.

### Former Public Company Directorships Held in the Past Five Years

- None

## William A. Hawkins



**Director Since:** 2019  
**Age:** 67  
**Biogen Board Committee:**  
 – Audit

### Experience

Mr. Hawkins serves as a Senior Advisor to EW Healthcare Partners, a life sciences private equity firm. Mr. Hawkins is the former Chairman and CEO of Medtronic, Inc., a global leader in medical technology. He was at Medtronic from 2002 until 2011. After retiring from Medtronic he served as President and Chief Executive Officer of Immucor, a private equity backed global leader in transfusion and transplant medicine from October 2011 to July 2015. From 1998 to 2001 Mr. Hawkins served as President and Chief Executive Officer of Novoste Corporation, an interventional cardiology company. Prior to that, Mr. Hawkins served in a variety of senior roles at American Home Products, a consumer, pharma and medical device company, Johnson & Johnson, a healthcare company, Guidant Corporation, a medical products company, and Eli Lilly and Company, a global pharmaceutical company. Mr. Hawkins also serves as Chairman of Bioventus Inc., a global medical device company, and as a director of Avanos Medical, Inc., a medical technology company, MiMedx Group, Inc., a biopharmaceutical company, and Virtue Labs, Cerius, Cetrec Medical Corp. and Baebies, Inc., all of which are medical products companies. Mr. Hawkins is Vice Chair of the Duke University Board of Trustees and is Chair of the Duke University Health System. Mr. Hawkins was elected as a member of the AIMBE College of Fellows and the National Academy of Engineering. He has a dual degree in Electrical and Biomedical Engineering from Duke University and a M.B.A. from the University of Virginia's Darden School of Business.

### Qualifications

Mr. Hawkins has significant leadership experience as a chief executive officer, significant knowledge of, and experience in, the healthcare industry and significant international experience. He also has extensive governance and public company board experience.

### Other Current Public Company Boards

- Avanos Medical, Inc.\*
- Bioventus Inc. (Chair).
- MiMedx Group, Inc.

### Former Public Company Directorships Held in the Past Five Years

- Thoratec Corporation

\* Mr. Hawkins has notified Avanos Medical, Inc. of his decision to not stand for re-election and to resign from the Board of Directors of Avanos Medical, Inc., effective April 29, 2021.



## 3 Board of Directors (continued)

### William D. Jones



**Director Since:** New Nominee  
**Age:** 65  
**Biogen Board Committee:**  
– New Nominee

#### Experience

Mr. Jones has been the President and Chief Executive Officer and a director of CityLink Investment Corporation, a commercial real estate investment and development services firm, since 1994. From 2001 through 2018 Mr. Jones was the President, Chief Executive Officer and a director of City Scene Management Company, a real estate management company. From 1989 to 1993 Mr. Jones served as General Manager/Senior Asset Manager and Investment Manager with certain real estate subsidiaries of The Prudential. Previously, he served as a San Diego City Council member and as Deputy Mayor of San Diego. Mr. Jones is the Lead Independent Director and Corporate Governance Chair for Sempra Energy, an energy infrastructure company. Mr. Jones is a director and, in some cases, Board Chair of certain funds under management by the Capital Group and Capital Group Private Client Services. He is an NACD Board Leadership Fellow. Mr. Jones is a trustee of the University of California San Diego Foundation and its Investment Committee and the Real Estate Advisory Council. Mr. Jones is a former director of The Price Real Estate Investment Trust, Southwest Water Company, the Federal Reserve Bank of San Francisco and the San Diego Padres baseball team and is a former Chairman of the Board of the Los Angeles Branch of the Federal Reserve Bank of San Francisco, the former Chairman of the Board of Trustees of the Francis Parker School and former Board Trustee of the University of San Diego. Mr. Jones has extensive experience as a real estate developer in San Diego, where he built the City Heights Urban Village, an award-winning redevelopment project.

#### Qualifications

Mr. Jones' extensive leadership experience in business, not-for profit boards and government provides vital insights to our Board of Directors about governance and significant issues affecting the highly regulated life sciences industry. He brings financial, corporate governance and public policy sector expertise to our Board of Directors.

#### Other Current Public Company Boards

– Sempra Energy (Lead Independent Director)

#### Former Public Company Directorships Held in the Past Five Years

– None

### Nancy L. Leaming



**Director Since:** 2008  
**Age:** 73  
**Biogen Board Committee:**  
– Audit

#### Experience

Ms. Leaming is an independent consultant and, prior to that, she served as the Chief Executive Officer and President of Tufts Health Plan, a provider of healthcare insurance. Ms. Leaming also served in several executive positions at Tufts Health Plan, including President, Chief Operating Officer and Chief Financial Officer.

#### Qualifications

Ms. Leaming has well-developed leadership skills and financial acumen and provides insights into the healthcare reimbursement and payor market, where she served for 20 years in senior operational, financial and managerial roles.

#### Other Current Public Company Boards

– None

#### Former Public Company Directorships Held in the Past Five Years

– Edgewater Technology, Inc.  
– Hologic, Inc.



## 3 Board of Directors (continued)

### Jesus B. Mantas



**Director Since:** 2019  
**Age:** 52  
**Biogen Board Committee:**  
– Corporate Governance

#### Experience

Mr. Mantas serves as the Senior Managing Partner responsible for worldwide strategy, innovation and corporate development for IBM Global Services, a \$17 billion unit of IBM. He is responsible for the global portfolio of offerings, acquisitions, strategic alliances and ventures globally and IBM Institute of Business Value, the thought leadership arm of IBM. Mr. Mantas is a member of the IBM Executive Performance Team, IBM Executive Technology Team and IBM Chairman Acceleration Team and is the co-chair of the IBM Hispanic Diversity Council. He serves in the Global AI Council of the World Economic Forum and on the board of HITEC, a non-profit organization focused on developing and advancing the careers of Hispanic executives in the Technology Industry. From 2002 through 2016 Mr. Mantas led IBM's Business Consulting unit, one of the largest consulting organizations in the world. Prior roles included leading IBM Global Process Services and the Business Services unit in Latin America after he held multiple leadership positions as Vice President in North America. Before joining IBM, Mr. Mantas was a Partner in PricewaterhouseCoopers Consulting, an adjunct professor at University of California Irvine – Graduate School of Management and an officer in the Air Force of Spain.

#### Qualifications

Mr. Mantas has significant global operating, business and technology leadership experience across Europe, North America and Latin America. He has demonstrated leadership designing new strategies and translating them into execution, applying technology to improve business performance, advocating for diversity and developing talent in multi-cultural environments. He brings over 30 years of experience in information technology, data science and artificial intelligence.

#### Other Current Public Company Boards

– None

#### Former Public Company Directorships Held in the Past Five Years

– None

### Richard C. Mulligan, Ph.D.



**Director Since:** 2009  
**Age:** 66  
**Biogen Board Committee:**  
– Compensation and Management Development

#### Experience

Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative from 1996 to 2013. He also currently serves as the Head of SanaX, the research arm of Sana Biotechnology, Inc. (Sana), a biotechnology company, and Executive Vice Chairman of the Board of Sana. From March 2017 to October 2018 Dr. Mulligan served as a Portfolio Manager at Icahn Capital LP. Prior to that, Dr. Mulligan was a founding partner of Sarissa Capital Management LP, a registered investment advisor, from 2013 to 2016. Prior to Harvard, Dr. Mulligan was a Professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and the Chief Scientific Officer of Somatix Therapy Corporation, a drug discovery and development company that he founded. Dr. Mulligan was named a MacArthur Foundation Fellow in 1981.

#### Qualifications

Dr. Mulligan has scientific expertise in the areas of molecular biology, genetics, gene therapy and biotechnology as well as extensive experience within the healthcare industry, including overseeing the operations and research and development of healthcare companies.

#### Other Current Public Company Boards

– Sana Biotechnology, Inc. (Executive Vice Chairman)

#### Former Public Company Directorships Held in the Past Five Years

– None



## 3 Board of Directors (continued)

### Stelios Papadopoulos, Ph.D.



**Director Since:** 2008  
**Independent Chairman Since:** 2014  
**Age:** 72  
**Biogen Board Committee:**  
– Corporate Governance

#### Experience

Dr. Papadopoulos serves as the Chairman of Exelixis, Inc., a drug discovery and development company that he co-founded in 1994, Regulus Therapeutics Inc., a biopharmaceutical company, and Eucrates Biomedical Acquisition Corp., a special purpose acquisition company. Previously, he was an investment banker with Cowen & Co., LLC, a financial services company, focusing on the biotechnology and pharmaceutical sectors, from 2000 until his retirement as Vice Chairman in August 2006. Prior to joining Cowen & Co., Dr. Papadopoulos served for 13 years as an investment banker at PaineWebber, Inc., a financial services company, where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology.

#### Qualifications

Having founded multiple life sciences companies and worked as an investment banker focused on the life sciences industry, Dr. Papadopoulos brings to our Board of Directors a first-hand understanding of the demands of establishing, growing and running life sciences businesses.

#### Other Current Public Company Boards

- Eucrates Biomedical Acquisition Corp. (Chair)
- Exelixis, Inc. (Chair)
- Regulus Therapeutics Inc. (Chair)

#### Former Public Company Directorships Held in the Past Five Years

- BG Medicine, Inc.

### Brian S. Posner



**Director Since:** 2008  
**Age:** 59  
**Biogen Board Committee:**  
– Compensation and Management Development

#### Experience

Mr. Posner has been a private investor since March 2008 and is the founder and Managing Partner of Point Rider Group LLC, a boutique consulting and advisory services firm that provides customized solutions to senior executives and boards of financial, bio-pharmaceutical and other services-related companies as well as strategic investors that make direct and control investments in those sectors. From 2005 to March 2008 Mr. Posner served as the President, Chief Executive Officer and co-Chief Investment Officer of ClearBridge Advisors LLC, an asset management company. Prior to that, Mr. Posner co-founded Hygrove Partners LLC, a private investment fund, in 2000 and served as its Managing Partner for five years. He served as a portfolio manager and an analyst at Fidelity Investments, a financial services company, from 1987 to 1996 and, from 1997 to 1999, at Warburg Pincus Asset Management/Credit Suisse Asset Management where he also served as co-Chief Investment Officer and Director of Research. Mr. Posner also serves as the Chairman of AQR Funds, an investment fund, and as a director of Arch Capital Group Ltd., a specialty insurance and reinsurance provider.

#### Qualifications

With more than 30 years of experience as a senior corporate executive, leading investment professional and director on public company and not-for-profit boards, Mr. Posner brings significant management and financial expertise, a professional investor's perspective and extensive experience in areas of corporate governance to our Board of Directors.

#### Other Current Public Company Boards

- AQR Funds (Chair)
- Arch Capital Group Ltd.


#### Former Public Company Directorships Held in the Past Five Years

- Bioverativ Inc. (Chair)



## 3 Board of Directors (continued)

### Eric K. Rowinsky, M.D.



**Director Since:** 2010  
**Age:** 64  
**Biogen Board Committee:**  
 – Corporate Governance

#### Experience

Dr. Rowinsky has served as President of RGenix, Inc., a privately-held life sciences company, since November 2015 and as its Executive Chairman since December 2016. Since June 2016 he has also been the Chief Scientific Officer of Clearpath Development Co., which rapidly advances development stage therapeutic assets to pre-defined human proof-of-concept milestones. From January 2012 to November 2015 he was the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells, and has been an independent consultant since January 2010. Prior to that, he was the Chief Executive Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009 he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, a life sciences company. From 1996 to 2004 he held several positions at the Cancer Therapy & Research Center's Institute for Drug Development, including Director of the Institute and Director of Clinical Research. During that time, he held the SBC Endowed Chair for Early Drug Development and Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996 he was an Associate Professor of Oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital. He also serves as a director of Fortress Biotech Inc., Purple Biotech Ltd. (f/k/a Kitov Pharma Ltd.) and Verastem, Inc., which are biopharmaceutical companies.

#### Qualifications

Dr. Rowinsky has extensive research and drug development experience and broad scientific and medical knowledge.

#### Other Current Public Company Boards

- Fortress Biotech Inc.
- Purple Biotech Ltd. (f/k/a Kitov Pharma Ltd.)
- Verastem, Inc.

#### Former Public Company Directorships Held in the Past Five Years

- BIND Therapeutics, Inc.
- Biophytis S.A.
- Navidea Biopharmaceuticals, Inc.

### Stephen A. Sherwin, M.D.



**Director Since:** 2010  
**Age:** 72  
**Biogen Board Committee:**  
 – Audit

#### Experience

Dr. Sherwin currently divides his time between advisory work in the life sciences industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. Dr. Sherwin also currently serves as a venture partner with Third Rock Ventures, LLC. He previously served as the Chairman of Ceregene, Inc., a life sciences company that he co-founded, from 2001 until its acquisition by Sangamo Biosciences, Inc. in 2013. He was also a co-founder and chairman of Abgenix, Inc., an antibody company which was acquired by Amgen Inc. in 2006. From 1990 to October 2009 he served as the Chief Executive Officer of Cell Genesys, Inc., a life sciences company, and was its Chairman from 1994 until the company's merger with BioSante Pharmaceuticals, Inc. (now ANI Pharmaceuticals, Inc.) in October 2009. Prior to that, he held various positions at Genentech, Inc., a life sciences company, most recently as Vice President, Clinical Research. In addition, Dr. Sherwin previously served on the board of directors of the Biotechnology Industry Organization from 2001 to 2014 and as its chairman from 2009 to 2011. Dr. Sherwin currently serves as a director of Neurocrine Biosciences, Inc., a life sciences company.

#### Qualifications

Dr. Sherwin has extensive knowledge of the life sciences industry and brings more than 30 years of experience in senior leadership positions at large and small publicly traded life sciences companies to our Board of Directors.

#### Other Current Public Company Boards

- Neurocrine Biosciences, Inc.

#### Former Public Company Directorships Held in the Past Five Years

- Aduro Biotech, Inc.
- Neon Therapeutics, Inc.



## 3 Board of Directors (continued)

### Michel Vounatsos



**Director Since:** 2017

**Age:** 59

**Biogen Board Committee:**

– None

#### Experience

Mr. Vounatsos has served as our Chief Executive Officer and one of our directors since January 2017. Prior to that, from April 2016 to December 2016, Mr. Vounatsos served as our Executive Vice President, Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck & Co., Inc., a pharmaceutical company, where he most recently served as President, Primary Care, Customer Business Line and Merck Customer Centricity. In this role, he led Merck's global primary care business unit, a role which encompassed Merck's cardiology-metabolic, general medicine, women's health and biosimilars groups and developed and instituted a strategic framework for enhancing the company's relationships with key constituents, including the most significant providers, payers and retailers and the world's largest governments.

Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company. Mr. Vounatsos currently serves as a director of PerkinElmer, Inc., a global scientific technology and life science research company, on the advisory board of Tsinghua University School of Pharmaceutical Sciences, on the Supervisory Board of Liryc, the Electrophysiology and Heart Modeling Institute at the University of Bordeaux, on the board of directors of N-Lorem Foundation and as a member of the MIT Presidential CEO Advisory Board.

Mr. Vounatsos received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.

#### Qualifications

Mr. Vounatsos has significant knowledge and experience with respect to the biotechnology, healthcare and pharmaceutical industries, a comprehensive global leadership background resulting from service as an executive in the pharmaceutical industry and studied medicine and business as part of his educational background.

#### Other Current Public Company Boards

– PerkinElmer, Inc.

#### Former Public Company Directorships Held in the Past Five Years

– None

**OUR BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE FOR THE ELECTION OF EACH DIRECTOR NOMINEE NAMED ABOVE.**

# 3 Board of Directors (continued)

## Committees and Meetings

Our Board of Directors met 21 times in 2020. Our Board of Directors also has three standing committees. The principal functions of each committee, the committee composition in 2020 and the number of meetings held in 2020 are described in the table below. The Chair of each committee periodically reports to our Board of Directors on committee deliberations and decisions. The charter of each of our committees is posted on our website, [www.biogen.com](http://www.biogen.com), under the “Corporate Governance” subsection of the “Investors” section of the website. Also posted there are our Corporate Governance Principles, which, together with our committee charters, comprise our governance framework.

Committee	Function	2020 Members	Meetings in 2020
Audit	<p>Assists our Board of Directors in its oversight of:</p> <ul style="list-style-type: none"> <li>the integrity of our financial statements;</li> <li>our accounting and financial reporting processes;</li> <li>the independence, qualifications and performance of our independent registered public accounting firm;</li> <li>our global tax compliance and tax audit processes;</li> <li>our internal audit and corporate compliance functions;</li> <li>our financial strategy, policies and practices;</li> <li>management’s exercise of its responsibility to assess and manage risks associated with our business and operations; and</li> <li>the adequacy and effectiveness of the Company’s insurance programs.</li> </ul> <p>Our Audit Committee has the sole authority and direct responsibility for the appointment, compensation, retention, evaluation and oversight of the work of our independent registered public accounting firm.</p>	<p>Caroline D. Dorsa† (Chair)                      William A. Hawkins†                      Nancy L. Leaming†                      Stephen A. Sherwin†</p>	11
Compensation and Management Development	<p>Assists our Board of Directors with oversight of executive compensation and management development, including:</p> <ul style="list-style-type: none"> <li>recommending to our Board of Directors the compensation for our Chief Executive Officer and approving the compensation for our other executive officers;</li> <li>administration of our short- and long-term incentive plans;</li> <li>reviewing executive and senior management development programs; and</li> <li>recommending to our Board of Directors the compensation of our non-employee directors.</li> </ul>	<p>Robert W. Pangia (Chair)                      Richard C. Mulligan                      Brian S. Posner                      Lynn Schenk*</p>	8
Corporate Governance	<p>Assists our Board of Directors in assuring sound corporate governance practices and identifying qualified nominees to our Board of Directors and its committees.</p>	<p>Alexander J. Denner (Chair)                      Jesus B. Mantas                      Stelios Papadopoulos                      Eric K. Rowinsky</p>	5

† Determined by our Board of Directors to be an audit committee financial expert.

\* Ms. Schenk retired from our Board of Directors, effective as of June 3, 2020.

- **Attendance at Board and Committee Meetings.** No director attended fewer than 75% of the total number of meetings of our Board of Directors and the committees on which he or she served during 2020.
- **Executive Sessions.** Under our Corporate Governance Principles, the independent directors of our full Board of Directors are required to meet without management present at least four times each year and may also meet without management present at such other times as determined by our Chairman or if requested by at least two other directors. In 2020 the independent directors of our full Board of Directors met without management present six times. Each committee of our Board of Directors also had numerous executive sessions throughout the year.
- **Attendance at Stockholder Meeting.** We expect all of our directors and director nominees to attend our annual meetings of stockholders. All of our directors attended our 2020 annual meeting of stockholders.



# 3 Board of Directors (continued)

## Director Compensation

This section describes our compensation program for our non-employee directors and shows the compensation paid to or earned by our non-employee directors during 2020. Mr. Vounatsos, our Chief Executive Officer, receives no compensation for his service on our Board of Directors.

### 2020 Changes to Director Compensation

Our C&MD Committee, working with Pearl Meyer & Partners LLC (Pearl Meyer), our C&MD Committee's independent compensation consultant, reviews the structure and philosophy of our non-employee director compensation program annually and uses the same peer group companies that are used in assessing compensation for our executive officers when reviewing and evaluating the competitiveness of a non-employee director compensation.

In September 2019 our Board of Directors, upon the recommendation of our C&MD Committee, approved changes to the compensation paid to non-employee directors, effective January 1, 2020. In order to align the director compensation elements with our peers, our Board eliminated meeting fees as an element of non-employee director compensation and increased annual retainers for members of our Board and its committees. Our Board believes that Board service extends beyond meeting attendance and that these changes are appropriate given structural changes to director pay that were observed in the market and the pay levels that were indicated by the market data. Our C&MD Committee believes that the structure of our non-employee director compensation program, including its mix of cash and equity compensation after giving effect to these changes, is consistent with market practice and better aligns the long-term financial interests of our non-employee directors with those of our stockholders.

### Retainers and Expenses

The following table presents the annual retainers for all non-employee members of our Board of Directors in effect in 2020:

Retainers	
Annual Board Retainer	\$125,000
Annual Retainers (in addition to Annual Board Retainer):	
Independent Chairman of the Board	\$ 75,000
Audit Committee Chair	\$ 30,000
Compensation and Management Development Committee Chair	\$ 30,000
Corporate Governance Committee Chair	\$ 30,000
Audit Committee Member (other than Chair)	\$ 15,000
Compensation and Management Development Committee Member (other than Chair)	\$ 15,000
Corporate Governance Committee Member (other than Chair)	\$ 15,000

Our non-employee directors are also eligible to be paid a fee of \$1,000 for each full day of service to the Company other than in connection with meetings of our Board of Directors or one of its committees.

Our non-employee directors may defer all or part of their cash compensation under our Voluntary Board of Directors Savings Plan, which is similar to our Supplemental Savings Plan described in the narrative preceding the "2020 Non-Qualified Deferred Compensation" table in Part 6 – Executive Compensation Matters of this Proxy Statement, but without any Company matching contributions. If a non-employee director chooses to defer compensation under our Voluntary Board of Directors Savings Plan, his or her notional account under the plan will periodically be credited with amounts of deemed investment earnings as if the deferred compensation was actually invested in the notional investment(s) selected by the director or in a default investment if the director does not make a selection. These notional investment options include the mutual funds available under our 401(k) plan as well as a fixed rate option which earns a rate of return determined each year by the Company's retirement committee. For 2020 non-employee director deferrals notionally invested in the fixed rate option, this rate of return was set at 5%. Deferrals notionally invested in the fixed rate option continue to be credited with the rate of return that was in effect during the year of deferral.



# 3 Board of Directors (continued)

Non-employee directors are also reimbursed for actual expenses incurred in attending meetings of our Board of Directors and any of its committees as well as service to our Board of Directors or any of its committees that is unrelated to such meetings.

## Equity Awards

### *Awards Under Our Non-Employee Directors Equity Plan*

Our non-employee directors receive awards under our 2006 Non-Employee Directors Equity Plan (the Non-Employee Directors Equity Plan). The Non-Employee Directors Equity Plan was initially approved by our stockholders at our 2006 annual meeting of stockholders. In 2015 our stockholders approved an amendment to extend the term of the plan until June 10, 2025.

### *General Provisions of the Non-Employee Directors Equity Plan*

Non-employee directors receive an annual award under the Non-Employee Directors Equity Plan effective on the date of each annual meeting of stockholders (or a pro rata award upon election other than at an annual meeting of stockholders). Under the Non-Employee Directors Equity Plan, a maximum of 17,500 shares of our common stock (or 30,000 shares for the independent Chairman of the Board) may be granted to a non-employee director pursuant to such annual awards each calendar year. Annual awards vest on the one-year anniversary of the date of grant or over a longer period determined at the discretion of our Board of Directors.

Awards to non-employee directors are recommended by our C&MD Committee and approved by our Board of Directors, with the independent Chairman recused from discussion and voting upon his own awards.

Awards granted under the Non-Employee Directors Equity Plan are subject to accelerated vesting upon termination of a director's service by reason of death, disability or retirement and upon a change in control (as such terms are defined in the Non-Employee Directors Equity Plan). In addition, non-employee director awards will become fully vested upon an involuntary termination of a director's service within two years following certain mergers or other corporate transactions, as described in the Non-Employee Directors Equity Plan.

### *Awards During 2020*

In June 2020 our C&MD Committee recommended, and our Board of Directors approved, annual awards with a grant date fair value of approximately \$270,000 for each non-employee director and an additional annual award with a grant date fair value of approximately \$175,000 for the independent Chairman. These annual awards were below the limits set forth in the Non-Employee Directors Equity Plan described above and were consistent with the awards made in 2019. The June 2020 annual awards were made in the form of restricted stock units (RSUs) that vest in full on the first anniversary of the grant date, generally subject to the director's continued service.

## 10b5-1 Trading Plans

Our non-employee directors must use pre-established trading plans to sell shares of our common stock from their personal accounts. A trading plan may only be entered into during an open trading window and when the applicable director is not in possession of material non-public information about the Company. We require a waiting period following the establishment of a trading plan before any trades may be executed. Our policy is designed to provide safeguards while allowing our non-employee directors to have an opportunity to realize the value intended by the Company in granting equity-based awards.

## Non-Employee Director Stock Ownership Guidelines

We maintain the following stock ownership guidelines for our non-employee directors:

Position	Stock Ownership Requirement <sup>(1)</sup>
Independent Chairman	Number of shares equal in value to 5x the total annual cash retainer for serving as (i) independent Chairman and (ii) as a non-employee Board member
Non-Employee Directors (excluding Chairman)	Number of shares equal in value to 5x the annual cash retainer for non-employee Board members

(1) Each non-employee director has five years from the date of initial election or appointment to meet the stock ownership requirement. All of our non-employee directors meet the stock ownership requirement or are still within the five-year period to meet such requirement.



# 3 Board of Directors (continued)

## 2020 Director Compensation

Name (a)	Fees Earned or Paid in Cash (b)	Stock Awards <sup>(1)</sup> (c)	Change in Pension Value and Nonqualified Deferred Compensation Earnings <sup>(2)</sup> (d)	All Other Compensation <sup>(3)</sup> (e)	Total (f)
Alexander J. Denner	\$ 155,000	\$269,314	—	\$15,000	\$439,314
Caroline D. Dorsa	\$ 155,000	\$269,314	—	—	\$424,314
William A. Hawkins	\$ 140,000	\$269,314	—	—	\$409,314
Nancy L. Leaming	\$ 140,000	\$269,314	—	\$28,500	\$437,814
Jesus B. Mantas	\$ 140,000	\$269,314	—	—	\$409,314
Richard C. Mulligan	\$ 140,000	\$269,314	—	—	\$409,314
Robert W. Pangia <sup>(4)</sup>	\$ 155,000	\$269,314	\$104,890	—	\$529,204
Stelios Papadopoulos	\$ 215,000	\$444,822	—	\$10,000	\$669,822
Brian S. Posner	\$ 140,000	\$269,314	—	\$25,000	\$434,314
Eric K. Rowinsky	\$ 140,000	\$269,314	—	—	\$409,314
Lynn Schenk <sup>(5)</sup>	\$ 70,000	—	—	\$25,000	\$ 95,000
Stephen A. Sherwin	\$ 140,000	\$269,314	—	—	\$409,314

### Notes to the 2020 Director Compensation Table

- (1) The amounts in column (c) represent the grant date fair value of RSU awards made in 2020 to non-employee directors under the Non-Employee Directors Equity Plan, as described in the narrative preceding this table. These RSUs are scheduled to vest in full and be settled in shares on the first anniversary of the grant date, generally subject to continued service. Grant date fair values were computed in accordance with Accounting Standards Codification (ASC) 718, excluding the effect of estimated forfeitures, and determined by multiplying the number of RSUs awarded by the fair market value of the Company's common stock on the relevant grant date.
- (2) The amounts in column (d) represent earnings under the Voluntary Board of Directors Savings Plan that are in excess of 120% of the average applicable federal long-term rate. The federal long-term rate for 2020 applied in this calculation is 1.61%, which was the federal long-term rate effective in January 2020 when the Fixed Rate Option (FRO) under this plan was established for 2020. Only Mr. Pangia had deferred compensation notionally invested in the FRO during 2020.
- (3) The amounts in column (e) represent the amount of matching contributions made in 2020 by the Biogen Foundation on behalf of the director pursuant to the terms of a matching gift program offered by the Biogen Foundation to all U.S. employees and non-employee directors of Biogen. Under the matching gift program, the Biogen Foundation matches gifts to eligible U.S.-based non-profit organizations, in accordance with the Biogen Foundation's guidelines, up to an annual maximum per donor amount of \$25,000 per calendar year and up to an aggregate program total of \$1.5 million per calendar year. The matching contributions made by the Biogen Foundation are not taxable income to the director, and the director may not take any tax deductions for such matching contributions. The amount for Ms. Leaming includes a matching gift contribution of \$3,500, which was made by the Biogen Foundation in 2020 for a gift made by Ms. Leaming in 2019.
- (4) Mr. Pangia is retiring from our Board of Directors, effective as of the Annual Meeting.
- (5) Ms. Schenk retired from our Board of Directors, effective as of June 3, 2020. In June 2020 the Company entered into a consulting agreement with Ms. Schenk after she retired from our Board of Directors. In 2020 Ms. Schenk earned \$70,000 under the consulting agreement.



# 3 Board of Directors (continued)

## Director Equity Outstanding at 2020 Fiscal Year-End

The following table summarizes the equity awards that were outstanding as of December 31, 2020, for each of the non-employee directors serving during 2020.

Name	Option Awards Number of Securities Underlying Unexercised Options	Stock Awards <sup>(1)</sup> Number of Shares or Units of Stock That Have Not Vested
Alexander J. Denner	—	890
Caroline D. Dorsa	—	890
William A. Hawkins	—	890
Nancy L. Leaming	—	890
Jesus B. Mantas	—	890
Richard C. Mulligan	—	890
Robert W. Pangia	—	890
Stelios Papadopoulos	—	1,470
Brian S. Posner	—	890
Eric K. Rowinsky	—	890
Lynn Schenk <sup>(2)</sup>	—	—
Stephen A. Sherwin	—	890

*Notes to the Director Equity Outstanding at 2020 Fiscal Year-End Table*

- (1) Represents the number of RSUs awarded to non-employee directors in 2020 under the Non-Employee Directors Equity Plan, as described in the narrative preceding the “2020 Director Compensation” table above. These RSU awards are scheduled to vest in full and be settled in shares on the first anniversary of the grant date, generally subject to continued service.
- (2) Ms. Schenk retired from our Board of Directors, effective as of June 3, 2020, and was not eligible for an award.

## Board Risk Oversight

Our Board of Directors believes that a fundamental part of risk management is understanding the risks that we face, monitoring these risks and adopting appropriate control and mitigation of these risks. As stated in our Corporate Governance Principles, our Board of Directors and its committees are responsible for “reviewing the Company’s risk framework and governance and management’s exercise of its responsibility to assess, monitor and manage the Company’s significant risk exposures.”

Our Board of Directors oversees the management of material risks facing the Company. Biogen is committed to fostering a company culture of risk-adjusted decision-making without constraining reasonable risk-taking and innovation. Our Board of Directors and its committees oversee our efforts to foster this culture. Our Board of Directors regularly receives information about our material strategic, operational, financial and compliance risks and management’s response to, and mitigation of, such risks. In addition, our risk management systems, including our risk assessment processes, internal control over financial reporting, compliance programs and internal and external auditing procedures, are designed to inform management and our Board of Directors about our material risks. As part of its risk oversight function, our Board of Directors and its committees review this framework, its operation and our strategies for generating long-term value for our stockholders to ensure that such strategies will not motivate management to take excessive risks.

Our Board of Directors also reviews enterprise risks and discusses them with our management, including issues relevant to our business, reputation and strategy, including intellectual property risk, pipeline and business development, pricing and patient access, legal and regulatory matters and manufacturing. In addition, our Board of Directors and its committees oversee elements of our culture. Management updates our C&MD Committee on our compensation practices and progress against strategies and objectives in the areas of management and leadership development and diversity as well as steps taken to address matters such as inappropriate workplace behavior, including harassment and retaliation. In addition, our Audit Committee is responsible for the oversight of our compliance program.



# 3 Board of Directors (continued)

In determining the allocation of risk oversight responsibilities, our Board of Directors and its committees generally oversee material risks within their identified areas of concern. Our Board of Directors and each of its committees meet regularly with management to ensure that management is exercising its responsibility to identify relevant risks and is adequately assessing, monitoring and taking appropriate action to mitigate risk. In the event a committee receives a report from members of management on areas of material risk to the Company, the Chair of the relevant committee reports on the discussion to the full Board of Directors at the next Board of Directors meeting. This enables our Board of Directors and its committees to coordinate their oversight of risk and identify risk interrelationships.

Our independent Chairman of the Board promotes effective communication and consideration of matters presenting significant risks to the Company through his role in developing our Board of Directors' meeting agendas, advising committee chairs, chairing meetings of the independent directors and facilitating communications between independent directors and our Chief Executive Officer.

A summary of the key areas of risk oversight responsibility of our Board of Directors and each of its committees is set forth below:

Board or Committee	Area of Risk Oversight
Board	<ul style="list-style-type: none"> <li>• Corporate and commercial strategy and execution, pricing and reimbursement, competition, reputational, environmental, health and sustainability and other material risks</li> <li>• Research and development activities, clinical development, drug safety and intellectual property</li> <li>• Material government and other investigations and litigation</li> <li>• Risk governance framework and infrastructure designed to identify, assess, manage and monitor the Company's material risks</li> <li>• Risk management policies, guidelines and practices implemented by Company management</li> </ul>
Audit	<ul style="list-style-type: none"> <li>• Financial, accounting, disclosure, corporate compliance, distributors, insurance, capital, credit, anti-bribery and anti-corruption matters and other risks reviewed in its oversight of the internal audit and corporate compliance functions</li> <li>• Information technology and cybersecurity risks</li> </ul>
Compensation and Management Development	<ul style="list-style-type: none"> <li>• Workforce matters, including harassment</li> <li>• Compensation policies and practices, including whether such policies and practices balance risk-taking and rewards in an appropriate manner as discussed further below</li> </ul>
Corporate Governance	<ul style="list-style-type: none"> <li>• Corporate governance and board succession, director independence, potential conflicts of interest and related party transactions involving directors and executive officers</li> </ul>

## Compensation Risk Assessment

The Compensation Discussion and Analysis (CD&A) section of this Proxy Statement describes our compensation policies, programs and practices for our named executive officers. Our goal-setting, performance assessment and compensation decision-making processes described in the CD&A generally apply to all employees. We offer a limited number of short-term cash incentive plans, with employees eligible for either our annual bonus plan or a sales incentive compensation plan. Except in limited circumstances, no employee is eligible to participate in more than one cash incentive plan at any time. Our annual bonus plan is consistently maintained for all participants globally, with the same Company performance goals, payout levels (as a percentage of target) and administrative provisions regardless of the participant's job level, location or function in the Company. We also have a long-term incentive program that provides different forms of awards depending upon an employee's level but is otherwise consistent throughout the Company.

In the CD&A, we describe the risk-mitigation controls for our executive compensation programs. These controls include C&MD Committee review and approval of the design, goals and payouts under our annual bonus plan and long-term incentive program and each executive officer's compensation (or, in the case of our Chief Executive Officer's compensation, a recommendation of that compensation to our Board of Directors for its approval). In addition, we review the processes, controls and design of our sales incentive compensation plans.



## 3 Board of Directors (continued)

---

The C&MD Committee, working with its independent compensation consultant, also conducts an annual assessment of potential risks related to our compensation policies, programs and practices. Among other factors, this risk assessment considers the form of compensation (i.e., award type, fixed versus variable and short-term versus long-term), pay alignment, performance measures and goals, payout maximums, vesting periods and C&MD Committee oversight and independence. This assessment is focused on (1) having an appropriate balance in our program structure to mitigate compensation-related risk with cash versus stock, short-term versus long-term measurement and financial versus non-financial goals; and (2) policies and practices to mitigate compensation-related risk including recoupment of compensation, stock ownership guidelines, equity administration rules and insider-trading and hedging prohibitions.

Based on our assessment, we believe that, through a combination of risk-mitigating features and incentives guided by relevant market practices and Company-wide goals, our compensation policies, programs and practices do not create risks that are reasonably likely to have a material adverse effect on the Company.



# 4 Stock Ownership

## STOCK OWNERSHIP

The following table and accompanying notes provide information about the beneficial ownership of our common stock by:

- each stockholder known by us to be the beneficial owner of more than 5% of our common stock;
- each of our named executive officers;
- each of our directors and nominees for director; and
- all of our directors and executive officers as a group.

Except as otherwise noted, the persons identified have sole voting and investment power with respect to the shares of our common stock beneficially owned. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting and investment power with respect to the shares. Except as otherwise noted, the information below is as of April 5, 2021 (Ownership Date).

Unless otherwise indicated in the footnotes, the address of each of the individuals named below is: c/o Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142.

Name	Shares Owned <sup>(1)</sup>	Shares Subject to Options and Stock Units <sup>(2)</sup>	Total Number of Shares Beneficially Owned <sup>(1)</sup>	Percentage of Outstanding Shares <sup>(3)</sup>
<b>5% Stockholders</b>				
PRIMECAP Management Company <sup>(4)</sup> 177 East Colorado Boulevard 11th Floor Pasadena, CA 91105	15,822,066	—	15,822,066	10.28%
BlackRock, Inc. <sup>(5)</sup> 55 East 52nd Street New York, NY 10055	13,419,601	—	13,419,601	8.7%
The Vanguard Group <sup>(6)</sup> 100 Vanguard Boulevard Malvern, PA 19355	11,896,510	—	11,896,510	7.73%
<b>Named Executive Officers</b>				
Michel Vounatsos	53,072	—	53,072	*
Michael R. McDonnell	—	—	—	—
Alfred W. Sandroek, Jr.	17,841	—	17,841	*
Susan H. Alexander	41,576	—	41,576	*
Chirfi Guindo	6,006	—	6,006	*
Jeffrey D. Capello <sup>(7)</sup>	3,118	—	3,118	*
<b>Directors</b>				
Alexander J. Denner <sup>(8)</sup>	655,064	890	655,954	*
Caroline D. Dorsa	20,207	890	21,097	*
Maria C. Freire	—	—	—	—
William A. Hawkins	1,115	890	2,045	*
William D. Jones	—	—	—	—
Nancy L. Leaming	12,098	890	12,988	*
Jesus B. Mantas	2,053	890	2,943	*
Richard C. Mulligan	12,064	890	12,954	*
Robert W. Pangia <sup>(9)</sup>	19,742	890	20,632	*
Stelios Papadopoulos <sup>(10)</sup>	33,301	1,470	34,771	*
Brian S. Posner	6,870	890	7,760	*
Eric K. Rowinsky	16,179	890	17,069	*
Stephen A. Sherwin	15,438	890	16,328	*
Executive officers and directors as a group (21 persons) <sup>(11)</sup>	926,695	10,370	937,065	*

\* Represents beneficial ownership of less than 1% of our outstanding shares of common stock.

## 4 Stock Ownership (continued)

- (1) The shares described as “owned” are shares of our common stock directly or indirectly owned by each listed person, rounded up to the nearest whole share.
- (2) Includes RSUs that will vest within 60 days of the Ownership Date.
- (3) The calculation of percentages is based upon 150,554,556 shares outstanding on the Ownership Date, plus for each of the individuals listed above the shares subject to RSUs exercisable within 60 days of the Ownership Date, as reflected in the column under the heading “Shares Subject to Options and Stock Units.”
- (4) Based solely on information as of December 31, 2020, contained in a Schedule 13G/A filed with the SEC by PRIMECAP Management Company on February 12, 2021, which also indicates that it has sole voting power over 15,443,182 shares and sole dispositive power over 15,822,066 shares.
- (5) Based solely on information as of December 31, 2020, contained in a Schedule 13G/A filed with the SEC by BlackRock, Inc. on January 29, 2021, which also indicates that it has sole voting power with respect to 11,672,922 shares and sole dispositive power with respect to 13,419,601 shares.
- (6) Based solely on information as of December 31, 2020, contained in a Schedule 13G/A filed with the SEC by The Vanguard Group on February 10, 2021, which also indicates that it has sole dispositive power with respect to 11,213,323 shares, shared voting power with respect to 259,934 shares and shared dispositive power with respect to 638,187 shares.
- (7) Mr. Capello ceased to be our Executive Vice President and Chief Financial Officer on August 15, 2020, and separated from the Company on September 15, 2020.
- (8) Includes 643,000 shares beneficially owned by funds and accounts managed by Sarissa Capital Management LP, a Delaware limited partnership (Sarissa Capital). Dr. Denner is the Chief Investment Officer of Sarissa Capital and ultimately controls the funds and accounts managed by Sarissa Capital. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the 643,000 shares that those entities beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.
- (9) Includes 16,000 shares beneficially owned by Robin Drive, LLC, of which Mr. Pangia's wife is the Trustee. Mr. Pangia is retiring from our Board of Directors, effective as of the Annual Meeting.
- (10) Includes 28,206 shares held in limited liability companies of which Dr. Papadopoulos is the sole manager.
- (11) Includes 688,175 shares held indirectly through trusts, funds, defined benefit plans or limited liability companies.



## 5 Audit Committee Matters

### Proposal 2 – Ratification of the Selection of Our Independent Registered Public Accounting Firm

Our Audit Committee is directly responsible for the appointment, compensation, retention and oversight of the independent registered public accounting firm retained to audit our consolidated financial statements. Our Audit Committee has selected PwC as our independent registered public accounting firm for the fiscal year ending December 31, 2021. PwC has served as our independent registered public accounting firm since 2003.

In order to assure continuing auditor independence, our Audit Committee periodically considers whether there should be a rotation of the independent registered public accounting firm. Further, in conjunction with the rotation of the auditing firm's lead engagement partner required by applicable SEC rules, our Audit Committee and its Chair has in the past been, and in the future will be, directly involved in the selection of PwC's new lead engagement partner.

Our Audit Committee believes at this time that the continued retention of PwC to serve as our independent registered public accounting firm is in the best interest of Biogen and its stockholders.

Although stockholder approval of our Audit Committee's selection of PwC is not required, our Board of Directors believes that it is a matter of good corporate practice to solicit stockholder ratification of this selection. If our stockholders do not ratify the selection of PwC as our independent registered public accounting firm, our Audit Committee will reconsider its selection. Even if the selection is ratified, our Audit Committee always has the ability to change the engagement of PwC if it considers that a change is in Biogen's best interest. Representatives of PwC will participate in the Annual Meeting, have the opportunity to make a statement if they so desire and be available to respond to appropriate questions.

**OUR BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE *FOR* THE RATIFICATION OF THE SELECTION OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2021.**

# 5 Audit Committee Matters (continued)

## Audit Committee Report

The Audit Committee's role is to act on behalf of our Board of Directors in the oversight of Biogen's financial reporting, internal control and audit functions. The roles and responsibilities of the Audit Committee are set forth in the written charter adopted by our Board of Directors, which is posted on our website, [www.biogen.com](http://www.biogen.com), under the "Corporate Governance" subsection of the "Investors" section of the website. Management has primary responsibility for the financial statements and the reporting process, including the systems of internal control.

In fulfilling its oversight responsibilities, the Audit Committee, among other things:

- reviewed and discussed with management the audited consolidated financial statements contained in Biogen's 2020 Annual Report on Form 10-K;
- discussed with PwC, Biogen's independent registered public accounting firm, the overall scope and plans for the audit;
- met with PwC, with and without management present, to discuss the results of its examination, management's response to any significant findings, its observations of Biogen's internal control, the overall quality of Biogen's financial reporting, the selection, application and disclosure of critical accounting policies, new accounting developments and accounting-related disclosures, the key accounting judgments and assumptions made in preparing the financial statements and whether the financial statements would have materially changed had different judgments and assumptions been made and other pertinent items related to Biogen's accounting, internal control and financial reporting;
- discussed with representatives of Biogen's corporate internal audit staff, with and without management present, their purpose, authority, audit plan and reports;

- reviewed and discussed with PwC the matters required by the Public Company Accounting Oversight Board and the SEC;
- discussed with PwC its independence from management and Biogen, including the written disclosures and letter concerning independence received from PwC under applicable requirements of the Public Company Accounting Oversight Board. The Audit Committee has determined that the provision of non-audit services to Biogen by PwC is compatible with its independence;
- provided oversight and advice to management in connection with Biogen's system of internal control over financial reporting in response to the requirements set forth in Section 404 of the Sarbanes-Oxley Act of 2002 and related regulations. In connection with this oversight, the Audit Committee reviewed a report by management on the effectiveness of Biogen's internal control over financial reporting; and
- reviewed PwC's Report of Independent Registered Public Accounting Firm included in Biogen's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, related to its audit of the effectiveness of internal control over financial reporting.

In reliance on these reviews and discussions, the Audit Committee recommended to our Board of Directors that the audited consolidated financial statements be included in Biogen's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, for filing with the SEC.

### The Audit Committee of our Board of Directors:

Caroline D. Dorsa (Chair)  
William A. Hawkins  
Nancy L. Leaming  
Stephen A. Sherwin, M.D.



# 5 Audit Committee Matters (continued)

## Audit and Other Fees

The following table shows fees for professional audit services billed to us by PwC for the audit of our annual consolidated financial statements for the years ended December 31, 2020 and December 31, 2019, and fees billed to us by PwC for other services provided during 2020 and 2019:

Fees (amounts in thousands)	2020	2019
Audit fees	\$5,882.0	\$6,080.3
Audit-related fees	48.2	55.0
Tax fees*	392.5	641.8
All other fees	9.9	7.0
<b>Total</b>	<b>\$6,332.6</b>	<b>\$6,784.1</b>

\* Includes tax compliance fees of approximately \$0.1 million in 2020 and 2019.

*Audit fees* are fees for the audit of our 2020 and 2019 consolidated financial statements included in our Annual

Reports on Form 10-K, reviews of our condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q, review of the consolidated financial statements incorporated by reference into our outstanding registration statements and statutory audit fees in overseas jurisdictions.

*Audit-related fees* are fees that principally relate to assurance and related services that are also performed by our independent registered public accounting firm. More specifically, these services include audits of employee benefit plan information, accounting consultations, due diligence and audits in connection with business development activity, internal control reviews and attest services related to financial reporting that are not required by statute or regulation.

*Tax fees* are fees for tax compliance and planning services.

*All other fees* in 2020 and 2019 also include license fees for a web-based accounting research tool.

## Policy on Pre-Approval of Audit and Non-Audit Services

Our Audit Committee has the sole authority to approve the scope of the audit and any audit-related services as well as all audit fees and terms. Our Audit Committee must pre-approve any audit and non-audit services provided by our independent registered public accounting firm. Our Audit Committee will not approve the engagement of the independent registered public accounting firm to perform any services that the independent registered public accounting firm would be prohibited from providing under applicable securities laws, Nasdaq requirements or Public Company Accounting Oversight Board rules. In assessing whether to approve the use of our independent registered public accounting firm to provide permitted non-audit services, our Audit Committee tries to minimize relationships that could appear to impair the objectivity of our independent registered public accounting firm. Our Audit Committee will approve permitted non-audit services by our independent registered public accounting firm only when it will be more effective or economical to have such services provided by our independent registered public accounting firm than by another firm.

Our Audit Committee annually reviews and pre-approves the audit, audit-related, tax and other permissible non-audit services that can be provided by the independent registered public accounting firm. After the annual review, any proposed services exceeding pre-set levels or amounts, or additional services not previously approved requires separate pre-approval by our Audit Committee or the Chair of our Audit Committee. Any pre-approval decision made by the Chair of our Audit Committee is reported to our Audit Committee at the next regularly scheduled Audit Committee meeting. Our Chief Financial Officer and our Chief Accounting Officer can approve up to an additional \$50,000 in the aggregate per calendar year for categories of services that our Audit Committee (or the Chair through its delegated authority) has pre-approved.

All of the services provided by PwC during 2020 and 2019 were pre-approved in accordance with this policy.



# 6 Executive Compensation Matters

## Proposal 3 – Advisory Vote on Executive Compensation

Our Compensation Discussion and Analysis, which appears below, describes our executive compensation programs and the compensation decisions that our C&MD Committee and our Board of Directors made with respect to the 2020 compensation of our named executive officers. As required pursuant to Section 14A of the Exchange Act, our Board of Directors is asking that stockholders cast a non-binding, advisory vote FOR the following resolution:

“RESOLVED, that the compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion, is hereby APPROVED.”

Our Board of Directors is asking that our stockholders support this proposal. Although the vote you are being asked to cast is non-binding, we value the views of our stockholders, and our C&MD Committee and our Board of Directors will consider the outcome of the vote when making future compensation decisions for our named executive officers.

As we describe in our Compensation Discussion and Analysis, our executive compensation programs embody a pay-for-performance philosophy that supports our business strategy and aligns the interests of our executives with those of our stockholders. In particular, our executive compensation programs reward financial, strategic and operational performance, and the goals set under our plans support our short- and long-range plans. In addition, to discourage excessive risk taking, we maintain policies for stock ownership, and our equity and annual bonus incentive plans have provisions providing for the recoupment of compensation. We also cap payments under our annual bonus plan, and we generally require multi-year vesting periods for long-term incentive awards.

We will hold a non-binding, advisory vote of our stockholders on the compensation of our named executive officers every year until the next required stockholder vote on the frequency of such advisory vote. The next stockholder vote on the frequency of such advisory vote is expected to be held at the 2023 annual meeting of stockholders.

**OUR BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE  
FOR THE APPROVAL OF THE RESOLUTION SET FORTH ABOVE.**



# 6 Executive Compensation Matters (continued)

## COMPENSATION DISCUSSION AND ANALYSIS

This Compensation Discussion and Analysis (CD&A) describes our compensation strategy, philosophy, policies and practices underlying our executive compensation programs for 2020. It also provides information regarding the compensation that was earned by and awarded to our 2020 named executive officers listed below, whom we refer to collectively as “named executive officers” or “NEOs.” Our named executive officers include our current executive officers listed below as well as Jeffrey D. Capello\*, our former Executive Vice President and Chief Financial Officer.



**Michel Vounatsos**  
Chief Executive Officer



**Susan H. Alexander**  
Executive Vice President,  
Chief Legal Officer and Secretary



**Michael R. McDonnell\***  
Executive Vice President and  
Chief Financial Officer



**Chirfi Guindo**  
Executive Vice President,  
Global Product Strategy and  
Commercialization



**Alfred W. Sandrock, Jr., M.D., Ph.D.\*\***  
Executive Vice President,  
Research and Development

\* Mr. McDonnell was appointed as Executive Vice President and Chief Financial Officer effective August 15, 2020. Mr. Capello ceased to be our Executive Vice President and Chief Financial Officer on August 15, 2020, and separated from the Company on September 15, 2020.

\*\* Dr. Sandrock was appointed as Executive Vice President, Research and Development on October 1, 2019. Prior to this appointment, Dr. Sandrock served as our Executive Vice President, Chief Medical Officer, and continued in this role, in addition to his duties as Executive Vice President, Research and Development, until January 27, 2020.

## Executive Summary

We had a productive and successful 2020 as we continued to execute well against our corporate strategy.

Our full year revenue for 2020 was \$13.4 billion, a 6% decrease from the prior year primarily due to the entry of multiple TECFIDERA generic entrants in the U.S. with deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA significantly reduced our TECFIDERA revenues during the year ended December 31, 2020, and is expected to have a substantial negative impact on our TECFIDERA revenues for as long as there is generic competition.

Excluding TECFIDERA in the U.S., our global MS revenue, including OCREVUS royalties, remained relatively stable for 2020, as compared to 2019, demonstrating the resilience of

our MS business in a competitive market. We continued our launch of VUMERITY in the U.S., which was the number two MS product and the number one oral in terms of new prescriptions in the U.S. as of December 31, 2020.

We maintained our leadership in our SMA business despite increased competition and delays in SPINRAZA doses due, directly or indirectly, to the COVID-19 pandemic. Although our full year 2020 SPINRAZA revenue decreased 2% as compared to 2019, we continued to see growth outside of the U.S., with full year 2020 revenue outside the U.S. growing 9% as compared to 2019, and we believe that SPINRAZA will remain a foundation of care in the treatment of SMA.



## 6 Executive Compensation Matters (continued)

Our full year 2020 biosimilars revenue increased 8% as compared to 2019. Although our biosimilars business was negatively impacted by pricing pressure and a slowdown in new treatments and reduced clinic capacity due to the COVID-19 pandemic, we were the leading anti-TNF biosimilar provider in Europe in 2020, and BENEPALI was the #1 prescribed etanercept product across Europe.

We also made significant progress toward building a multi-franchise portfolio, with 10 programs now in either Phase 3 or filed across a number of key therapeutic areas, including regulatory filings for aducanumab in the U.S., the E.U. and Japan. We added or advanced 12 clinical programs in Alzheimer's disease, MS, ALS, Parkinson's disease and other movement disorders, depression and biosimilars and had a strong year for business development, including multiple new strategic collaborations.

We provided value to our stockholders through the return of approximately \$6.7 billion in capital through share repurchases, and we continued our leading efforts in environmental, sustainability and diversity issues.

To help ensure the health and safety of our employees, we took several actions in response to the ongoing COVID-19 pandemic. In the U.S. and in most other key markets, our office-based employees began working from home in early March 2020, while we ensured essential staffing levels in our operations remained in place, including maintaining key personnel in our laboratories and manufacturing facilities. To provide a safe work environment for our employees, we have, among other things, increased our cleaning and sanitation routines on our campuses, implemented various social distancing measures on our campuses, created electronic health attestation forms, issued travel advisories to our employees consistent with government regulations and restricted participation of our employees in any events that have large gatherings.

We have also suspended the vast majority of our in-person interactions by our customer-facing professionals in healthcare settings and are engaging with these customers remotely as we seek to continue to support healthcare professionals and patient care.

Our C&MD Committee considered all of these achievements, and challenges, as they navigated compensation decisions not just for our executive officers but for all of our employees.

As described below, our C&MD Committee exercised its discretion and made adjustments to take into account items that were not originally contemplated, or whose magnitude or timing were uncertain, when the performance goals were originally established.

Our C&MD Committee believed these adjustments were appropriate because the items were beyond the control of management, were not contemplated and/or could not be quantified due to uncertainty regarding magnitude and timing when the Company performance goals were originally set. Our C&MD Committee also believed that these adjustments were necessary to appropriately motivate and reward employees for their performance during a challenging year in which we continued to perform well despite the challenges that we faced.

However, notwithstanding the attainment of our performance goals and the strength of management's performance, our C&MD Committee also believed it was important to hold the members of our Executive Committee, which includes all of our NEOs, accountable for the Company's overall financial results and business performance compared to the original performance goals. As a result, our C&MD Committee exercised its discretion and decreased the payouts under certain of our incentive compensation plans for the members of our Executive Committee, including all of our NEOs, as described below.

Our C&MD Committee believes that our executive compensation program for 2020 is consistent with our compensation philosophies and principles described below and demonstrates our commitment to linking compensation to Company performance and strategy during a challenging year.




# 6 Executive Compensation Matters (continued)

## 2020 Highlights

A brief summary of our 2020 business, financial and executive compensation highlights is as follows:

### Financial Performance

The following chart provides a summary of our financial performance for 2020 compared to 2019:



A reconciliation of our GAAP to Non-GAAP financial measures is provided in Appendix A to this Proxy Statement.

### Product and Pipeline Developments

The following provides a summary of our product and pipeline developments for 2020:

#### Applications for Marketing and Agency Actions

##### Aducanumab

- In July 2020 we completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab. In August 2020 the FDA accepted the BLA and granted Priority Review with a Prescription Drug User Fee Act (PDUFA) action date on March 7, 2021. In January 2021 the FDA extended the review period for the BLA for aducanumab by three months. The updated PDUFA action date is June 7, 2021.
- In October 2020 the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for aducanumab.
- In December 2020 the Ministry of Health, Labor and Welfare accepted for review the Japanese New Drug Application for aducanumab.

##### SB11 (referencing LUCENTIS)

- In October 2020 the EMA accepted for review the MAA for SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and in November 2020 the FDA accepted the BLA for SB11. Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular disorders, which are a leading cause of blindness.

##### MS

- In March 2020 we made a regulatory submission to the EMA for a subcutaneous (SC) formulation of TYSABRI (natalizumab). In June 2020 we submitted a Supplemental Biologics License Application for a SC formulation of natalizumab to the FDA.
- In October 2020 the first patient in the Phase 1 study of BIIB107 (anti-VLA4) in MS was dosed.
- In November 2020 we submitted a MAA for VUMERITY (diroximel fumarate; DRF) to the EMA.



## 6 Executive Compensation Matters (continued)

- In December 2020 the European Commission approved a new intramuscular injection route of administration for PLEGRIDY (peginterferon beta-1a) for the treatment of relapsing-remitting MS.

### Clinical Trials

#### *Alzheimer's Disease and Dementia*

- In March 2020 the first patient was dosed in the aducanumab re-dosing study, EMBARK, which is a global re-dosing clinical study designed to evaluate aducanumab in eligible Alzheimer's disease patients who were actively enrolled in aducanumab studies (PRIME, EVOLVE, EMERGE and ENGAGE) in March 2019.
- In September 2020 the first patient was dosed in the Phase 3 AHEAD 3-45 clinical study of BAN2401 (lecanemab), an anti-amyloid beta antibody, in individuals with preclinical Alzheimer's disease who have intermediate or elevated levels of amyloid in their brains. We are collaborating with Eisai on the development of BAN2401.

#### *Neuromuscular Disorders*

- In March 2020 the first patient was dosed in the global DEVOTE study, which is evaluating the safety, tolerability and potential for even greater efficacy of SPINRAZA when administered at a higher dose than currently approved for the treatment of SMA.
- In September 2020 the first patient in a Phase 1 study of BIIB105 (ataxin-2 ASO), an antisense oligonucleotide (ASO) targeting ataxin-2 in ALS, was dosed.

#### *Movement Disorders*

- In July 2020 the first patient in the Phase 1 study of BIIB101 (ION464), an ASO targeting alpha synuclein in multiple system atrophy, was dosed.

#### *Immunology*

- In August 2020 the first patient was dosed in the Phase 3 program for dapirolizumab pegol (anti-CD40L) in patients with active systemic lupus erythematosus despite being treated by standard of care therapies. Dapirolizumab pegol is being developed in collaboration with UCB Pharma S.A.

#### *Biosimilars – Samsung Bioepis – Biogen's Joint Venture with Samsung BioLogics*

- In May 2020 Samsung Bioepis announced that the primary endpoints were met in the randomized, double-masked, Phase 3 trial comparing the efficacy, safety and immunogenicity of SB11 to the reference product (LUCENTIS).
- In June 2020 Samsung Bioepis initiated a Phase 3 study for SB15, a proposed aflibercept biosimilar referencing EYLEA. EYLEA is widely used to treat ophthalmologic conditions such as neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME) and diabetic retinopathy in patients with DME.

#### *Discontinued Programs*

- In March 2020 we announced that the Phase 2 OPUS study investigating natalizumab as an adjunctive therapy in adults with drug-resistant focal epilepsy did not meet its primary endpoint. Safety data were in-line with the known safety profile of natalizumab. Based on these results, we discontinued development of natalizumab in drug-resistant focal epilepsy.
- In October 2020 we announced that the Phase 2 AFFINITY study of opicinumab (anti-LINGO) in MS did not meet its primary or secondary endpoints. Based on these results, we discontinued development of opicinumab.

#### *Business Development*

- In March 2020 we acquired BIIB118 (CK1 inhibitor), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. We are developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder in Parkinson's disease and plan to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease.

## 6 Executive Compensation Matters (continued)

- In April 2020 we closed a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson's disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo's proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases.
- In October 2020 we closed a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali's Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have a right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.
- In December 2020 we closed a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.

### Share Repurchase Activity

- In October 2020 our Board of Directors authorized a program to repurchase up to \$5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired.
- We returned approximately \$6.7 billion to stockholders in 2020 through share repurchases under our 2020 Share Repurchase Program, our March 2019 Share Repurchase Program, which was a program authorized by our Board of Directors in March 2019 to repurchase up to \$5.0 billion of our common stock that was completed as of March 31, 2020, and our December 2019 Share Repurchase Program, which was a program authorized by our Board of Directors in December 2019 to repurchase up to \$5.0 billion of our common stock that was completed as of September 30, 2020.

### Other Notable Achievements in the Workplace and Community

- In September 2020 we announced Healthy Climate, Healthy Lives, a \$250.0 million, 20-year initiative to eliminate fossil fuels across our operations and collaborate with renowned institutions with the aim to improve health, especially for the world's most vulnerable populations. We are the first *Fortune 500* company to commit to become fossil fuel free across our operations by 2040.
- The approximately €2.4 billion of healthcare savings in 2020 across Europe that we estimate was contributed by our three anti-TNF biosimilars.
- Named the number one biotechnology company on the Dow Jones Sustainability World Index for the fifth time.
- Launched our electric vehicle fleet program, expanding our battery electric vehicles to 12 and office chargers to 49 as of December 31, 2020.
- Recognized as a corporate sustainability leader with the Gold Class Sustainability Award from RobecoSAM.
- Used green chemistry processes and techniques to reduce our waste and energy consumption.
- Committed to a climate target consistent with reductions required to keep warming to 1.5°C and joined the Business Ambition to 1.5°C.
- Began engaging our employees and suppliers in the transition to a fossil fuel-free future with 100% renewable electricity targets for suppliers and sustainable benefit programs for employees.
- Earned a perfect score of 100% on the Human Rights Campaign's Corporate Equality Index (a national benchmarking tool on corporate policies and practices pertinent to LGBTQ employees) for the seventh consecutive year and a perfect score of 100% on the Disability Equality Index for the third consecutive year.
- Continued our commitment to diversity, equity and inclusion. As of December 31, 2020, 48% of director-level positions and above were held by women, and, in the U.S., 28% were held by ethnic or racial minorities.
- Launched an enhanced strategy with the aim to boost diversity\* in U.S. manager positions and above by 30% by the end of 2021.
- Engaged more than 57,000 students in hands-on learning to inspire their passion for science since the inception of Biogen's Community Labs in 2002 with priority focus on underrepresented students.




# 6 Executive Compensation Matters (continued)

\* Percent of U.S. manager positions and above held by Black, African American and Latinx employees as well as Asian employees where underrepresented.

## 2020 Executive Compensation Programs and Pay-for-Performance Alignment


We believe our executive compensation programs are effectively designed and have worked well to implement a pay-for-performance culture that is aligned with the interests of our stockholders. In 2020 our executive compensation programs consisted of base salary, short- and long-term incentives and other benefits.

**91% of our CEO's and 85% of our other currently-employed NEOs' (other than our CEO) 2020 target compensation was performance-based and at-risk.**



\* Reflects annual salary, target bonus and target grant value of the 2020 annual long-term incentive awards. The NEO compensation mix excludes the one-time sign-on bonus paid to Mr. McDonnell in connection with his hire, as described in further detail below, as well as compensation for Mr. Capello due to his partial year employment with Biogen in 2020.

**100% of our NEOs' 2020 annual long-term incentive (LTI) grants were performance-based and at-risk\***



\* Does not include sign-on LTI awards granted to Mr. McDonnell in connection with his hire in August 2020.

### Our 2020 performance-based compensation payouts align with our commitment to strong performance and accountability.

Our executive compensation program is structured to closely align with our business purpose and commitment to drive the creation of long-term stockholder value. Our C&MD Committee considered our achievements in 2020 as well as the challenges we faced and made adjustments to certain of the performance goals in our incentive compensation plans to take into account items that were not originally contemplated, or whose magnitude or timing were uncertain, when the performance goals were originally established. At the same time, our C&MD Committee believed it was important to hold the members of our Executive Committee, which includes all of our NEOs, accountable for the Company's overall financial results and business performance compared to the original performance goals and decreased the payouts under certain of our incentive plans for our NEOs. As a result, the payouts for our NEOs, as a percentage of target, for our 2020 annual bonus plan and the portions of our PSUs and our MSUs that were eligible to be earned based on 2020 performance were below target payout amounts, as described in further detail below.




## 6 Executive Compensation Matters (continued)

We believe that our 2020 executive compensation program, including the adjustments made by our C&MD Committee, demonstrates our commitment to linking compensation to Company performance and strategy during a challenging year while holding our executive officers accountable.

### 2020 Advisory Vote on Executive Compensation

At our 2020 annual meeting of stockholders, we continued to receive support for our executive compensation programs with approximately 83% of the votes cast for approval of our annual “say-on-pay” proposal. Our C&MD Committee viewed this as positive support for our executive compensation programs and their alignment with long-term stockholder value creation and determined that the Company’s executive compensation programs have been effective in implementing the Company’s stated compensation philosophy and objectives.



Our C&MD Committee is committed to continually reviewing our executive compensation programs on a proactive basis to ensure the ongoing alignment of such programs with the interests of our stockholders.

In 2020 our C&MD Committee reviewed our executive compensation programs in light of market data, the results from our “say-on-pay” proposal at last year’s annual meeting of stockholders and the Company’s performance. Our C&MD Committee was satisfied that our existing executive compensation programs further our pay-for-performance philosophy and, accordingly, did not recommend any significant changes to our executive compensation programs for 2020.

### Roles and Responsibilities

#### Role of our C&MD Committee

Our C&MD Committee, which is composed of three independent directors, oversees and administers our executive compensation programs. In making executive compensation decisions, our C&MD Committee reviews a variety of factors and data, most importantly our performance and individual executive performance, and considers the totality of compensation that may be paid or the value of which that may be granted. In addition, our C&MD Committee administers our annual bonus plan and our equity plans, reviews business achievements relevant to payouts under our compensation plans, makes recommendations to our Board of Directors with respect to compensation policies and practices as well as the compensation of our CEO and seeks to ensure that total compensation paid to our executive officers is fair, competitive and aligned with stockholder interests. Our C&MD Committee retains the right to hire outside advisors as needed to assist it in reviewing and revising our executive compensation programs.

The duties and responsibilities of our C&MD Committee are described on page 19 and can be found in our C&MD Committee’s written charter adopted by our Board of Directors, which can be found on our website, [www.biogen.com](http://www.biogen.com), under the “Corporate Governance” subsection of the “Investors” section of the website.

#### Role of the Independent Compensation Consultant

Our C&MD Committee believes that independent advice is important in developing and overseeing our executive

compensation programs. Pearl Meyer is currently engaged as our C&MD Committee’s independent compensation consultant. Pearl Meyer does not provide any other services to Biogen and engages in other matters as needed and as directed solely by our C&MD Committee.

Reporting directly to our C&MD Committee, Pearl Meyer provides guidance on trends in CEO, executive and non-employee director compensation, the development of specific executive compensation programs and the composition of the Company’s compensation peer group used for market comparisons. Additionally, Pearl Meyer prepares a comprehensive report on CEO pay that compares each element of compensation to that of CEOs at companies in our peer group. Using this and other similar information, our C&MD Committee recommends, and our Board of Directors approves, the elements and target levels of our CEO’s compensation and our C&MD Committee approves the elements and target levels of compensation for our other executive officers. During 2020 Pearl Meyer also provided guidance to our C&MD regarding the impact of the COVID-19 pandemic on executive compensation programs, including at peer group companies.

Our C&MD Committee assesses Pearl Meyer’s independence annually and, in accordance with applicable SEC and Nasdaq rules, confirmed in December 2020 that Pearl Meyer’s work did not raise any conflicts of interest and that Pearl Meyer remains independent under applicable rules.



# 6 Executive Compensation Matters (continued)

## Role of our CEO

Each year our CEO provides an assessment of the performance of each executive officer, other than himself, during the prior year and recommends to our C&MD Committee the compensation to be paid or awarded to each executive. Our CEO's recommendations are based on numerous factors, including:

- Company, team and individual performance;
- potential for future contributions;
- leadership competencies, skills and experience;
- external market competitiveness;
- internal pay comparisons; and
- other factors deemed relevant.

To understand the external market competitiveness of the compensation for our executive officers, our CEO and our C&MD Committee review a report analyzing publicly-available information and surveys prepared by our internal compensation group and reviewed by Pearl Meyer. The report compares the compensation of each executive officer, other than our CEO, to data available for comparable positions at companies in our peer group and, in certain circumstances, the broader market, by compensation element (please see "External Market Competitiveness and Peer Group" below for further details). Our C&MD Committee considers all of the information presented, discusses the recommendations with our CEO and with Pearl Meyer and applies its judgment to determine the elements of compensation and target compensation levels for each executive officer other than the CEO.

Our CEO also provides a self-assessment of his achievements for the prior year. Our C&MD Committee reviews and considers this in analyzing the CEO's performance, and in recommending the compensation of our CEO for approval by our Board of Directors. Our CEO does not participate in any deliberations regarding his own compensation.

## Executive Compensation Philosophy and Objectives

Our executive compensation programs are designed to drive the creation of long-term stockholder value by delivering performance-based compensation that is competitive with our peer group in order to attract and retain extraordinary leaders who can perform at high levels and succeed in a demanding business environment. We aim to achieve this by designing programs that are:

- *Mission Focused and Business Driven.* Our executive compensation programs support the relentless pursuit of

delivering meaningful and innovative therapies to patients by providing our executives with incentives to achieve the near- and long-term objectives of our business. Substantially all of our incentive compensation programs for our executives are tied directly, and meaningfully, to Company performance. Our objective is to emphasize the importance of achieving short-term goals while building and sustaining a foundation for long-term success.

- *Competitively Advantageous.* We benchmark our executive compensation programs against a peer group of biotechnology and pharmaceutical companies that we believe are representative of the companies we primarily compete with for talent, that are similar to us in business scope and size, including revenue and market capitalization, business focus and geographic scope of operations. We also review broader market data, as further described below, to provide additional context for compensation decisions. Peer group and market practices are among the many factors we take into account in developing executive compensation programs that we believe are most effective, and which enable us to recruit, retain and motivate our leadership team to achieve their best for Biogen and our stockholders.
- *Performance Differentiated.* We believe strongly in pay-for-performance and endeavor to significantly differentiate rewards by delivering the highest rewards to our best performers that exceed our expectations and lesser rewards to those who meet or do not meet our performance expectations.
- *Ownership Aligned.* At Biogen, we believe every employee contributes to the success of the Company and, as such, every employee has a vested interest in the Company's success. To reinforce this alignment with our stockholders, we strongly encourage stock ownership through our equity-based compensation programs. For members of our executive team, including our NEOs, who set and lead the future strategic direction of our Company, we ensure that a significant portion of their total pay opportunities are equity-based to maintain alignment between the interests of our executive officers and our stockholders.
- *Flexible.* We are committed to providing flexible benefits designed to allow our diverse global workforce to have reward opportunities that meet their varied needs so that they are inspired to perform their very best on behalf of patients and stockholders each day.



# 6 Executive Compensation Matters (continued)

## External Market Competitiveness and Peer Group

We consider market practices and trends when determining executive compensation levels and compensation program designs at Biogen. We do not target a specific market percentile or simply replicate the market practice. Instead, we review external market practices as a reference point to assist us in providing programs designed to attract, retain and inspire extraordinary talent. Our C&MD Committee also uses a peer group and other market data to provide context for its executive compensation decision-making. Each year Pearl Meyer reviews the external market data and evaluates the composition of our peer group for appropriateness.

Our C&MD Committee reviews the information provided from internal sources as well as the information provided by Pearl Meyer to select our peer group based on comparable companies that approximate (1) our scope of business, including revenue and market capitalization, (2) our global geographical reach, (3) our research-based business with multiple marketed products and (4) a comparable pool of talent for which we compete.

The peer group used for our 2020 compensation decisions consisted of the biotechnology and pharmaceutical companies listed below, as we compete with companies in both of these sectors for executive talent.

### Biotechnology Peers

Alexion Pharmaceuticals, Inc.  
Amgen Inc.  
Gilead Sciences Inc.  
Regeneron Pharmaceuticals, Inc.  
Vertex Pharmaceuticals Incorporated

### Pharmaceutical Peers

AbbVie Inc.  
Allergan plc  
Bristol-Myers Squibb Company  
Eli Lilly and Company  
Merck & Co, Inc.  
Mylan N.V.  
Bausch Health Companies

For each of the companies in our peer group, when available, we analyze the company's Compensation Discussion and Analysis and other data publicly filed during the prior year to identify the executives at such companies whose positions are comparable to those held by our executive officers. We then compile and analyze the data for each comparable position. Our competitive analysis includes the structure and design of the executive compensation programs as well as the targeted value of the compensation under these programs.

For our executive officers other than our CEO, we may supplement the data from our peer group with published compensation surveys. For 2020, consistent with past years, we used the *Willis Towers Watson Pharmaceutical and Health Sciences Executive Compensation* survey (which we refer to as the Willis Towers Watson survey). We chose the Willis Towers Watson survey because of the number of companies in our peer group that participate in it, the number of positions reported by the survey that continue to be comparable to our executive positions and the high standards under which we understand the survey is conducted (including data collection and analysis methodologies). All of the companies in our peer group are represented in a special cross-section of the Willis Towers Watson survey focused on our peer group other than Allergan plc, Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated, none of which participated in the survey.



# 6 Executive Compensation Matters (continued)

## Compensation Elements

Our C&MD Committee determines the elements of compensation we provide to our executive officers. The elements of our executive compensation programs and their objectives are as follows:

Element	Objective(s)
Base Salary	<ul style="list-style-type: none"> <li>Provides a fixed level of compensation that is competitive with the external market and reflects each executive's contributions, experience, skills, responsibilities and potential to contribute to our future success.</li> </ul>
Annual Bonus Plan	<ul style="list-style-type: none"> <li>Aligns short-term compensation with the annual goals of the Company.</li> <li>Motivates and rewards the achievement of annual Company and individual performance goals that support short- and long-term value creation.</li> </ul>
Long-term Incentives	<ul style="list-style-type: none"> <li>Aligns executives' interests with the long-term interests of our stockholders by linking the value of awards to increases in our stock price.</li> <li>Motivates and rewards the achievement of stock price growth and pre-established Company performance goals, including those with a longer-term focus.</li> <li>Promotes executive retention and stock ownership and focuses executives on enhancing long-term stockholder value.</li> </ul>
Benefits	<ul style="list-style-type: none"> <li>Promotes health and wellness.</li> <li>Provides financial protection in the event of disability or death.</li> <li>Provides tax-beneficial ways for executives to save towards their retirement and encourages savings through competitive employer matches to executives' retirement savings.</li> </ul>

## Compensation Mix

Our C&MD Committee determines the general mix of the elements of our executive compensation programs. It does not target a specific mix of value for the compensation elements within these programs in either the program design or pay decisions. Rather, our C&MD Committee reviews the mix of compensation elements to ensure an appropriate level of performance-based compensation is apportioned to the short-term and even more to the long-term to ensure alignment with our business goals, performance and stockholder interests.

Additionally, our C&MD Committee believes the greater the leadership responsibilities, the greater the potential impact an individual will have on Biogen's future strategic direction. Therefore, for our executive officers, including our NEOs, a greater portion of their compensation is performance-based, with a particular emphasis on LTI.

The 2020 compensation mix for Mr. Vounatsos and our other NEOs was highly performance-based and at-risk; 91% of 2020 compensation was performance-based for Mr. Vounatsos and 85% of 2020 compensation was performance-based for our other currently-employed NEOs (other than Mr. Vounatsos), assuming target level achievement of applicable Company and individual performance goals and with LTI awards measured at target grant date values, and excluding the one-time sign-on bonus paid to Mr. McDonnell in connection with his hire.

## Performance Goals and Target Setting Process


Early each year, our C&MD Committee reviews and establishes the pay levels of each element of total compensation for our executive officers. Total compensation is comprised of base salary, annual bonus and LTI awards.

As part of this process, our C&MD Committee reviews the mix of compensation elements to ensure our performance-based compensation is appropriately apportioned and aligns with our business goals and performance and the annual business plan approved by our Board of Directors. In addition, the total compensation opportunity and mix of compensation elements for our executive officers are evaluated based on qualitative factors, such as individual, strategic and leadership achievements. Our CM&D Committee is aware of the risks associated with incentive compensation in general and specific factors, such as drug pricing, in particular, that may contribute to the achievement of particular performance goals. Our CM&D Committee considers these risks carefully when determining compensation and believes that the use and weighting of multiple metrics and the use of quantitative and qualitative metrics can mitigate these risks and create appropriate incentives to focus on achievement of the Company's overall performance goals.



# 6 Executive Compensation Matters (continued)

A summary of the process our C&MD Committee follows in setting compensation is described below:



# 6 Executive Compensation Matters (continued)

## 2020 Hiring- and Transition-Related Compensation Decisions

### Arrangements with Mr. McDonnell

We appointed Mr. McDonnell as our Executive Vice President and Chief Financial Officer, effective as of August 15, 2020.

In determining the annual and long-term compensation for Mr. McDonnell, our C&MD Committee followed the same process as it did when setting compensation for our other NEOs as described in this CD&A and also took into consideration the value of compensation that Mr. McDonnell would have been eligible to earn had he remained employed by his prior employer. After considering the compensation opportunities that Mr. McDonnell would be required to forfeit in order to join us, and in order to incentivize him to do so, our C&MD Committee granted Mr. McDonnell a one-time cash sign-on bonus of \$1.0 million. Our C&MD Committee also approved an annual base salary for Mr. McDonnell of \$850,000 and a target bonus of 75% of his annual base salary under our annual bonus plan, in each case, prorated for 2020.

Mr. McDonnell's one-time cash sign-on bonus is subject to repayment to the Company in the event Mr. McDonnell voluntarily terminates his employment or his employment is terminated by us for cause (as defined in our 2017 Omnibus Equity Plan) or for misconduct or poor performance, as determined by us in good faith, as follows: 100% of his cash sign-on bonus is subject to repayment if such termination occurs within the first year of his employment, 70% of his cash sign-on bonus is subject to repayment if such termination occurs within the second year of his employment and 35% of his cash sign-on bonus is subject to repayment if such termination occurs within the third year of his employment, in each case, net of applicable tax withholdings.

In connection with Mr. McDonnell's appointment, our C&MD Committee also granted him a LTI award in September 2020, which consisted of RSUs and MSUs with an aggregate grant date target value of \$4.5 million. The terms of the RSUs and MSUs awards granted to Mr. McDonnell are described below under the heading "Long-Term Incentives."

### Arrangements with Mr. Capello

Mr. Capello ceased to be our Executive Vice President and Chief Financial Officer on August 15, 2020, and separated from the Company on September 15, 2020. We provided him the severance benefits required under our executive severance policy for Executive Vice Presidents, which con-

sisted of a lump sum payment of \$1,892,625 (16 months of base salary and target bonus) and continuation of certain subsidized medical, dental and vision benefits until the earlier of (1) December 31, 2021, or (2) the date on which he becomes eligible to receive benefits through another employer. In addition, in recognition of Mr. Capello's contributions to the Company and to facilitate a successful transition to Mr. McDonnell, our CM&D Committee waived the requirement that Mr. Capello repay 35% of his cash sign-on bonus and approved an additional cash payment to him of \$2.6 million.

### 2020 Base Salary

For 2020 our Board of Directors reviewed the base salaries of chief executive officers in our peer group and considered Mr. Vounatsos' compensation mix, capabilities, performance, future expected contributions and positioning relative to the peer group. Mr. Vounatsos' annual base salary was increased to \$1.5 million, which positioned him below the market median when compared to the chief executive officers of our peer group.

Our C&MD Committee undertook a similar review when approving the annual base salaries for our other NEOs, which positioned them, on average, below the market median compared to persons with comparable jobs within our peer group.

The annual base salary of each of our NEOs in 2020, compared to 2019, is as follows:

Name	2020 Salary	2019 Salary	% Increase <sup>(1)</sup>
M. Vounatsos	\$1,500,000	\$1,400,000	7.1%
M. McDonnell <sup>(2)</sup>	\$ 850,000	n/a	n/a
A. Sandrock	\$ 901,680	\$ 803,136	12.3%
S. Alexander	\$ 814,168	\$ 775,398	5.0%
C. Guindo	\$ 567,100	\$ 530,000	7.0%
J. Capello	\$ 811,125	\$ 787,500	3.0%

(1) Percentage increase reflects the annual merit increase and, in the case of Dr. Sandrock, also includes a market adjustment.

(2) Mr. McDonnell was hired in 2020. The initial determination of his base salary took into account the Company's peer group data.

### 2020 Performance-Based Plans and Goal Setting

Our executive compensation programs place a heavy emphasis on performance-based compensation.

We maintain a short-term incentive plan, known as our annual bonus plan, as well as a LTI plan.



# 6 Executive Compensation Matters (continued)

Awards to our NEOs under our annual bonus plan were made under our 2020 Performance-Based Management Incentive Plan, and awards under our LTI plan were granted under our 2017 Omnibus Equity Plan.

Awards made under our annual bonus plan are directly tied to the achievement of our Company performance goals, which are aligned with the Company's short- and long-term strategic plans, as well as individual performance goals.

Awards made under our LTI plan are directly tied to the performance of the price of our common stock, which aligns our executives' long-term interests with the interests of our stockholders. A portion of our LTI awards is also tied to the Company's financial performance, as described below under "Long-Term Incentives – 2020 PSUs."

In setting our annual goals under our short- and long-term incentive plans, in addition to our internal forecasts, we consider analysts' projections for our performance and the performance of companies in our peer group as well as broad economic and industry trends. We strive to establish challenging targets that result in payouts at or above target levels only when Company performance warrants it. Our C&MD Committee is responsible for reviewing and approving our metrics, goals, targets and levels of payout (e.g., threshold, target and maximum) for our executive incentive compensation plans and awards and for reviewing and determining actual performance results at the end of the applicable performance period.

In setting and approving the performance goals for our executive officers and for the Company under both the short- and long-term incentive plans, our C&MD Committee also considers the alignment of such goals to our business plan, the degree of difficulty of attainment and the potential for the goals to encourage inappropriate risk-taking. Our C&MD Committee has determined that the structures of our executive compensation programs do not put our patients, investors or the Company at any material risk.

## Annual Bonus Plan

Our annual bonus plan is a cash incentive plan that rewards near-term financial, strategic and operational performance. Our C&MD Committee reviews the annual target bonus opportunities for each executive officer by position each year to ensure such opportunities remain competitive.

No changes were made in 2020 to the target annual bonus opportunities, as a percentage of year-end annual base salary, for any of our NEOs. Mr. McDonnell's target annual bonus opportunity was set in connection with his hire, based

on the factors described above, and was prorated for 2020 based on the portion of 2020 he was employed by us.

The target annual bonus opportunity as a percentage of year-end annual base salary for each of our NEOs in 2020 compared to 2019 was as follows:

Name	2020 Target	2019 Target
M. Vounatsos	150%	150%
M. McDonnell	75%	n/a
A. Sandroch	75%	75%
S. Alexander	70%	70%
C. Guindo	70%	70%
J. Capello <sup>(1)</sup>	75%	75%

(1) Mr. Capello ceased to be employed by the Company during 2020 and, as a result, was ineligible for a payout under our 2020 annual bonus plan.

## 2020 Annual Bonus Plan Design

Awards for our NEOs under our 2020 annual bonus plan were based on the achievement of Company performance goals and individual performance goals.

At the beginning of 2020 our C&MD Committee set multiple Company performance goals for our 2020 annual bonus plan and a payout multiplier, which we refer to as the Company Multiplier, ranging from 0% to 150%. The Company Multiplier was applied to each Company goal based on the determination of the level of achievement of each goal and application of the weighting assigned to each goal to determine the total Company Multiplier applied to the bonus calculation.

The Company Multiplier ranged from 0% to 150% as follows:

Performance Multipliers	Below Threshold	Threshold	Target	Max
Company	0%	50%	100%	150%

In addition, our 2020 annual bonus plan payouts were based on an assessment of each NEO's individual performance, taking into account his or her achievement of pre-determined individual performance goals. Evaluating individual performance allows our C&MD Committee the discretion to increase or decrease each NEO's bonus amount based on the NEO's performance by applying an individual performance multiplier, ranging from 0% to 150%, which we refer to as the Individual Multiplier.



# 6 Executive Compensation Matters (continued)

We determined the individual annual bonus payments for 2020 using the following calculation:



Our 2020 annual bonus plan provided that if the Company Multiplier was less than 50%, there would be no payout, regardless of individual performance, consistent with our pay-for-performance philosophy. Further, because the Individual Multiplier and the Company Multiplier each have a maximum of 150%, the combined multiplier result for each NEO could not exceed 225%.

### 2020 Company Performance Goals and Results


Company performance goals were established in the early part of 2020 with assigned weightings that reflected the Company's focus on attaining both financial and strategic goals (pipeline performance, MS leadership, accelerate neuromuscular leadership, prepare for Alzheimer's disease leadership, biosimilars growth and executing strategic transactions that progress our multi-franchise neuroscience portfolio and/or optimize capital allocation).

The goals and weightings selected reflect the importance of linking reward opportunities to both near-term results and our progress in achieving longer-term goals.

The strategic performance goals selected in 2020 were designed to measure the achievement of our annual strategic priorities relating to our commercial opportunities and pipeline progress. Our financial performance goals were based on the Company's annual operating plan and long-range plan approved by our Board of Directors and with

reference to analyst consensus for Biogen revenue and Non-GAAP diluted earnings per share (EPS) based on the most current analyst reports at the time we set our targets.

The following table presents our financial targets relative to analysts' consensus for 2020:



(1) Please see "2020 Annual Bonus Plan Company Performance Targets and Results Table" below for more details.

(2) Wall Street figures reflect estimates made in January 2020 for the Biogen fiscal year ending December 31, 2020.

(3) Reflects Non-GAAP diluted EPS.

### 2020 Annual Bonus Plan Company Performance Targets and Results Table

Set forth below is a summary of the Company performance goals and weightings that our C&MD Committee established for our 2020 annual bonus plan and the degree to which we attained these Company performance goals.

At the time our C&MD Committee established the Company performance goals in the beginning of the year, we did not know what impact, including the timing, that generic competition for TECFIDERA would have on our 2020 financial results as it was dependent on a number of factors beyond our control, including decisions in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. Due to this uncertainty, our C&MD Committee exercised its discretion to make certain adjustments to the results to take into account items that were not originally contemplated, or whose magnitude or timing were uncertain, at the time the Company performance goals were originally determined. In particular, the entry of multiple TECFIDERA generic entrants in the U.S. with deeply discounted prices compared to TECFIDERA had real and negative impacts on our financial results.



# 6 Executive Compensation Matters (continued)

Our C&MD Committee believed these adjustments were appropriate because the items were beyond the control of management, were not contemplated and/or could not be quantified due to uncertainty regarding magnitude and timing when the Company performance goals were originally set. Our C&MD Committee also believed that adjustments were necessary to appropriately motivate and reward employees for their performance during a challenging year in which we continued to perform well despite the challenges that we faced.

Based on our overall performance, and following these adjustments, the Company Multiplier for the 2020 Annual Bonus Plan was 106%.

However, notwithstanding the attainment of these performance goals and the strength of management's performance, our C&MD Committee believed it was important to hold the members of our Executive Committee, which includes all of our NEOs, accountable for the Company's overall financial results and business performance compared to the original performance. As a result, our C&MD Committee exercised its discretion and decreased the Company Multiplier for the members of our Executive Committee, including all of our NEOs, by 11%, which resulted in a Company Multiplier for our NEOs of 95%.

Company Goals	Weight	Performance Range			Results	Company Multiplier
		Threshold	Target	Max		
<b>FINANCIAL PERFORMANCE</b>						
Revenue	20%	\$13,280M	\$14,102M	\$14,923M	\$13,952M <sup>(1)</sup>	90.9%
Non-GAAP diluted EPS	20%	\$ 29.26	\$ 32.37	\$ 35.48	\$ 33.30 <sup>(1)</sup>	114.9%
<b>MARKET PERFORMANCE</b>						
Achieve Global MS Market Share	7.5%	Specific market goals are not disclosed for competitive reasons			Above Goal <sup>(2)</sup>	116.5%
MS Leader in Customer Trust and Value Survey	2.5%	Specific market goals are not disclosed for competitive reasons			Above Goal <sup>(3)</sup>	150.0%
Achieve Global SMA Market Share	10%	Specific market goals are not disclosed for competitive reasons			Goal Not Met <sup>(3)</sup>	0%
Prepare for Alzheimer's Disease Leadership	15%	Specific market goals are not disclosed for competitive reasons			Above Goal <sup>(3)</sup>	115.0%
Achieve anti-TNF Biosimilars Market Share	2.5%	Specific market goals are not disclosed for competitive reasons			Below Goal <sup>(3)</sup>	96.0%
<b>PIPELINE DEVELOPMENT</b>						
Build and Advance Total Pipeline	15%	Specific pipeline goals are not disclosed for competitive reasons			Above Goal <sup>(4)</sup>	140.0%
<b>COLLABORATION</b>						
Execute Strategic Transactions that Progress our Multi-Franchise Neuroscience Portfolio and/or Optimize Capital Allocation	7.5%	Specific strategic transactions goals are not disclosed for competitive reasons			Above Goal <sup>(5)</sup>	150.0%
					<b>Company Multiplier</b>	106.0%*
					<b>Adjusted Company Multiplier for NEOs</b>	95.0% <sup>*(6)</sup>

\* Numbers may not recalculate due to rounding.

*Notes to 2020 Annual Bonus Plan Company Performance Targets and Results Table*

(1) These financial measures were based on our publicly reported revenue of \$13,445 million and our publicly announced Non-GAAP diluted EPS of \$33.70, as adjusted as follows: for purposes of our 2020 annual bonus plan, revenue was adjusted to neutralize the effects of foreign exchange rate fluctuations and exclude the adverse impact of multiple TECFIDERA generic entrants that entered the U.S. market in 2020. Non-GAAP diluted EPS was further adjusted to subtract \$2.62 related to share repurchases in 2020 under our 2020 Share Repurchase Program, our December 2019 Share Repurchase Program and our March 2019 Share Repurchase Program and \$0.28 related to the delay in the payment of a milestone payment related to the potential approval of aducanumab, partially offset



# 6 Executive Compensation Matters (continued)

by the addition of \$2.50 to exclude the adverse impact of multiple TECFIDERA generic entrants that entered the U.S. market in 2020. These items were either not originally contemplated or their magnitude or timing was uncertain at the time the Company performance goals were originally established.

- (2) Our market goal for MS was adjusted to exclude the adverse impact of multiple TECFIDERA generic entrants that entered the U.S. market in 2020, which was not originally contemplated at the time the Company performance goals were determined. Specific details are not disclosed for competitive reasons.
- (3) Our achievement of MS leader and preparation for Alzheimer's disease leadership were above goals, achievement of market goals for biosimilars was below goal and we did not meet our market goals for SMA. Specific details are not disclosed for competitive reasons.
- (4) The Company continued to expand and re-shape its pipeline of pre-clinical and clinical stage programs through the advancement of internal programs, external business development activities and exceeding expectations with respect to the level of confidence in and momentum of its clinical stage portfolio. Specific details are not disclosed for competitive reasons.
- (5) We exceeded our key strategic alliance and business development goal. Specific details are not disclosed for competitive reasons.
- (6) Notwithstanding the attainment of these performance goals and the strength of management's performance, our C&MD Committee believed it was important to hold the members of our Executive Committee, which includes all of our NEOs, accountable for the Company's overall financial results and business performance compared to the original performance. As a result, our C&MD Committee exercised its discretion and decreased the Company Multiplier for the members of our Executive Committee, including all of our NEOs, by 11%, which resulted in a Company Multiplier for our NEOs of 95%.

## 2020 Individual Performance Goals and Results

The Individual Multiplier reflects each named executive officer's overall individual performance rating that is determined as part of our performance assessment process. Unlike our calculation of performance against Company performance goals in determining the Company Multiplier, each named executive officer's Individual Multiplier, other than Mr. Vounatsos, is based on a subjective evaluation of his or her overall performance and consideration of the achievement of individual goals established at the beginning of the year. Goals may be both quantitative and qualitative. For 2020 Mr. Vounatsos recommended to our C&MD Committee an Individual Multiplier for each currently-employed NEO other than himself based on his assessment of their individual contributions for the full year. Our C&MD Committee considered all of the information presented, discussed our CEO's recommendations with him and Pearl Meyer and applied its judgment to determine the Individual Multiplier for each currently-employed NEO. Our Board of Directors determined Mr. Vounatsos' Individual Multiplier based on its assessment of his performance.

In its evaluation, our C&MD Committee assigned Individual Multipliers to our named executive officers of between 112% and 140% based on the following accomplishments during 2020:

### Michel Vounatsos

- Excelled in leading the Company in achieving its financial and business development goals, executing on its corporate strategy and advancing Biogen's values.

- Contributed to our business development activities and the diversification of our pipeline.
- Contributed to the demonstrated resilience in our MS business, the continued successful launch of SPINRAZA worldwide and the expansion of our biosimilars business.
- Supported the filing of applications to the FDA, the EMA and the Japanese Ministry of Health, Labor and Welfare for marketing approval of aducanumab as well as the preparation for the potential launch of aducanumab.
- Drove our ongoing improvements in our core processes to improve operating efficiencies, capital allocation and asset optimization while adhering to our core values.
- Supported our continued leadership in corporate responsibility, including through the launch of Healthy Climate, Health Lives and diversity, equity and inclusion initiatives.

### Michael McDonnell

- Successfully transitioned into the role of our Chief Financial Officer.
- Significantly improved our Finance and IT organization structure, including improvements in our core processes to improve operating efficiencies.
- Added new capabilities and talent to our Finance organization.
- Contributed to our business development activities and the diversification of our pipeline.
- Contributed to interactions with investors that led to transparent and productive dialogue.
- Supported our Board of Directors, the CEO and executive team.



# 6 Executive Compensation Matters (continued)

## Alfred W. Sandrock, Jr.

- Supported the significant progression and development of our pipeline.
- Supported the filing of applications to the FDA, the EMA and the Japanese Ministry of Health, Labor and Welfare for marketing approval of aducanumab.
- Contributed to our business development activities and the diversification of our pipeline.
- Significantly improved our Research & Development organization structure, key processes and productivity.
- Excelled in leadership of our Research & Development organization.
- Contributed to interactions with investors that led to transparent and productive dialogue.

## Susan H. Alexander

- Supported our Board of Directors, the CEO and executive team.
- Led our compliance with SEC disclosure requirements.
- Provided strategic legal advice to support the filing of applications to the FDA, the EMA and the Japanese Ministry of Health, Labor and Welfare for marketing approval of aducanumab as well as the preparation for the potential launch of aducanumab.
- Co-led our response to the COVID-19 pandemic and established guidance for on-site safety of personnel.
- Excelled in leadership of our Legal and Compliance teams fostering a culture of diversity, equity and inclusion and advancing Biogen's values.

- Provided transaction and litigation support, including supporting key business development and regulatory matters.

## Chirfi Guindo

- Excelled in leadership of our Global Product Strategy and Commercialization organization and our Government Affairs, Value and Access and Corporate Affairs organizations.
- Contributed to the continued successful expansion of SPINRAZA worldwide and the continued launch of VUMERITY.
- Supported the preparation for the potential launch of aducanumab.
- Contributed to our strategy, product development and lifecycle management in a competitive environment.
- Supported our continued geographic expansion, including in emerging growth markets.
- Exhibited outstanding leadership, fostering a culture of diversity, equity and inclusion, including through the launch of Healthy Climate, Health Lives and diversity, equity and inclusion initiatives, as well as focusing on continuous improvement and implementing operational efficiencies.

In addition, our C&MD Committee reviews on a qualitative basis each named executive officer's other contributions to the Company and our business, leadership competencies and relative performance among all of our executive officers in determining Individual Multipliers.

## 2020 Annual Bonus Plan Awards

Our C&MD Committee determined that the final bonus awards under our 2020 annual bonus plan were as follows:

Name	Year-end Salary (A) x	Target Bonus% (B) x	Company Multiplier (C) x	Individual Multiplier (D) =	Bonus Award (E)
M. Vounatsos	\$1,500,000	150%	95%	120%	\$2,565,000
M. McDonnell <sup>(1)</sup>	\$ 850,000	75%	95%	115%	\$ 263,322
A. Sandrock	\$ 901,680	75%	95%	112%	\$ 719,541
S. Alexander	\$ 814,168	70%	95%	112%	\$ 606,392
C. Guindo	\$ 567,100	70%	95%	140%	\$ 527,970
J. Capello <sup>(2)</sup>	\$ 811,125	75%	n/a	n/a	n/a

### Notes to the 2020 Annual Bonus Plan Awards Table

- (1) Mr. McDonnell was appointed as our Executive Vice President and Chief Financial Officer effective August 15, 2020. Mr. McDonnell's award under our 2020 Annual Bonus Plan was based on his prorated salary for 2020.
- (2) Mr. Capello ceased to be employed by the Company during 2020 and, as a result, was ineligible for a payout under our 2020 annual bonus plan.



# 6 Executive Compensation Matters (continued)

## Long-Term Incentives

Below is a summary of the types of annual LTI awards granted to our NEOs for 2020.\*

Terms	Performance Stock Units (PSUs)		Market Share Units (MSUs)
Proportion of Annual Target Value	50%		50%
Settlement	60% Stock Settled	40% Cash Settled	100% Stock Settled
Performance Period(s)	3 years (2020-2022)	1 year (each of 2020, 2021, 2022)	1 year, 2 years, 3 years (from grant date)
Metrics and Weighting	Pipeline Milestone Performance: 60%	Adjusted Free Cash Flow: 28% Revenue: 12%	Stock Price: 100%
Threshold / Maximum Payout (% of Target Award)	50% / 200%	50% / 200%	50% / 200%
Vesting	3-year Cliff Vesting	3-year Cliff Vesting	Annual Ratable Vesting over 3 years (1/3 per year)

\* Does not include the sign-on LTI awards granted to Mr. McDonnell in connection with his hire.

All annual LTI awards granted to our executive officers are performance-based and designed to reward long-term Company performance.

Our executive annual LTI program for 2020 consisted of PSUs and MSUs, with the annual LTI total target grant value of awards being split evenly between PSUs and MSUs. The PSUs we granted to executive officers are performance-based RSUs that are settled, as applicable, in cash and shares of our common stock. The MSUs we granted to executive officers are performance-based RSUs that are settled in shares of our common stock. The performance conditions applicable to these PSUs and MSUs are described in further detail below.

Our annual LTI target grant values are determined based on an executive's individual performance, potential future contributions and market competitiveness as well as other factors. In determining the annual LTI target grant value, our C&MD Committee reviews LTI awards of our peer group and, in certain circumstances, the broader market, and also reviews the total compensation of our executive officers against our peer group and, in certain circumstances, the broader market. In general, we have a heavier weighting in our executive compensation mix towards LTI awards in order to better align the interests of our executives with

those of our stockholders. On average, annual LTI target grant values for our NEOs position their total compensation at or around the median values of our peer group in cases where there are comparable positions at the peer companies.

We have an established annual LTI grant practice where LTI grants are made following the completion of our internal performance reviews of our executive officers as well as our external market review of equity practices of our peer group and the broader market, including the data from the Willis Towers Watson survey described above. Since 2004 we have made our annual LTI grants in February of each year following our annual earnings release.

We generally grant time-based RSUs in lieu of PSUs at the time an executive is hired if employment commences after June 30<sup>th</sup> with three-year cliff-vesting to mirror the vesting terms of the PSUs. These grants are generally granted on the first trading day of the month following the date of hire. From time to time, we also grant time-based RSUs to recognize extraordinary contributions to the Company or for transition or retention purposes. In connection with Mr. McDonnell's hire in August 2020, we granted him time-based RSUs, in addition to MSUs.



# 6 Executive Compensation Matters (continued)

In 2020 the LTI grant values for our NEOs were as follows:

Name	Annual LTI Grant Value
M. Vounatsos	\$12,500,000
M. McDonnell <sup>(1)</sup>	\$ 4,500,000
A. Sandrock	\$ 4,000,000
S. Alexander	\$ 3,200,000
C. Guindo	\$ 3,800,000
J. Capello <sup>(2)</sup>	\$ 3,500,000

Notes to the 2020 LTI Awards Table

- (1) Mr. McDonnell joined Biogen after the annual LTI awards were granted. Mr. McDonnell received a new hire grant in September 2020, which consisted of RSUs and MSUs with an aggregate grant date value of \$4.5 million. The RSUs will vest in three annual installments beginning on the first anniversary of the grant date.
- (2) Mr. Capello forfeited his 2020 grants in connection with the termination of his employment.

The actual value that will be realized from PSU awards depends on the degree of achievement of performance goals, with 60% of the PSUs (based on the grant date target value) settled in shares of our common stock based upon achievement of cumulative three-year pipeline milestone goals and the remaining 40% of the PSUs settled in cash based upon the achievement of two annual financial goals that are determined at the beginning of each relevant year. The actual value that will be realized from MSU awards depends on our 30-day average common stock price growth between the grant date and each of the dates such awards vest. If the vesting price is higher than the grant price, the number of shares that vest will be increased and in contrast, if the vesting price is lower than the grant price, the number of shares that vest will be decreased. Our common stock price is influenced by the Company's performance as well as external market factors.

## 2020 PSUs

PSUs comprised 50% of our NEO's target annual LTI awards for 2020. PSUs are performance-based RSUs that have three-year cliff vesting in furtherance of the Company's long-term pay-for-performance philosophy and to encourage employee retention. PSUs align executive compensation to Company goals through performance against pipeline milestone performance goals. The actual value (if any) of PSUs will not be realized by the NEOs until the three-year period ends and then only if the applicable performance goals are achieved.

For our 2020 PSU awards, 60% of the PSUs (based on the grant date target value) will be settled in shares of our common stock based on achievement of pipeline performance goals over a three-year performance period (2020 to 2022) (the 2020 Stock-Settled PSUs) and continued employment through the vesting date. The remaining 40% of the PSUs will be settled in cash based on the achievement of three one-year financial goals (2020, 2021 and 2022) (the 2021 Cash-Settled PSUs) and continued employment through the vesting date. Our 2020 PSU awards are scheduled to vest in February 2023.

For our 2020 PSU awards, the number of PSUs earned at the end of the three-year performance period will be determined as follows:



In designing our 2020 PSU LTI program, our C&MD Committee acknowledged the need to balance driving long-term performance and investing for the future with achieving key milestones along the way. Cash-based payments are primarily aligned with and reward more recent performance, while equity awards encourage our executives to continue to deliver results over a longer period of time and also serve as a retention tool. Our C&MD Committee determined that delivering a substantial portion of compensation in the form of equity awards with longer-term goals would further align our executive officers' interests with those of Biogen's stockholders in creating long-term stockholder value.

## 2019 PSUs

For our 2019 PSU awards, 60% of the PSUs (based on the grant date target value) will be settled in shares of our common stock based on achievement of financial and pipeline milestone performance goals over a three-year performance period (2019 to 2021) (the 2019 Stock-Settled PSUs) and continued employment through the vesting date. The remaining 40% of the PSUs will be settled in cash based on the achievement of three one-year financial goals (2019, 2020 and 2021) (the 2019 Cash-Settled PSUs) and continued employment through the vesting date. Our 2019 PSU awards are scheduled to vest in February 2022.

## 6 Executive Compensation Matters (continued)

### 2018 PSUs

For our 2018 PSU awards, 60% of the PSUs (based on the grant date target value) were settled in shares of our common stock based on achievement of financial and pipeline milestone performance goals over a three-year performance period (2018 to 2020) (the 2018 Stock-Settled PSUs). The remaining 40% of the PSUs were settled in

cash based on the achievement of three one-year financial goals (2018, 2019 and 2020) (the 2018 Cash-Settled PSUs) and continued employment through the vesting date. Our 2018 PSU awards vested on February 12, 2021. The performance metrics and weightings, and the degree to which we achieved the performance goals, for the 2018 Stock-Settled PSUs and the 2018 Cash-Settled PSUs are described in further detail below.

### 2020 PSU Awards Table

Set forth below is a summary of the performance metrics and weightings that our C&MD Committee established for our 2020 PSU awards and the degree to which we achieved the performance goals for the 2020 tranche of the 2020 Cash-Settled PSUs.

At the time our C&MD Committee established the performance goals for the 2020 tranche of the 2020 Cash-Settled PSUs in the beginning of the year, we did not know what impact, including the timing, that generic competition for TECFIDERA would have on our 2020 financial results as it was dependent on a number of factors beyond our control, including decisions in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Hatch-Waxman Act in West Virginia and Delaware. Due to this uncertainty, our C&MD Committee exercised its discretion to make certain adjustments to the results to take into account items that were not originally contemplated, or whose magnitude or timing were uncertain, at the time the performance goals for the 2020 tranche of the 2020 Cash-Settled PSUs were originally determined. In particular, the entry of multiple TECFIDERA generic entrants in the U.S. with deeply discounted prices compared to TECFIDERA had real and negative impacts on our financial results.

Our C&MD Committee believed these adjustments were appropriate because the items were beyond the control of management, were not contemplated and/or could not be quantified due to uncertainty regarding magnitude and timing when the performance goals for the 2020 tranche of the 2020 Cash-Settled PSUs were originally set. Our C&MD Committee also believed that adjustments were necessary to appropriately motivate and reward employees for their performance during a challenging year in which we continued to perform well despite the challenges that we faced.

Based on our overall performance, and following these adjustments, the multiplier for the 2020 tranche of the 2020 Cash-Settled PSUs was 100%.

However, notwithstanding the attainment of these performance metrics and the strength of management's performance, our C&MD Committee believed it was important to hold the members of our Executive Committee, which includes all of our NEOs, accountable for the Company's overall financial results and business performance. As a result, our C&MD Committee exercised its discretion and decreased the multiplier for the 2020 tranche of the 2020 Cash-Settled PSUs for the members of our Executive Committee, including all of our NEOs, by 10%, which resulted in a multiplier for our NEOs of 90%.



# 6 Executive Compensation Matters (continued)

We utilized the same performance metrics for the 2020 (i.e., second) tranche of the 2019 Cash-Settled PSUs and the 2020 (i.e., third) tranche of the 2018 Cash-Settled PSUs and, therefore, the multiplier for the 2020 tranche of the 2019 Cash-Settled PSUs and the 2018 Cash-Settled PSUs for the NEOs was also 90% for our NEOs.

Percentage of PSU Award	Percentage of PSU Target Value / Total LTI Target Value	Performance Metrics	Performance Metrics Weight	Performance Period	Target Performance	Actual Performance
Stock-Settled: 60%	60% / 30%	Pipeline Milestone Performance	60%	2020-2022	Specific goals are not disclosed for competitive reasons	
				2020	\$ 6.3B	\$ 6.3B <sup>(1)</sup>
				2021	Target set at beginning of 2021	TBD
		Adjusted Free Cash Flow	28%	2022	Target set at beginning of 2022	TBD
Cash-Settled: 40%	40% / 20%			2020	\$ 14.1B	\$ 13.9B <sup>(2)</sup>
				2021	Target set at beginning of 2021	TBD
		Revenue	12%	2022	Target set at beginning of 2022	TBD

Notes to the 2020 PSU Awards Table

- (1) This financial measure was based on our Non-GAAP free cash flow, as adjusted to exclude the adverse impact of multiple TECFIDERA generic entrants that entered the U.S. market in 2020, the addition of \$177.0 million related to a one-time license payment from a contract manufacturing customer and \$52.0 million related to share repurchases in 2020 under our 2020 Share Repurchase Program, our December 2019 Share Repurchase Program and our March 2019 Share Repurchase Program. These items were either not originally contemplated or their magnitude or timing was uncertain at the time the Company performance goals were originally established.
- (2) This financial measure was based on our publicly reported revenue of \$13.4 billion, as adjusted to neutralize the effects of foreign exchange rate fluctuations and exclude the adverse impact of multiple TECFIDERA generic entrants that entered the U.S. market in 2020.

The 2020 Stock-Settled PSUs metric, which was approved by our C&MD Committee, was the achievement of a pipeline milestone performance for the three-year period of 2020 through 2022.

Pipeline milestone performance over the three-year period of 2020 through 2022 was selected to drive our long-term strategic direction and stockholder value creation through our pipeline progress and development.

The 2020 Cash-Settled PSUs financial metrics are adjusted free cash flow and revenue. At the beginning of each year during the performance period for our 2020 Cash-Settled PSU awards, our C&MD Committee will approve the targets for each of these financial metrics for such year. Our C&MD Committee decided that because of the nature of our business, in which operating metrics can potentially be impacted positively or negatively by events outside of the control of executives, the design of the PSU program would be based, in part, on the use of three one-year financial goals.

- Our C&MD Committee views free cash flow as a critical measure to align the interests of management with those

of our stockholders as it reflects the net cash flow available to the Company to pursue opportunities and investments that enhance stockholder value. As such, a cash flow performance goal encourages management to optimize capital expenditures, invest prudently in high return projects and optimize working capital.

- We selected revenue as a performance measure to further reinforce the importance of achieving and exceeding our revenue goal and to provide further incentive to achieve such goal and its tie to stockholder value creation through the longer-term vesting requirements associated with the goal.

In order to further motivate our executives to drive the organization toward the achievement and potential over-achievement of these goals, we provide for a maximum payout opportunity of 200% for our PSU awards. Participants may ultimately earn between 0% and 200% of the target number of PSUs granted based on the degree of actual performance goal achievement, generally subject to continued service with the Company.



# 6 Executive Compensation Matters (continued)

## 2018 PSU Award Payout

Set forth below is a summary of the performance metrics and weightings that our C&MD Committee established for our 2018 PSU awards and the degree to which we achieved the performance goals for the 2018 Stock-Settled PSUs and the 2018 Cash-Settled PSUs.

### 2018 Stock-Settled PSUs

Performance Metrics	Performance Period	Performance Target			Results	Weight	Payout
		Threshold	Target	Max			
Adjusted Non-GAAP diluted EPS	2018-2020	\$ 26.98	\$ 28.11	\$ 29.76	\$30.79(1)	30%	200.0%
Pipeline Milestone Performance	2018-2020	Specific goals are not disclosed for competitive reasons			Met Goal(2)	30%	100.0%
<b>2018 Stock-Settled PSU Multiplier</b>							<b>150.0%</b>

#### Notes to the 2018 Stock-Settled PSUs Table

- (1) These financial measures were based on our publicly announced Non-GAAP diluted EPS of \$33.70, as adjusted as follows: the addition of \$0.80 to exclude the impact of business development transactions and \$2.09 to exclude the adverse impact of multiple TECFIDERA generic entrants that entered the U.S. market in 2020, partially offset by the subtraction of \$5.80 to exclude the impact of share repurchases. These items were either not originally contemplated or their magnitude or timing was uncertain at the time the Company performance goals were originally established.
- (2) The Company continued to expand and re-shape its pipeline of pre-clinical and clinical stage programs through the advancement of internal programs, external business development activities and meeting expectations with respect to the level of confidence in and momentum of its clinical stage portfolio. Specific details are not disclosed for competitive reasons.

### 2018 Cash-Settled PSUs

Performance Metrics	Performance Period	Performance Target			Results	Weight	Multiplier
		Threshold	Target	Max			
Adjusted Free Cash Flow	2018	\$ 2.7B	\$ 2.9B	\$ 3.3B	\$4.0B(1)	28%	200.0%
Revenue	2018	\$ 12.3B	\$12.8B	\$13.5B	\$13.4B(2)	12%	172.6%
<b>2018 Tranche of 2018 Cash-Settled PSU Multiplier</b>							<b>192.0%*</b>
Adjusted Free Cash Flow	2019	\$ 4.9B	\$ 5.5B	\$ 6.3B	\$6.0B(3)(3)	28%	165.9%
Revenue	2019	\$ 13.0B	\$13.7B	\$14.6B	\$14.4B(4)	12%	149.5%
<b>2019 Tranche of 2018 Cash-Settled PSU Multiplier</b>							<b>161.0%*</b>
Adjusted Free Cash Flow	2020	\$ 5.7B	\$ 6.3B	\$ 7.0B	\$6.3B(5)	28%	104.5%
Revenue	2020	\$ 13.3B	\$14.1B	\$15.0B	\$13.9B(6)	12%	90.9%
<b>2020 Tranche of 2018 Cash-Settled PSU Multiplier</b>							<b>100.0%</b>
<b>Adjusted 2020 Tranche of 2018 Cash-Settled PSU Multiplier for NEOs</b>							<b>90.0%*(7)</b>

\* Numbers may not recalculate due to rounding.

#### Notes to the 2018 Cash-Settled PSUs Table

- (1) This financial measure was based on our Non-GAAP free cash flow, as adjusted to add back \$256.0 million to reflect the cash impact of additional research and development expense recognized in 2018 resulting from our 2018 agreement with Ionis Pharmaceuticals, Inc. to develop novel ASO drug candidates for a broad range of neurological diseases, \$16.0 million to neutralize the unfavorable cash impact of the worldwide withdrawal of ZINBRYTA and \$33.0 million related to higher than originally contemplated stock repurchases in 2018, partially offset by the subtraction of \$235.0 million to reflect tax payments made in connection with tax reform, as these charges were not originally contemplated at the time these performance goals were determined.
- (2) This financial measure was based on our publicly reported revenue of \$13.5 billion, as adjusted to neutralize the effects of foreign exchange rate fluctuations.

## 6 Executive Compensation Matters (continued)

- (3) This financial measure was based on our Non-GAAP free cash flow, as adjusted to subtract \$170.0 million for the decline in operating taxes due to the change in the Company's tax profile, \$58.0 million for cost savings due to the termination of certain clinical programs in 2019 and \$78.0 million to remove the favorable impact of the launch delay of rituximab biosimilars, partially offset by the addition of \$33.0 million to reflect the impact of our acquisition of Nightstar Therapeutics plc and \$50.0 million related to higher than originally contemplated stock repurchases in 2019, as none of these items were originally contemplated at the time these performance goals were determined.
- (4) This financial measure was based on our publicly reported revenue of \$14.4 billion, as adjusted to neutralize the effects of foreign exchange rate fluctuations.
- (5) This financial measure was based on our Non-GAAP free cash flow, as adjusted to exclude the adverse impact of multiple TECFIDERA generic entrants that entered the U.S. market in 2020, the addition of \$177.0 million related to a one-time license payment from a contract manufacturing customer and \$52.0 million related to share repurchases in 2020 under our 2020 Share Repurchase Program, our December 2019 Share Repurchase Program and our March 2019 Share Repurchase Program. These items were either not originally contemplated or their magnitude or timing was uncertain at the time the Company performance goals were originally established.
- (6) This financial measure was based on our publicly reported revenue of \$13.4 billion, as adjusted to neutralize the effects of foreign exchange rate fluctuations and exclude the adverse impact of multiple TECFIDERA generic entrants that entered the U.S. market in 2020.
- (7) Notwithstanding the attainment of these performance metrics and the strength of management's performance, our C&MD Committee believed it was important to hold the members of our Executive Committee, which includes all of our NEOs, accountable for the Company's overall financial results and business performance. As a result, our C&MD Committee exercised its discretion and decreased the multiplier for the 2018 tranche of the 2020 Cash-Settled PSUs for the members of our Executive Committee, including all of our NEOs, by 10%, which resulted in a multiplier for our NEOs of 90%.

### 2018 PSUs Payout

The final payouts under our 2018 Stock-Settled PSUs and 2018 Cash-Settled PSUs were as follows:

Name	Target 2018 Stock-Settled PSU Award at Grant (#)	Actual 2018 Stock-Settled PSU Award Earned (#)	Target 2018 Cash-Settled PSU Award at Grant (\$)	Actual 2018 Cash-Settled PSU Award Earned (\$)
M. Vounatsos	10,895	16,343	\$ 2,300,000	\$ 2,912,816
M. McDonnell	—	—	—	—
A. Sandrock	2,485	3,728	\$ 525,000	\$ 665,229
S. Alexander	3,030	4,545	\$ 640,000	\$ 809,617
C. Guindo	—	—	—	—
J. Capello	—	—	—	—

### 2020 MSUs

MSUs comprised 50% of our executives' target LTI for 2020. MSUs are performance-based RSUs that are earned based on our common stock price performance from the date of grant to each of the three annual vesting dates. Each annual tranche is assessed against our stock price on the original grant date, such that the awards vesting in 2021, 2022 and 2023 will be assessed against the 2020 grant date stock price, thereby aligning long-term executive interests with those of our stockholders. On each vesting date, the performance multiplier is determined based on the stock price growth measured from the grant date to such vesting date using the average closing stock price for the 30


calendar days following and including the grant date and 30 calendar days prior to and including such vesting date for MSUs granted in 2020.

Participants may ultimately earn between 0% and 200% of the target number of MSUs awarded based on our actual stock performance. The maximum payout percentage of MSUs granted in 2020 is consistent with those granted in 2019 (200%). Once the performance multiplier is determined, it is applied to the target number of MSUs granted to each executive and can increase or decrease the overall number of MSUs earned based on our stock price performance.



# 6 Executive Compensation Matters (continued)

## MSU Illustration



The three-year vesting period ties executive compensation directly to our common stock price performance, as both the MSUs earned and the value actually received in respect of MSUs are dependent on the performance of our common stock over the three-year vesting period. On each vesting date, the earned MSUs are settled in shares of our common stock. MSUs directly align long-term interests of our executives with stockholders, as the payout is directly tied to stock price performance.

The following table shows the vesting date, performance period and performance multiplier applied for MSUs vesting in 2020 and 2021:

Grant Date	Vesting Date	Performance Period	Performance Multiplier
2/2020	2/2021	1 year	85%
2/2019	2/2021	2 years	84%
	2/2020	1 year	92%
2/2018	2/2021	3 years	94%
	2/2020	2 years	103%

## Total Target Direct Compensation and Realizable Pay

As part of its review of our NEOs' compensation, our C&MD Committee considers total target direct compensation as well as realizable pay. Total target direct compensation refers to the sum of salary, target bonus and target LTI. Realizable pay refers to the sum of salary, actual bonus and the tracked potential payout value of LTI, including performance criteria and stock price. Other elements such as changes in pension value and nonqualified deferred compensation earnings, shown in the Summary Compensation Table, are not considered in these analyses because they are program-based benefits whose plan designs are not typically subject to annual change. Our C&MD Committee believes these assessments can be used to better align pay with market by focusing on core compensation elements as well as the intended target value and actual value of these awards consistent with our pay for performance philosophy.

For example, Mr. Vounatsos' 2020 total target direct compensation was \$16.25 million, comprised of \$1.5 million base salary, \$2.25 million target bonus (150% of base salary) and \$12.5 million target LTI. As of December 31, 2020, Mr. Vounatsos' realizable pay was calculated at \$13.18 million, which reflects 81% of the target intended value to be delivered, and is comprised of \$1.5 million base salary, \$2.57 million actual bonus payout and \$9.12 million LTI tracking value (numbers may not foot based on rounding). The LTI value in the Summary Compensation Table differs from our C&MD Committee approved target value for 2020 because of the valuation methodology used for accounting purposes in reporting the grant date fair value of equity awards. This valuation is done in accordance with ASC 718. Because incentive compensation makes up such a large portion of compensation for our NEOs, we believe tracking the actual payout and potential realizable value of awards compared to the intended target value to be delivered can help ensure our performance-based incentives and overall compensation are aligned with stockholders.

## Retirement Plans

We maintain a Supplemental Savings Plan (SSP), which is a non-qualified deferred compensation plan covering our executive officers and other eligible employees in the U.S. We offer the SSP as part of the retirement savings component of our benefits program. We designed the SSP to be competitive with the non-qualified deferred compensation plans offered by companies in our peer group at that time. Details of the SSP are discussed under the heading "2020 Non-Qualified Deferred Compensation" below.

## Other Benefits

In addition to eligibility for the benefit programs generally provided to all employees, such as our employee stock purchase plan, 401(k) plan and medical, dental, vision, life and disability insurance, we provide certain supplemental benefits to our executives. These benefits include:

### Life Insurance

All of our U.S. executives, including our NEOs, receive Company-paid term life insurance equal to three times their annual base salary, up to a maximum benefit amount. In 2020 the maximum benefit amount for the CEO was \$1.5 million and was \$2.25 million for the other NEOs. Employees who are not executives receive Company-paid term life insurance equal to two times their annual base salary. The additional value of Company-provided life



# 6 Executive Compensation Matters (continued)

insurance for our executive officers reflects competitive practices and is consistent with our philosophy to provide appropriate levels of financial security for our employees based on their positions within the Company. The cost of Company-paid life insurance in excess of a \$50,000 insurance level is taxable income to U.S. employees and is not grossed up by the Company.

## **Executive Physicals, Tax Preparation, Financial and Estate Planning**

Our executive officers, other than our CEO, are eligible for reimbursement of expenses incurred for tax preparation and financial and estate planning services as well as the purchase of tax preparation and financial planning software, subject to annual expense limits of \$7,500 for Executive Vice Presidents. Such reimbursements are taxable income to our executives and are not grossed up.

All of our executive officers, including our CEO, are eligible for reimbursement for the cost of their executive physicals, subject to the annual expense limits noted above of \$7,500 for our Executive Vice Presidents and CEO. This benefit provides our executives with additional flexibility to proactively manage their health and wellness.

## **Relocation Expenses**

Under our Executive Relocation Policy, we will, in certain circumstances, provide relocation benefits when employees first join us.

## **Post-Termination Compensation and Benefits**

We provide severance benefits to all of our executive officers if their employment is terminated without cause or in certain other circumstances. The terms of these arrangements and the amounts payable under them are described below for each NEO under the heading "Potential Payments Upon Termination or Change in Control." We provide these benefits because we believe that severance protection is necessary to help our executives maintain their focus on the best interests of the Company when providing advice to the Company and when making strategic decisions about a potential corporate transaction or change in control, and further encourages effective leadership in the closing and integration of significant transactions affecting the Company.

## **Stock Ownership Guidelines**

We maintain stock ownership guidelines for our executive officers to strengthen and reinforce the link our compensation programs create between our executives and our stockholders. A summary of our stock ownership guidelines is set forth below.

Level	Number of Shares Equal in Value to:
CEO	6x base salary
Executive Vice Presidents	3x base salary

Executive officers have five years from their initial appointment to meet this requirement. In the event the requirement is not met within that time, 100% of vested shares received in respect of LTI awards are required to be held until the requirement is satisfied. Only stock owned outright and underlying vested or earned performance-based equity awards is credited toward the stock ownership requirement. Shares underlying unvested or unearned performance-based equity awards are not included in the calculation. All of our executive officers currently meet the stock ownership requirement or are still within the five-year period to meet such requirement.

## **Recoupment of Compensation**

We may recover compensation from our employees, including our executive officers, who engage in detrimental or competitive activity. Detrimental activity includes any action or failure to act that constitutes financial malfeasance that is materially injurious to the Company, violates our Code of Business Conduct (Values in Action), results in a restatement of our earnings or financial results or results in a violation or breach of law or contract. Competitive activity includes any action or failure to act that violates non-disclosure, non-competition and/or non-solicitation agreements. Our 2020 Performance-Based Management Incentive Plan allows for the forfeiture and/or repayment of cash-based awards, and our 2008 Omnibus Equity Plan and our 2017 Omnibus Equity Plan each allow for the cancellation of LTI awards in these circumstances as well as the forfeiture of stock or cash acquired upon vesting or sale of LTI awards. In addition, cash sign-on bonuses paid to our NEOs may be subject to repayment if the NEO voluntarily resigns from the Company or if his or her employment is terminated by the Company in certain circumstances.



## 6 Executive Compensation Matters (continued)

### Insider Trading, Hedging and Pledging Policy Prohibitions

We maintain a Global Insider Trading and Information Policy that prohibits our employees, officers, temporary staff and directors, members of their immediate family and family trusts (or similar entities) controlled by or benefitting such persons from, among other things, engaging in hedging or derivative or similar transactions with respect to the Company's equity securities, including, purchases or sales of puts and calls, options, forward contracts, put and call collars, equity or performance swap or exchange fund agreements, or any similar agreements or arrangements, purchasing Company stock on margin, borrowing against any account in which Company securities are held, pledging Company securities as collateral for a loan or engaging in short sales of the Company's securities. No categories of hedging transactions are specifically permitted by our Global Insider Trading and Information Policy and those that are specifically prohibited are noted above.

### Tax-Deductibility of Compensation

Section 162(m) of the Internal Revenue Code generally limits the amount a company may deduct for compensation in excess of \$1.0 million paid to certain "covered employees," subject to certain transition relief applicable to certain arrangements in place as of November 2, 2017, and not materially modified after such date.

Our C&MD Committee regularly reviews the provisions of our plans and programs, works with its independent compensation consultant and reviews and considers, among other things, the tax deductibility of compensation payments. Our C&MD Committee, however, believes that compensation programs that attract, retain and reward executive talent and achievement are necessary for our success and, therefore, are in the best interests of the Company and our stockholders without regard to the potential deductibility of the compensation payable under such programs. Consequently, our C&MD Committee may pay or provide, and has paid or provided, compensation that is not tax deductible in whole or in part.

### Compensation Committee Report

The Compensation and Management Development Committee furnishes the following report:

The Compensation and Management Development Committee has reviewed and discussed the Compensation Discussion and Analysis with Biogen management. Based on this review and discussion, the Compensation and Management Development Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this Proxy Statement.

**Submitted by,**  
Robert W. Pangia (Chair)  
Richard C. Mulligan  
Brian S. Posner

# 6 Executive Compensation Matters (continued)

## Summary Compensation Table

The following table shows the compensation paid to or earned by our NEOs during the years ended December 31, 2020, December 31, 2019, and December 31, 2018, for the year(s) in which they were a named executive officer.

Name and Principal Position (a)	Year (b)	Salary (c)	Bonus <sup>(1)</sup> (d)	Stock Awards <sup>(2)</sup> (e)	Non-Equity Incentive Plan Compensation <sup>(3)</sup> (f)	Change in Pension Value and Nonqualified Deferred Compensation Earnings <sup>(4)</sup> (g)	All Other Compensation <sup>(5)</sup> (h)	Total (i)
<b>Michel Vounatsos</b> Chief Executive Officer	2020	\$1,488,462	—	\$13,887,064	\$2,565,000	\$ 264,358	\$ 454,945	\$18,659,829
	2019	\$1,388,461	—	\$12,352,030	\$3,884,000	\$ 85,667	\$ 449,700	\$18,159,858
	2018	\$1,276,923	—	\$11,064,897	\$3,337,880	\$ 80,663	\$ 408,283	\$16,168,646
<b>Michael R. McDonnell<sup>(6)</sup></b> Executive Vice President and Chief Financial Officer	2020	\$ 294,231	\$1,000,000	\$ 5,012,308	\$ 263,322	—	\$ 5,696	\$ 6,575,557
<b>Alfred W. Sandrock, Jr.</b> Executive Vice President, Research & Development	2020	\$ 890,310	—	\$ 4,331,654	\$ 719,541	\$ 138,444	\$ 147,020	\$ 6,226,969
	2019	\$ 798,723	—	\$ 3,360,682	\$ 893,038	\$ 78,506	\$ 181,616	\$ 5,312,565
<b>Susan H. Alexander</b> Executive Vice President, Chief Legal Officer And Secretary	2020	\$ 809,695	—	\$ 3,583,281	\$ 606,392	\$ 311,416	\$ 159,261	\$ 5,470,045
	2019	\$ 772,373	—	\$ 3,302,619	\$1,033,451	\$ 164,782	\$ 181,785	\$ 5,455,010
	2018	\$ 746,254	—	\$ 4,359,590	\$ 858,744	\$ 188,056	\$ 201,140	\$ 6,353,784
<b>Chirfi Guindo</b> Executive Vice President, Global Product Strategy and Commercialization	2020	\$ 562,819	—	\$ 3,961,285	\$ 527,970	—	\$ 80,721	\$ 5,132,795
	2019	\$ 526,539	—	\$ 3,379,426	\$ 706,384	—	\$ 82,173	\$ 4,694,522
<b>Jeffrey D. Capello<sup>(7)</sup></b> Former Executive Vice President and Chief Financial Officer	2020	\$ 671,132	—	\$ 3,901,503	—	—	\$4,648,876	\$ 9,221,511
	2019	\$ 783,173	—	\$ 4,051,891	\$ 883,575	—	\$ 95,450	\$ 5,814,089
	2018	\$ 750,000	—	\$ 2,889,224	\$ 790,913	—	\$ 46,582	\$ 4,476,719

### Notes to the Summary Compensation Table

- (1) The amount in column (d) reflects a sign-on bonus paid to Mr. McDonnell in connection with his hire. All other cash bonuses, which were based on achievement of performance goals under our annual bonus plan, are disclosed in column (f).
- (2) The amounts in column (e) reflect the grant date fair value, computed in accordance with ASC 718, for RSUs, MSUs and PSUs granted during 2020, 2019 and 2018, as applicable, excluding the effect of estimated forfeitures. The cash portion of PSUs are included in the year when the applicable performance goals are set and the fair value of the PSUs is determinable. The 2020 amounts include one-third of the 2020 Cash-Settled PSUs, one-third of the 2019 Cash-Settled PSUs and one-third of the 2018 Cash-Settled PSUs, which are the tranches of the awards for which performance goals were set in 2020 relating to the 2020 performance period. The 2020 amounts also include a one-time hire award of RSUs granted to Mr. McDonnell as described under the heading "2020 Hiring-Related Compensation Decisions—Arrangements with Mr. McDonnell." The 2019 amounts include one-third of the 2019 Cash-Settled PSUs and one-third of the 2018 Cash-Settled PSUs, which are the tranches of the awards for which performance goals were set in 2019 relating to the 2019 performance period. The 2018 amounts include one-third of the 2018 Cash-Settled PSUs, which is the tranche of the award for which performance goals were set in 2018 relating to the 2018 performance period. The 2018 amounts also include one-time transition awards of RSUs granted to Dr. Sandrock and Ms. Alexander. The grant date fair value for MSU awards are estimated as of the date of grant using a lattice model with a Monte Carlo simulation, based on the probable outcome of applicable performance conditions. The grant date fair value for PSU and RSU awards was determined by multiplying the number of shares subject to the award (assuming target performance for such PSUs) by the closing price of the Company's common stock on the grant date. The assumptions used to calculate the grant date fair value of stock awards are included in footnote 15 of our 2020 Annual Report on Form 10-K. The table below shows the target and maximum payouts possible for the 2020, 2019 and 2018 MSU and PSU awards based on the grant date fair value assuming target and maximum payout levels.

## 6 Executive Compensation Matters (continued)

Executive Officer	2020		2019		2018	
	Target Payout	Maximum Payout	Target Payout	Maximum Payout	Target Payout	Maximum Payout
Mr. Vounatsos	\$13,887,064	\$27,774,128	\$12,352,030	\$24,704,060	\$11,064,897	\$22,129,794
Mr. McDonnell	\$ 2,761,719	\$ 5,523,437	—	—	—	—
Dr. Sandrock	\$ 4,331,654	\$ 8,663,308	\$ 3,360,682	\$ 6,721,364	—	—
Ms. Alexander	\$ 3,583,281	\$ 7,166,562	\$ 3,302,619	\$ 6,605,238	\$ 3,078,822	\$ 6,157,644
Mr. Guindo	\$ 3,961,285	\$ 7,992,570	\$ 3,379,426	\$ 6,758,852	—	—
Mr. Capello	\$ 3,901,503	\$ 7,803,006	\$ 4,051,891	\$ 8,103,782	\$ 2,889,224	\$ 5,778,448

(3) The amounts in column (f) reflect actual bonuses paid under our annual bonus plan for the applicable year.

(4) The amounts in column (g) reflect earnings in the SSP that are in excess of 120% of the applicable federal long-term rate. The federal long-term rates applied in this calculation are 1.61%, 3.73% and 3.06% for 2020, 2019 and 2018, respectively. The SSP is described under the heading "2020 Non-Qualified Deferred Compensation" below.

(5) The amounts in column (h) for 2020 reflect the following:

Executive Officer	Company Matching Contribution to 401(k) Plan Account	Company Contribution to SSP Account	Personal Health and Financial Planning <sup>(8)</sup>	Value of Company-Paid Life Insurance Premiums	Severance <sup>(9)</sup>
Mr. Vounatsos	\$ 17,100	\$ 433,320	\$ 3,470	\$ 1,055	—
Mr. McDonnell	—	—	\$ 5,037	\$ 659	—
Dr. Sandrock	\$ 17,100	\$ 120,725	\$ 7,500	\$ 1,695	—
Ms. Alexander	\$ 17,100	\$ 134,365	\$ 6,160	\$ 1,636	—
Mr. Guindo	\$ 17,100	\$ 58,453	\$ 4,050	\$ 1,118	—
Mr. Capello	\$ 17,100	\$ 72,806	\$ 3,540	\$ 1,662	\$4,553,768

(6) Mr. McDonnell was appointed as our Executive Vice President and Chief Financial Officer effective August 15, 2020. His base salary and annual bonus for 2020 were prorated for the period of the year during which he was employed by the Company.

(7) Mr. Capello ceased to be our Executive Vice President and Chief Financial Officer on August 15, 2020, and separated from the Company on September 15, 2020. Mr. Capello's base salary was prorated for the period of the year during which he was employed by the Company. Mr. Capello was not eligible to receive a bonus under our 2020 annual bonus plan and, in connection with his termination of employment, all of his then unvested RSUs, MSUs and PSUs were forfeited.

(8) Represents reimbursements of expenses relating to tax, financial and estate planning and executive physicals as described under the heading "Executive Physicals, Tax Preparation, Financial and Estate Planning" above.

(9) Mr. Capello ceased to be our Executive Vice President and Chief Financial Officer on August 15, 2020, and separated from the Company on September 15, 2020. The Company provided him the severance benefits required under our executive severance policy for Executive Vice Presidents, which consisted of (a) a lump sum cash payment of \$1,892,625 (16 months of base salary and target bonus), (b) continuation of certain subsidized medical, dental and vision benefits until the earlier of (1) December 31, 2021, or (2) the date on which he becomes eligible to receive benefits through another employer, and (c) up to 12 months of executive-level outplacement services at a cost of up to \$32,000. In addition, in recognition of Mr. Capello's contributions to the Company and to facilitate a successful transition to Mr. McDonnell, our C&MD Committee waived the requirement that Mr. Capello repay 35% of his cash sign-on bonus and approved an additional cash payment to him of \$2,600,000. The cost of the continuation of certain subsidized medical, dental and vision benefits equaled (assuming the benefits continue until December 31, 2021) is \$29,143 and also included the employer portion of premiums for the period April 1, 2021 through September 30, 2021, pursuant to the American Rescue Plan Act of 2021.

# 6 Executive Compensation Matters (continued)

## 2020 Grants of Plan-Based Awards

The following table shows additional information regarding all grants of plan-based awards made to our NEOs for the year ended December 31, 2020.

Name (a)	Grant Date (b)	Notes	Estimated Future Payouts Under Non-Equity Incentive Plan Awards <sup>(1)</sup>			Estimated Future Payouts Under Equity Incentive Plan Awards <sup>(#)(1)</sup>			All Other Stock Awards: Number of Shares or Units (#) (i)	Grant Date Fair Value of Stock Awards <sup>(2)</sup> (j)
			Threshold (c)	Target (d)	Maximum (e)	Threshold (f)	Target (g)	Maximum (h)		
Michel Vounatsos	02/12/2020	(3)	—	—	—	9,420	18,840	37,680	—	\$ 7,669,882
	02/12/2020	(4)	—	—	—	9,370	18,740	37,480	—	\$ 6,217,182
	02/12/2020	(5)	\$ 562,500	\$ 2,250,000	\$ 5,062,500	—	—	—	—	—
Michael R. McDonnell	09/01/2020	(3)	—	—	—	4,023	8,045	16,090	—	\$ 2,761,719
	09/01/2020	(5)	\$ 60,257	\$ 241,027	\$ 542,312	—	—	—	—	—
	09/01/2020	(6)	—	—	—	—	—	—	8,045	\$ 2,250,589
Alfred W. Sandrock, Jr.	02/12/2020	(3)	—	—	—	3,015	6,030	12,060	—	\$ 2,454,888
	02/12/2020	(4)	—	—	—	2,829	5,657	11,314	—	\$ 1,876,766
	02/12/2020	(5)	\$ 169,065	\$ 676,260	\$ 1,521,585	—	—	—	—	—
Susan H. Alexander	02/12/2020	(3)	—	—	—	2,413	4,825	9,650	—	\$ 1,964,292
	02/12/2020	(4)	—	—	—	2,440	4,880	9,760	—	\$ 1,618,989
	02/12/2020	(5)	\$ 142,479	\$ 569,918	\$ 1,282,315	—	—	—	—	—
Chirfi Guindo	02/12/2020	(3)	—	—	—	2,863	5,725	11,450	—	\$ 2,330,685
	02/12/2020	(4)	—	—	—	2,458	4,915	9,830	—	\$ 1,630,600
	02/12/2020	(5)	\$ 99,243	\$ 396,970	\$ 893,183	—	—	—	—	—
Jeffrey D. Capello <sup>(7)</sup>	02/12/2020	(3)	—	—	—	2,638	5,275	10,550	—	\$ 2,147,488
	02/12/2020	(4)	—	—	—	2,644	5,287	10,574	—	\$ 1,754,015
	02/12/2020	(5)	\$ 152,086	\$ 608,344	\$ 1,368,773	—	—	—	—	—

### Notes to the 2020 Grants of Plan-Based Awards Table

- (1) Reflects the potential future payouts of awards granted in 2020 under our 2020 annual bonus plan and our LTI program for each NEO as of the respective grant dates.
- (2) Represents the grant date fair value of PSUs, MSUs and RSUs, as applicable, computed in accordance with ASC 718, excluding the effect of estimated forfeitures. The grant date fair value for MSU awards is estimated as of the date of grant using a lattice model with a Monte Carlo simulation based on the probable outcome of applicable performance conditions. In addition to the grant date fair value of the 2020 Stock-Settled PSUs, for all NEOs other than Mr. McDonnell, the grant date fair value for PSU awards is determined by multiplying the number of shares subject to the award (assuming target performance) by the closing price of our common stock on the grant date. The grant date value of one-third of the 2020 Cash-Settled PSUs, one third of the 2019 Cash-Settled PSUs and one-third of the 2018 Cash-Settled PSUs are included in 2020, which are the tranches of the awards for which performance goals were set relating to the 2020 performance period and the fair value was determinable in 2020. The grant date fair value of the remaining tranches of the 2019 and 2020 Cash-Settled PSUs will be included, as applicable, in the compensation tables for 2021 and 2022, the years when performance goals will be set with respect to such performance periods and fair value will be determinable. The assumptions used to calculate the grant date fair value of stock awards are included in footnote 15 of our 2020 Annual Report on Form 10-K. The maximum payouts for these awards are included in the footnotes following the Summary Compensation Table above.
- (3) These amounts relate to the annual grant of MSUs. These are performance-based RSUs tied to the growth in our stock price between the grant date and each of three annual vesting dates. The number of MSUs earned is determined on each vesting date. Columns (f), (g) and (h) represent the number of MSUs that can be earned based on performance at the threshold level of 50%, target level of 100% and the maximum level of 200%, respectively. To the extent earned, the award becomes eligible to vest ratably over three years, generally subject to continued service, as described in further detail under the heading "Long-Term Incentives" above.
- (4) These amounts relate to the annual grant of PSUs. The PSUs have three-year cliff vesting. The amounts shown include the 2020 Stock-Settled PSUs, one-third of the 2018 Cash-Settled PSUs, one-third of the 2019 Cash-Settled PSUs and one-third of the 2020 Cash-Settled PSUs, which are the tranches of the awards for which performance goals were set in 2020 relating to the 2020 performance period and the fair value was determinable in 2020. The remaining tranches of the 2019 and 2020 Cash-Settled PSUs will be included, as applicable, in the compensation tables for 2021 and 2022, the years when performance goals will be set with respect to such performance periods and fair value will be determinable. Columns (f), (g) and (h) represent the number of 2020 Stock-Settled PSUs and the 2020 tranche of the 2018, 2019 and 2020 Cash-Settled PSUs that can be earned if the Company Multiplier were 50%, 100% and 200%, respectively. For additional information on our PSU awards, please see "Long-Term Incentives" above.



# 6 Executive Compensation Matters (continued)

- (5) These amounts relate to our 2020 annual bonus plan. The amounts shown in column (d) represent the 2020 target payout amount based on the target percentage applied to each NEO's base salary as of December 31, 2020. For 2020 the bonus targets were 150% of base salary for Mr. Vounatsos, 75% of base salary for Messrs. McDonnell and Capello and Dr. Sandrock and 70% of base salary for Ms. Alexander and Mr. Guindo. For Mr. McDonnell, the amounts reported are based on a prorated bonus target for 2020 based on his August 15, 2020, hire date, as described in further detail under the heading "Annual Bonus Plan" above. The amounts in column (c), (d) and (e) represent a payment if the Company Multiplier and the Individual Multiplier were each 50%, 100% and 150%, respectively. Actual amounts paid to each NEO under our 2020 annual bonus plan are included in the "Non-Equity Incentive Plan Compensation" column of the Summary Compensation Table above.
- (6) These amounts relate to a one-time grant of time-based RSUs for Mr. McDonnell, as described in further detail in the CD&A above under the heading "2020 Hiring-Related Compensation Decisions—Arrangements with Mr. McDonnell."
- (7) Mr. Capello separated from the Company on September 15, 2020. As a result of his termination of employment, Mr. Capello forfeited all then unvested RSUs, MSUs and PSUs that were held by him and was not eligible to receive a bonus for 2020 under our 2020 annual bonus plan.

## Outstanding Equity Awards at 2020 Fiscal Year-End

The following table summarizes the equity awards that were outstanding as of December 31, 2020, for each of our NEOs.

(a)	Grant Date (b)	Notes	Stock Awards			
			Number of Shares or Units of Stock That Have Not Vested (c)	Market Value of Shares or Units of Stock That Have Not Vested (d)	Equity Incentive Plan Awards	
					Number of Unearned Shares or Units That Have Not Vested (e)	Market Value of Unearned Shares or Units That Have Not Vested(1) (f)
<b>Michel Vounatsos</b>	2/12/2018	(2)	—	—	6,056	\$ 1,482,872
	2/12/2018	(3)	27,028	\$ 6,618,076	—	—
	2/12/2019	(2)	—	—	12,524	\$ 3,066,627
	2/12/2019	(3)	6,222	\$ 1,523,519	13,827	\$ 3,385,679
	2/12/2020	(2)	—	—	18,840	\$ 4,613,162
	2/12/2020	(3)	2,237	\$ 547,752	16,355	\$ 4,004,685
<b>Michael R. McDonnell</b>	9/1/2020	(2)	—	—	8,045	\$ 1,969,899
	9/1/2020	(4)	8,045	\$ 1,969,889	—	—
<b>Alfred W. Sandrock, Jr.</b>	2/12/2018	(2)	—	—	1,383	\$ 338,641
	2/12/2018	(3)	6,168	\$ 1,510,296	—	—
	2/12/2019	(2)	—	—	3,444	\$ 843,298
	2/12/2019	(3)	1,709	\$ 418,466	3,803	\$ 931,203
	2/12/2020	(2)	—	—	6,030	\$ 1,476,506
2/12/2020	(3)	716	\$ 175,320	5,230	\$ 1,280,618	
<b>Susan H. Alexander</b>	2/12/2018	(2)	—	—	1,687	\$ 413,079
	2/12/2018	(3)	7,515	\$ 1,840,123	—	—
	2/12/2019	(2)	—	—	3,341	\$ 818,077
	2/12/2019	(3)	1,659	\$ 406,223	3,688	\$ 903,044
	2/12/2020	(2)	—	—	4,825	\$ 1,181,450
	2/12/2020	(3)	572	\$ 140,060	4,189	\$ 1,025,719
<b>Chirfi Guindo</b>	2/12/2019	(2)	—	—	3,654	\$ 894,718
	2/12/2019	(3)	1,817	\$ 444,911	4,032	\$ 987,276
	2/12/2020	(2)	—	—	5,725	\$ 1,401,824
	2/12/2020	(3)	680	\$ 166,505	4,974	\$ 1,217,934
<b>Jeffrey D. Capello</b>	—	—	—	—	—	—

Notes to the Outstanding Equity Awards at 2020 Fiscal Year End Table

- (1) The market value of awards is based on the closing price of our stock on December 31, 2020 (\$244.86), as reported on Nasdaq.
- (2) MSUs were granted in 2020, 2019 and 2018. These are performance-based RSUs earned based on the growth in our stock price between the dates of grant and vesting. Earned MSUs are eligible to vest in equal annual installments on each of the first three anniversaries of the grant date, generally subject to continued employment through the applicable vesting date. The number and value shown in columns (e) and (f), respectively, reflect target performance results for MSUs based on the estimated performance at year-end in each case.
- (3) PSUs were granted in 2020, 2019 and 2018. The PSUs, to the extent earned, cliff vest on the third anniversary of the date of grant, generally subject to continued employment through the vesting date. 60% of the PSUs (based on the grant date target value) will be settled in shares of our common stock and performance is based upon achievement of cumulative three-year pipeline goals for the 2020 award and cumulative three-year financial and pipeline goals for the 2019 and 2018 awards. The remaining 40% of the PSUs will

# 6 Executive Compensation Matters (continued)

be settled in cash and performance is based upon the achievement of three annual financial goals determined at the beginning of each relevant year. The number and value shown in columns (c) and (d), respectively, reflect the number of 2020 Cash-Settled PSUs, 2019 Cash-Settled PSUs and 2018 Cash-Settled and Stock-Settled PSUs that were earned based on our achievement of the performance goals, but that will not vest until February 12, 2023, February 12, 2022, and February 12, 2021, respectively. The number and value shown in columns (e) and (f), respectively, reflect the remaining portion of the PSUs granted in 2020 and 2019 (including the 2021 and 2022 tranches of the 2020 Cash-Settled PSUs and the 2021 tranche of the 2019 Cash-Settled PSUs) assuming target performance results. For additional information on our PSU awards, please see "Long-Term Incentive" above.

- (4) RSU awards for Mr. McDonnell reflect RSUs granted on September 1, 2020, in connection with his hiring.

## 2020 Option Exercises and Stock Vested

Our executive officers must use pre-established trading plans to sell shares of our common stock. Trading plans may only be entered into during an open trading window and when the executive is not in possession of material non-public information about the Company, and we require a waiting period following the establishment of a trading plan before any trades may be executed. Our policy is designed to provide safeguards while allowing our executives an opportunity to realize the value intended by the Company in granting equity-based LTI awards.

Our NEOs are also subject to the stock ownership guidelines described above under the heading "Stock Ownership Guidelines."

The following table shows information regarding the exercise of stock options and the vesting of stock awards for each NEO during the year ended December 31, 2020.

Name	Stock Awards	
	Number of Shares Acquired on Vesting <sup>(1)</sup>	Value Realized on Vesting <sup>(2)</sup>
Michel Vounatsos	23,986	\$7,754,636
Michael R. McDonnell	—	—
Alfred W. Sandrock, Jr.	8,215	\$2,674,660
Susan H. Alexander	9,807	\$3,188,471
Chirfi Guindo	2,945	\$ 864,954
Jeffrey D. Capello	3,221	\$1,019,748

Notes to the 2020 Option Exercises and Stock Vested Table

- (1) Cash-settled performance units (CSPUs) that were granted in 2017 were settled in cash for Mr. Vounatsos, Dr. Sandrock and Ms. Alexander. The number of actual shares of our common stock acquired on vesting of MSUs and RSUs in 2020, after shares were withheld to pay the minimum withholding of taxes, was as follows:

	Net Shares Acquired <sup>(3)</sup>
Mr. Vounatsos	9,796
Mr. McDonnell	—
Dr. Sandrock	3,990
Ms. Alexander	4,596
Mr. Guindo	1,879
Mr. Capello	2,201

- (2) The value realized for MSUs and RSUs was calculated by multiplying the closing price of a share of our common stock on the vesting date by the total number of shares that vested on such date. The value realized for CSPUs is calculated using the 30-day average closing price of the common stock of the Company through the vesting date.
- (3) MSUs and RSUs were settled in shares of our common stock. CSPUs were settled in cash.

## 6 Executive Compensation Matters (continued)

### 2020 Non-Qualified Deferred Compensation

The SSP covers our executive officers and other eligible employees in the U.S. Employees whose base salary and annual cash incentives for the year exceed a specified Internal Revenue Service's limit (\$285,000 in 2020) receive a Company-paid restoration match on the portion of their base salary, annual bonus and cash payments in respect of CSPUs, as applicable, that exceeds this limit; the restoration match equals 6% of this excess compensation. The restoration match feature is intended to provide the amount of matching employer contributions that the participant would otherwise have been eligible to receive under our 401(k) plan but for the \$285,000 limit imposed by Section 401(a)(17) of the Internal Revenue Code. In addition, eligible employees may make voluntary contributions of up to 80% of their base salary and 100% of their annual bonus and cash payments in respect of CSPUs, as applicable, to the SSP, and thereby defer income taxes on such amounts until distribution is made from the SSP. The Company does not match participants' voluntary contributions to the SSP. The SSP provides for immediate vesting of the restoration match consistent with our immediate vesting of the Company match provided under our 401(k) plan.

Notional SSP accounts are maintained for each participant. Accounts include employee and employer contributions and reflect the performance of notional investments selected by the employee or a default investment if the employee does not make a selection. These notional investment options

include the mutual funds offered under our 401(k) plan as well as a fixed rate option which earns a rate of return determined each year by the Company's retirement committee. For contributions to the SSP fixed rate option in 2020, this rate of return was set at 5%. Contributions to the fixed rate option continue to earn interest at the rate of return that was in effect during the year of contribution. The excess of the interest rate paid on the fixed rate option above 120% of the applicable federal long-term rate (compounded quarterly) earned by our NEOs during 2020 is shown in the Summary Compensation Table. We fund the SSP liabilities through corporate-owned life insurance (COLI), which we purchase with the written consent of SSP participants, and investments in mutual funds. We believe that the COLI policies and mutual funds will be sufficient to cover plan liabilities through the projected payout date so the plan will not require direct funding by the Company. Upon enrollment in the SSP, a participant must elect when and how distributions will be made from the participant's account. Distributions can be made upon termination of the participant's employment, either in a lump sum or up to 15 annual installments, or at a specified future date while the participant is still employed (an "in-service" distribution), either in a lump sum or up to 5 annual installments. Further, upon enrollment, a participant must also elect a distribution method upon death or a change in control of the Company, which can either be a lump sum payment or, if different, the method selected for payment upon termination of employment.

The following table shows a summary of all contributions to, earnings on and distributions received from the SSP for each of our NEOs for the year ended December 31, 2020. The account balances as of year-end include all contributions and interest amounts earned by our NEOs through the end of 2020 plus the SSP contributions that the Company made in early 2021 based on earnings in the last quarter of 2020.

Name	Executive Contributions in Last Fiscal Year <sup>(1)</sup>	Company Contributions in Last Fiscal Year <sup>(2)</sup>	Aggregate Earnings in Last Fiscal Year <sup>(3)</sup>	Aggregate Distributions in Last Fiscal Year	Aggregate Balance at Last Fiscal Year-End <sup>(4)</sup>
Michel Vounatsos <sup>(5)</sup>	\$3,193,708	\$433,320	\$518,977	—	\$11,835,075
Michael R. McDonnell	—	—	—	—	—
Alfred W. Sandrock, Jr.	\$ 223,260	\$120,725	\$235,734	—	\$ 4,279,898
Susan H. Alexander	\$1,000,194	\$134,365	\$548,853	—	\$10,406,185
Chirfi Guindo	\$ 677,671	\$ 58,453	\$233,703	—	\$ 1,833,959
Jeffrey D. Capello	—	\$ 72,806	\$ 480	—	\$ 167,923

Notes to the 2020 Non-Qualified Deferred Compensation Table

- (1) The amounts in this column are also included, in part, in columns (c) and/or (f) of the Summary Compensation Table and represent deferral of salary and deferral of payments under our 2020 annual bonus plan, respectively.
- (2) The amounts in this column are also included in column (h) of the Summary Compensation Table for 2020 as Company contributions to the SSP.
- (3) Earnings in excess of 120% of the applicable federal long-term rate are reported in column (g) of the Summary Compensation Table for 2020 for Mr. Vounatsos (\$264,358), Dr. Sandrock (\$138,444) and Ms. Alexander (\$311,416).



# 6 Executive Compensation Matters (continued)

- (4) The following table lists the compensation deferrals during 2019 and 2018 by the NEOs, as reported, where applicable, in the proxy statement for our 2020 and 2019 annual meetings of stockholders:

Name	Amounts Previously Reported as Deferred	
	2019	2018
Mr. Vounatsos	\$1,765,018	\$ 3,071,852
Dr. Sandrock	\$ 245,492	—
Ms. Alexander	\$ 838,564	\$ 826,451
Mr. Guindo	\$ 618,828	—
Mr. Capello	—	—

This column also includes Company contributions and compensation earned and deferred in prior years, which was disclosed in our prior proxy statements where applicable, together with earnings on these amounts.

- (5) On February 12, 2021, cash-settled PSUs that were elected as deferred by Mr. Vounatsos became vested and credited to the SSP. The earned amount was \$891,328.

## Potential Payments Upon Termination or Change in Control

### Executive Severance Policy

#### Definition of Key Terms Relating to our Executive Severance Policy

Our executive severance policy and benefits refer to certain key terms, including cause, change in control, retirement, involuntary employment action and disability. These terms are defined in our 2017 Omnibus Equity Plan.

#### Executive Vice President Arrangements

Each of our NEOs, other than Mr. Vounatsos, was covered by our executive severance policy in 2020 under which he or she was eligible to receive the following benefits if certain events occurred during 2020:

- In the event of a termination of employment other than for cause and other than by reason of the executive's death or disability, the NEO would be entitled to receive a lump sum severance payment equal to a minimum of 12 months of such NEO's then base salary and target bonus as then in effect, with an additional 2 months of base salary and target bonus for each full year of service, up to a maximum benefit of 21 months of base salary and target bonus. We refer to the number of months of severance an NEO is entitled to receive as the "severance period."
- If, within two years following a corporate transaction or a corporate change in control, the NEO experiences a termination of employment other than for cause and other than by reason of death or disability or experiences an involuntary employment action, the NEO would be entitled to a lump sum severance payment equal to two times the NEO's annual base salary plus target annual

bonus as then in effect. These payments are in lieu of any payment in the preceding paragraph.

The payment of these severance benefits is conditioned upon execution of an irrevocable release in favor of the Company.

The executive severance policy does not pay severance upon a termination for cause, voluntary resignation, retirement or death or disability.

In any case where severance is payable under our executive severance policy, our NEOs would also receive continuation of medical, dental and vision insurance benefits until the earlier of the end of the severance period or the date the executive becomes eligible to participate in another employer's medical, dental and vision insurance plans. NEOs would also be provided up to 12 months of executive-level outplacement services at our cost.

#### Annual Bonus Plan

Our annual bonus plan provides for a prorated target bonus payment upon a termination of employment due to the death or disability of the participant. As our annual bonus plan provides for payment of a full bonus to any participant remaining employed on the last day of the plan year, annual bonus amounts are not included in the Potential Post-Termination Payments Table below.

#### Mr. Vounatsos' Arrangements

We entered into an employment agreement with Mr. Vounatsos effective January 6, 2017. The agreement had an initial term that ended on December 31, 2019, and now the term automatically extends each year for additional 12-month periods until the agreement is otherwise terminated in accordance with its terms.

## 6 Executive Compensation Matters (continued)

Under Mr. Vounatsos' employment agreement, if his employment is terminated by the Company without cause or if he terminates his employment for good reason (referred to in his employment agreement as an involuntary employment action), then he would be entitled to a lump sum payment of cash severance in the amount of one and one-half times his annual base salary and target annual bonus. If, however, such termination of employment occurs within two years following a corporate transaction or a corporate change in control (CIC), then he would be entitled to a lump sum payment of cash severance in the amount of two times his annual base salary and target annual bonus. Mr. Vounatsos would also receive continuation of medical, dental and vision benefits until the earlier of 18 months (24 months if within 2 years of a CIC) following the date his employment terminates or the date upon which he becomes eligible to receive substantially comparable benefits through another employer. In addition, he would be entitled to receive a pro rata portion of his annual cash bonus for the year that such termination occurs based on actual performance or, in the event the termination occurs within two years following a CIC, a pro rata portion of his target annual bonus. Mr. Vounatsos would also be provided executive-level outplacement services for a 12-month period following the termination date at our cost. The payment of Mr. Vounatsos' severance benefits is conditioned upon execution of a general release in favor of the Company.

### *Mr. Capello Arrangements*

On August 15, 2020, Mr. Capello ceased to be our Executive Vice President and Chief Financial Officer and effective September 15, 2020, Mr. Capello ceased to be employed by us. We paid him the severance benefits payable under our executive severance policy for Executive Vice Presidents and certain additional benefits, as described in the CD&A above under the heading "2020 Hiring- and Transition-Related Compensation Decisions—Arrangements with Mr. Capello." The amounts received by Mr. Capello in connection with his termination of employment are included in the Summary Compensation Table above in the "All Other Compensation" column.

### *Excise Tax Provisions*

Before June 2009 we maintained an excise tax gross-up policy for all of our executives, including certain of our NEOs. Under this policy, if payments to these executive officers in the event of a corporate transaction or corporate change in control were subject to the excise tax under Internal Revenue Code Section 4999, we would pay the executive officer an additional amount that equals the

amount of the excise tax, plus the income and other payroll taxes arising from our payment of the excise tax amount (280G tax gross-up), so that the executive officer realized the full intended benefit.

In June 2009 we changed our excise tax gross-up policy so that newly-hired executives are not eligible for any 280G tax gross-up but may elect to have severance payments reduced to an amount that will not be subject to excise tax. Consistent with this policy, as Ms. Alexander and Dr. Sandrock were already eligible for this benefit prior to June 2009, they each remained eligible for a 280G tax gross up. In March 2020 Ms. Alexander and Dr. Sandrock each voluntarily waived their rights to this benefit. As a result, no executive officer is currently eligible for any such excise tax gross-up.

### *Awards Under Equity Plans*

Under the provisions of our 2008 Omnibus Equity Plan and our 2017 Omnibus Equity Plan, unless otherwise determined by our C&MD Committee at the time of grant, awards will vest or become exercisable in full immediately prior to an involuntary employment action that occurs within two years following a corporate change in control (i.e., upon a "double trigger").

In the event of a corporate transaction, we can either cause the surviving corporation to assume all equity awards or accelerate their vesting and exercisability immediately before the corporate transaction. If the equity awards are assumed and a NEO's employment is terminated in an involuntary employment action within two years following the corporate transaction, the equity awards that are assumed will become fully vested and, if applicable, exercisable.

If the holder of an equity award retires, which is defined under our equity plans as leaving the employment of Biogen after reaching age 55 with 10 consecutive years of service, each then outstanding time-based equity award or earned performance-based equity award not yet vested will become immediately vested upon such termination at a rate of 50% of the shares unvested at the time of retirement plus an additional 10% of the shares for each full year of service beyond 10 years of service (and performance-based awards would remain eligible to vest based on actual performance). Upon a termination of employment due to death or disability, all unvested time-based equity awards and earned performance-based equity awards vest in full and all unearned performance-based equity awards remain eligible to vest based on actual performance. As of December 31, 2020, Dr. Sandrock and Ms. Alexander were eligible for retirement under our equity plans.



# 6 Executive Compensation Matters (continued)

## Potential Post-Termination Payments Table

The following table summarizes the potential payments to each NEO under various termination events. The table assumes that the event occurred on December 31, 2020, for all NEOs except for Mr. Capello who separated from the Company during 2020. The calculations use the closing price of our common stock as reported by Nasdaq on December 31, 2020, which was \$244.86 per share.

Name and Payment Elements <sup>(1)</sup> (a)	Retirement <sup>(2)</sup> (b)	Qualifying Termination of Employment Not Following a Corporate Transaction or Change in Control (c) <sup>(3)</sup>	Qualifying Termination of Employment Following a Corporate Transaction or Change in Control (d) <sup>(3)</sup>
<b>Michel Vounatsos(4)</b>			
Severance	—	\$5,625,000	\$ 7,500,000
Performance-based RSUs	—	—	\$23,217,461
Medical, Dental and Vision	—	\$ 29,532	\$ 39,376
Outplacement <sup>(5)</sup>	—	\$ 32,000	\$ 32,000
<b>Total</b>	<b>—</b>	<b>\$5,686,532</b>	<b>\$30,788,837</b>
<b>Michael R. McDonnell</b>			
Severance	—	\$1,487,500	\$ 2,975,000
Performance-based RSUs	—	—	\$ 1,761,269
Time-based RSUs	—	—	\$ 1,969,899
Medical, Dental and Vision	—	\$ 19,656	\$ 39,312
Outplacement <sup>(5)</sup>	—	\$ 32,000	\$ 32,000
<b>Total</b>	<b>—</b>	<b>\$1,539,156</b>	<b>\$ 6,777,480</b>
<b>Alfred W. Sandrock, Jr.</b>			
Severance	—	\$2,761,396	\$ 3,155,881
Performance-based RSUs	\$6,380,053	\$6,380,053	\$ 6,380,053
Medical, Dental and Vision	—	\$ 24,943	\$ 28,506
Outplacement <sup>(5)</sup>	—	\$ 32,000	\$ 32,000
<b>Total</b>	<b>\$6,380,053</b>	<b>\$9,198,392</b>	<b>\$ 9,596,440</b>
<b>Susan H. Alexander</b>			
Severance	—	\$2,422,150	\$ 2,768,172
Performance-based RSUs	\$5,576,815	\$5,576,815	\$ 6,196,461
Medical, Dental and Vision	—	\$ 24,921	\$ 28,481
Outplacement <sup>(5)</sup>	—	\$ 32,000	\$ 32,000
<b>Total</b>	<b>\$5,576,815</b>	<b>\$8,055,886</b>	<b>\$ 9,025,114</b>
<b>Chirfi Guindo</b>			
Severance	—	\$1,446,105	\$ 1,928,140
Performance-based RSUs	—	—	\$ 4,575,719
Medical, Dental and Vision	—	\$ 30,269	\$ 40,359
Outplacement <sup>(5)</sup>	—	\$ 32,000	\$ 32,000
<b>Total</b>	<b>—</b>	<b>\$1,508,374</b>	<b>\$ 6,576,218</b>

### Notes to the Potential Post-Termination Payments Table

- (1) In the event of an executive's death or disability, all outstanding time-based equity awards and earned performance-based equity awards under our LTI program will vest in full and all unearned performance-based equity awards will remain outstanding and eligible to vest based on actual performance. The value of such accelerated awards for all NEOs would be the same amount as shown in column (d) for such NEO (based on actual performance estimated as of December 31, 2020).
- (2) Dr. Sandrock and Ms. Alexander were eligible for potential payments upon retirement at December 31, 2020. Based on years of service, Dr. Sandrock and Ms. Alexander were eligible for accelerated vesting on 100% and 90%, respectively, of their outstanding equity awards as of December 31, 2020. Any unvested PSU and MSU awards would, subject to the achievement of any applicable performance goals, remain outstanding and eligible to be earned and vest in accordance with the terms of such awards based on actual performance as to 100% for Dr. Sandrock and 90% for Ms. Alexander of the earned PSUs or MSUs, as applicable. The amount listed in column (b) is the estimated value of 100% of all unvested awards held by Dr. Sandrock and 90% of all unvested awards held by Ms. Alexander, based on actual performance estimated as of December 31, 2020, for unearned performance-based awards.
- (3) The amounts listed in column (c) and column (d) for Performance-based RSUs for the applicable named executive officers includes the value of applicable unvested awards based, where applicable, on actual performance estimated as of December 31, 2020.

## 6 Executive Compensation Matters (continued)

- (4) Pursuant to his employment agreement, upon an involuntary termination by the Company without cause or involuntary employment action not following a corporate transaction or CIC, Mr. Vounatsos is eligible to receive a lump sum payment within 60 days of such termination consisting of the pro rata portion of the target bonus for the year of termination and an amount equal to the sum of the annual base salary rate and target bonus in effect at the time of termination multiplied by a factor of 1.5, continuation of medical, dental and vision insurance for up to 18 months and up to 12 months of executive outplacement services. Upon an involuntary termination by the Company without cause or an involuntary employment action following a corporate transaction or CIC, Mr. Vounatsos is eligible to receive a lump sum payment within 60 days consisting of the pro rata portion of the target bonus for the year of termination and an amount equal to the sum of the annual base salary rate and target bonus in effect at the time of termination multiplied by a factor of 2.0, continuation of medical, dental and vision insurance for up to 24 months and up to 12 months of outplacement services.
- (5) The named executive officers are provided outplacement services at a cost of up to \$32,000 for the Executive Vice President level.

### CEO Pay Ratio

We believe executive pay must be internally consistent and equitable to motivate our employees to create stockholder value, and we are committed to internal pay equity. As discussed earlier in this Proxy Statement, our compensation programs are designed to drive the creation of long-term stockholder value by delivering performance-based compensation. We invest in our employees at all levels in the Company by rewarding performance that balances risk and reward, empowering professional growth and development and offering affordable benefits and programs that meet the diverse needs of our employees.

We believe strongly in pay-for-performance, and all of our employees are eligible to participate in our annual bonus plan, our LTI programs and our benefit plans. Our annual bonus plan is consistently maintained for all participants globally, with the same Company performance goals, payout levels (as a percentage of target) and administrative provisions regardless of the participant's job level, location or function in the Company. We also have a long-term incentive program that provides different forms of awards depending upon an employee's level but is otherwise consistent throughout the Company.

The following is a reasonable estimate, prepared under applicable SEC rules, of the ratio of the annual total compensation of our CEO to the median of the annual total compensation of our other employees. We determined our median employee as of December 31, 2020, based on a consistently applied compensation measure defined as the sum of base salary, target bonus and LTI target value. We annualized pay for employees who commenced employment during 2020.

Our median employee is a full-time employee based in the U.S. In December 2020, when we determined the median employee, approximately 61% of our workforce was based in the U.S. with the remaining approximately 39% of our workforce based in the rest of the world. In addition, approximately 98% of our workforce was full-time.

For our median employee, annual total compensation was calculated in accordance with the SEC's rules for the Summary Compensation Table, including salary, bonus, LTI grant date fair value and value of certain benefits provided. For our CEO, annual total compensation is equal to the amount included in the "Total" column of the Summary Compensation Table, and our CEO's annual total compensation for 2020 was \$18,659,829. The annual total compensation of the median employee, as determined in accordance with the SEC's rules, for 2020 was \$155,378. Based on the foregoing, our estimate of the ratio of the annual total compensation of our CEO to the median of the annual total compensation of our other employees was 120 to 1. This pay ratio is a reasonable estimate calculated in a manner consistent with SEC rules based on our payroll and employment records and the methodology described above. Given the different methodologies, estimates, assumptions and exclusions that other public companies use to determine an estimate of their pay ratio, the estimated ratio reported above should not be used as a basis for comparison between companies.



# 7 Other Management Proposal

## Proposal 4 – Approve an Amendment to Biogen’s Amended and Restated Certificate of Incorporation, as Amended, to Add a Federal Forum Selection Provision

Currently, our Amended and Restated Certificate of Incorporation, as amended (the Certificate of Incorporation), does not include a federal forum selection provision. In response to a decision in the Delaware Supreme Court validating federal forum selection provisions, our Board of Directors reviewed the provision from a legal and policy perspective. In light of this Delaware Supreme Court decision, our Board of Directors has determined that it is in the best interests of our company and our stockholders to seek to include a federal forum selection provision in our Certificate of Incorporation.

We are seeking stockholder approval to amend Article XII of our Certificate of Incorporation to provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. In other words, we are seeking to include a federal forum selection provision.

### Effect of the Amendment

Having the federal forum selection provision allows for (a) the consolidation of multi-jurisdiction litigation, (b) avoidance of state court forum shopping and (c) efficiencies in managing the procedural aspects of securities litigation. Given these considerations, our Board of Directors has determined that it is in the best interests of our company and our stockholders that our Certificate of Incorporation be amended to include this federal forum selection provision. There is, however, uncertainty as to whether a court would enforce this provision.

Although we are seeking approval of this provision for the reasons cited above, if this provision is approved and implemented, the effects of this amendment may include, but are not limited to, that this provision could discourage claims or limit investors’ ability to bring a claim in a judicial forum that they find favorable.

This federal forum selection clause, if it is approved by our stockholders and becomes effective, would be in addition to a provision in our Certificate of Incorporation which provides that the Court of Chancery of the State of Delaware is the exclusive forum for: (1) any derivative action brought on our behalf and (2) any direct action brought by a stockholder against us or any of our directors or officers alleging a violation of the Delaware General Corporation Law, our Certificate of Incorporation or our Bylaws or breach of fiduciary duties or other violation of Delaware decisional law relating to the internal affairs of the corporation. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Accordingly, the exclusive forum provision in our Certificate of Incorporation relating to the Court of Chancery of the State of Delaware does not apply to claims arising under the Exchange Act.

### Language of Proposed Amendment

If approved, the amendment would enable us to amend our Certificate of Incorporation by amending Article XII to read as follows:

#### “ARTICLE XII

(a) Exclusive Forum. Unless the Board of Directors or one of its committees otherwise consents to the selection of an alternate forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action brought on behalf of the corporation and (ii) any direct action brought by a stockholder against the corporation or any of its directors or officers alleging a violation of the Delaware General Corporation Law, the corporation’s certificate of incorporation or bylaws or breach of fiduciary duties or other violation of Delaware decisional law relating to the internal affairs of the corporation; in each case excluding actions in which the Court of Chancery of the State of Delaware concludes that an indispensable party is not subject to the jurisdiction of the Delaware courts and can be subject to the jurisdiction of another court within the United States.

(b) Federal Forum. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Any person or entity purchasing or otherwise acquiring any interest in any security of the Corporation shall be deemed to have notice of and consented to this provision.”

A copy of the proposed amendment to our Certificate of Incorporation is provided as [Appendix B](#) to this proxy statement.



## 7 Other Management Proposal (continued)

### Vote Required

Approval of the amendment to our Certificate of Incorporation requires the affirmative vote of a majority of shares issued and outstanding and entitled to vote on the proposal. Abstentions and broker non-votes will have the effect of votes against this proposal. If a proxy card is signed and returned but no direction is made, the persons named in your proxy will vote your shares "FOR" this proposal.

If our stockholders approve the proposed amendment to our Certificate of Incorporation, it will become effective upon filing with the Secretary of State of the State of Delaware of a certificate setting forth the amendment, which we anticipate doing as soon as practicable following stockholder approval.

**OUR BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE *FOR* THE APPROVAL OF AN AMENDMENT TO BIOGEN'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO ADD A FEDERAL FORUM SELECTION PROVISION**



# 8 Stockholder Proposals

## Proposal 5 – Stockholder Proposal Requesting a Report on Biogen’s Lobbying Activities

Mr. James McRitchie and Ms. Myra K. Young (whom we sometimes refer to as the Proposal 5 Proponents) have notified us that they intend to submit the following proposal for consideration at the Annual Meeting. The Proposal 5 Proponents have indicated that they beneficially own 25 shares of our common stock. We will provide their address promptly upon a stockholder’s oral or written request. The Proposal 5 Proponents are responsible for the content of the proposal, for which we and our Board of Directors accept no responsibility. The proposal will be voted on at the Annual Meeting if the Proposal 5 Proponents, or a qualified representative, is present at the Annual Meeting and submits the proposal for a vote. Our statement in opposition follows the proposal.

**OUR BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE AGAINST THE APPROVAL OF THIS STOCKHOLDER PROPOSAL.**

### Proposal 5 – Disclose Lobbying Expenditures

**Full disclosure of Biogen’s direct and indirect lobbying activities and expenditures is needed to assess whether Biogen’s lobbying is consistent with its expressed goals and stockholder interests.**

**Resolved:** Stockholders of Biogen request preparation of an annual report disclosing:

1. Company policy and procedures governing lobbying, both direct and indirect, and grassroots lobbying communications.
2. Payments by Biogen used for (a) direct or indirect lobbying or (b) grassroots lobbying communications, in each case including the amount of the payment and the recipient.
3. Biogen’s membership in and payments to any tax-exempt organization that writes and endorses model legislation.
4. Description of management’s decision-making process and the Board’s oversight for making payments described in section 2 above.

For purposes of this proposal, “grassroots lobbying communication” is communication directed to the general public that (a) refers to specific legislation or regulation, (b) reflects a view on legislation or regulation and (c) encourages the communication recipient to take action with respect to legislation or regulation. “Indirect lobbying” is lobbying engaged in by a trade association or other organization of which Biogen is a member.

Both “direct and indirect lobbying” and “grassroots lobbying communications” include efforts at local, state and federal levels.

The report shall be presented to the Corporate Governance Committee and posted on Biogen’s website.

### Supporting Statement

Biogen spent \$20,761,680 from 2010 – 2019 on federal lobbying. This does not include state lobbying, where Biogen also lobbies but disclosure is uneven or absent. For example, Biogen lobbied in at least 18 state in 2019 ([followthemoney.org](http://followthemoney.org)).

Biogen’s trade association and social welfare group disclosure has gaps for memberships and spending. Biogen discloses trade associations receiving more than \$25,000 and amounts used to lobby, including the Pharmaceutical Research and Manufacturers of America (PhRMA). Biogen’s disclosure fails to capture memberships in and support for the Healthcare Leadership Council, which spent \$660,000 lobbying in 2019, National Pharmaceutical Council, and Alliance for Patient Access (AfPA), a social welfare group. And Biogen reported \$8,916,842 in PhRMA lobbying payments, while reporting \$5,136,680 in federal lobbying for 2018 and 2019. Therefore, at least \$3,780,162 of Biogen’s payments were used for non-federal lobbying and grassroots. Grassroots lobbying is not reported at the federal level under the Lobbying Disclosure Act. State-level disclosure is uneven or absent.

We are concerned Biogen’s payments to third party groups are potentially used for undisclosed grassroots lobbying. For example, PhRMA, with 2018 revenues of \$459 million, gave millions to “dark money” social welfare groups, which “advocated policies favored by drugmakers”.<sup>1</sup> PhRMA has also been linked to “pharma-backed astroturf group” Coalition Against Socialized Medicine.<sup>2</sup> AfPA has been described as “a front group established solely to do the bidding of industry.”<sup>3</sup>

We urge Biogen to expand its lobbying disclosure.



# 8 Stockholder Proposals (continued)

- 1 <https://www.opensecrets.org/news/2019/11/big-pharma-bankrolled-conservative-groups-tax-returns-show/>
- 2 <https://prospect.org/health/pharma-backed-astrourf-group-drug-prices/>
- 3 <https://www.healthnewsreview.org/2017/10/non-profit-alliance-patient-access-uses-journalists-politicians-push-big-pharmas-agenda/>

## Company Statement in Opposition

**Our Board of Directors recommends that stockholders vote AGAINST this stockholder proposal for the following reasons:**

### Lobbying priorities and disclosure.

Our lobbying priorities consider the interests of patients, our company, stockholders, employees and other stakeholders. In 2020 our federal lobbying priorities focused on healthcare, access to prescription drugs and patent protection, all of which directly impact our business and stockholder value.

Our Board of Directors and its committees play an important role in our public policy engagement and have oversight responsibilities for these activities. The Corporate Governance Committee is responsible for reviewing annually the Company's actions related to our lobbying priorities and activities, including associations with certain trade and/or legislative organizations.

We value transparency in this process and appreciate the need for disclosure of our political activity to promote ethical corporate governance and confidence in the democratic process. Our corporate political contributions are disclosed in accordance with applicable federal and state campaign finance laws and in our semi-annual Political Contributions Disclosures. All Political Contributions Disclosures as well as our United States Political Contributions Policy are available on our website at <https://investors.biogen.com/governance/political-contributions-disclosures>.

In the U.S., we comply with important federal and state lobbying registration and disclosure laws. Our current disclosures, detailing our federal lobbying priorities, are fully compliant with the Federal Lobbying Disclosure Act and the Honest Leadership and Open Government Act and are filed quarterly with the U.S. House of Representatives and the U.S. Senate. Included in the report is the total amount spent on federal lobbying activity for the quarter, which includes the percentage of our dues to trade associations spent on federal lobbying activity, payments to outside consultants and the time spent by Biogen colleagues on federal lobbying activity. Our disclosures on federal lobbying activities may be viewed at: <https://soprweb.senate.gov/index.cfm?event=selectfields>.

We are also fully compliant with state registration and reporting requirements in all of the states where we operate. These state reports are publicly available at the appropriate state agency or on the state's public web site.

Moreover, our lobbying activities are subject to robust internal procedures designed to align these efforts with our public policy priorities and applicable law. We have a robust training and reporting program in place to ensure colleague compliance.

### Our engagement with lawmakers and trade and industry organizations.

We operate in a highly regulated and competitive industry and continue to face significant legislative and regulatory challenges. It is essential that we actively engage with lawmakers and trade and industry organizations to help build constructive discourse in the political and regulatory environment in support of our business priorities. To enhance these efforts, we are members of several industry and trade groups. We believe value exists in making sure our positions on issues important to us and our industry are communicated and understood within these organizations.

A listing of our current memberships with several industry and trade groups is available on our website at:

<https://investors.biogen.com/governance/political-contributions-disclosures>.

### Annual evaluation and oversight of our support for trade and industry groups.

We annually evaluate our support of industry and trade groups based on these organizations' expertise in healthcare policy and advocacy and support of key issues of importance to us. In addition to their positions on healthcare policy issues, we realize these organizations may engage in a broad range of other issues that extend beyond the scope of issues of primary importance to us. If concerns arise about an issue, we are able to convey our concerns, as appropriate, through our colleagues who serve on the boards and committees of these groups. Decisions to provide funding are based on an organization's support of issues that impact our industry, including advancing biomedical research, healthcare innovation, advocating for protecting intellectual property rights and access to medicines.

### Summary.

We believe our enhanced disclosures provide transparency into and accountability regarding lobbying activities that is responsive to the proposal and that the proposal's additional reporting obligation would be burdensome and unnecessary.



# 8 Stockholder Proposals (continued)

## Proposal 6 – Stockholder Proposal Requesting a Report on Biogen’s Gender Pay Gap

Proxy Impact (whom we sometimes refer to as the Proposal 6 Proponent) has notified us that it intends to submit the following proposal for consideration at the Annual Meeting. Proxy Impact has represented that it is authorized by owners of 50 shares of our common stock to submit this proposal. We will provide the Proposal 6 Proponent’s address promptly upon a stockholder’s oral or written request. The Proposal 6 Proponent is responsible for the content of the proposal, for which we and our Board accept no responsibility. The proposal will be voted on at the Annual Meeting if the Proposal 6 Proponent, or a qualified representative, is present at the Annual Meeting and submits the proposal for a vote. Our statement in opposition follows the proposal.

**OUR BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE AGAINST THE APPROVAL OF THIS STOCKHOLDER PROPOSAL.**

### Whereas:

The 2017 U.S. Census data on median earnings for full-time, year-round workers found that women made 80 percent of that of their male counterparts. The gap for African America and Latina women is 60 percent and 55 percent. At the current rate, women will not reach pay parity until 2059.

Mercer finds actively managing pay equity “is associated with higher current female representation at the professional through executive levels and a faster trajectory to improved representation.” Research from *Morgan Stanley, McKinsey, and Robeco Sam* suggests more gender diverse leadership leads to superior stock price performance and return on equity. *McKinsey* states, “the business case for the advancement and promotion of women is compelling.” Best practices include “tracking and eliminating gender pay gaps.”

Assessing if a company has a gender pay gap requires analyzing both equal pay and equal opportunity. This is most commonly done using adjusted and unadjusted (median) pay data. Median pay data is the key metric used by the Organization for Economic Cooperation and Development, the World Economic Forum, and the U.S. Department of Labor, among others.

Since 2018, the UK has mandated disclosures of both adjusted and unadjusted (median) gender pay data, demonstrating that the publication of such data is feasible and informative. Biogen UK provides an annual gender pay report that reports mean and median gender pay gap and bonus gap, and pay quartiles. The Biogen UK 2019-2020 gender pay gap report states that it has a sixteen percent mean and eight percent median hourly wage gap, and a twenty-eight percent mean and twenty-five percent median bonus pay gap.

Biogen does not report on the gender pay gap for its U.S. employees.

Investors seek quantitative, comparable data to understand the effectiveness of Biogen U.S. pay gap policies.

Regulatory risks associated with pay equity exist. The Paycheck Fairness Act, pending in Congress, would improve company-level transparency and strengthen penalties for equal pay violations. Massachusetts, California, New York and Maryland have enacted significant changes to their equal pay laws.

Companies would be well served by understanding the equity attributes of their pay, at all levels of the corporation, by gender as well as other facets of diversity, such as race and ethnicity. Leading large-cap companies across industry sectors including Apple, Starbucks and Bank of New York Mellon, among others, have publicly committed to pay equity and published the results of gender pay assessments.

### Resolved:

Shareholders request that Biogen publish annually, quantitative data assessing Biogen’s gender pay gap, at reasonable expense and excluding proprietary information. A report adequate for investors to assess company strategy and performance, including relative opportunities for women to attain higher paying positions in the company, would include the percentage mean and median pay gap between all male and female employees, across race and ethnicity where appropriate, and would include base, bonus and equity compensation.



# 8 Stockholder Proposals (continued)

## Company Statement in Opposition

**Our Board of Directors recommends that stockholders vote AGAINST this stockholder proposal for the following reasons:**

We are committed to ensuring that our employees receive equal pay for equal work.

Our Board of Directors and its committees oversee elements of our corporate culture, including human capital management, associated with their respective areas of responsibility. Our Board of Directors recognizes the value of Biogen's colleagues and the need for the Company to build and sustain a culture where colleagues of diverse backgrounds and abilities contribute their unique viewpoints and perspectives to all aspects of the business. Our Board of Directors is also committed to rewarding our employees equitably.

Our pay equity study confirms equitable pay practices.

We establish the components and ranges of compensation based on market and benchmark data. Within this context, we strive to pay all employees equitably within a reasonable range, taking into consideration factors such as role, function, market data, internal equity, job location, relevant experience and individual, business unit and company performance. In addition, we are committed to providing flexible benefits designed to allow our diverse global workforce to have reward opportunities that meet their varied needs so that they are inspired to perform their best on behalf of patients and stockholders each day.

We regularly review our compensation practices and analyze the equity of compensation decisions for individual employees and our workforce as a whole. If we identify employees with pay gaps, we review and take appropriate action to ensure fidelity between our stated philosophy and actions.

To better understand our pay equity performance, in 2020 we had an external consultant complete a global pay equity analysis to help us analyze comparable roles and evaluate whether gender impacted compensation at Biogen. In the U.S., where the law permits the collection of race data, we also included race in the analysis, consistent with our commitment to racial equity.

Overall, 85% of our global workforce was included in at least one analysis. Individuals not included in the analysis were either single-incumbent roles or in homogenous groups (by gender or by race), and therefore did not need to be analyzed.

We analyzed our employees' pay relative to race, gender, geography, responsibilities, level, performance and a wide range of other criteria. The pay equity analysis showed that the compensation of 99.7% of those analyzed was equitable. For the remaining 0.3% (17 employees) we made appropriate adjustments. The robust analysis confirmed that fairness and equity are embedded in our compensation practices around the globe.

We will continue to regularly review our diversity and our compensation philosophy, ensure employees understand our total compensation practices and provide training for managers and leaders to prevent bias during hiring, compensation decisions and performance management.

Summary.

We are confident that our current compensation philosophy, policies and practices regarding pay equity and opportunity parity as well as our recent commitment and our current disclosure practices make this proposal unnecessary.



## 9 Additional Information

### CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS

Our Code of Business Conduct (Values in Action), Corporate Governance Principles, Related Person Transaction Policy and Conflict of Interest Policy set forth our policies and procedures for the review and approval of transactions with related persons, including transactions that would be required to be disclosed in this Proxy Statement in accordance with SEC rules.

In circumstances where one of our directors or executive officers, or a family member, has a direct or indirect material interest in a transaction involving Biogen, our Corporate Governance Committee must review and approve all such proposed transactions or courses of dealing. In determining whether to approve or ratify a transaction with a related person, among the factors our Corporate Governance Committee may consider (as applicable) are:

- the business reasons for entering into the transaction;
- the size of the transaction and the nature of the related person's interest in the transaction;
- whether the transaction terms are as favorable to us as they would be to an unaffiliated third party;
- whether the transaction terms are more favorable to the related person than they would be to an unaffiliated third party;
- the availability of alternative sources for comparable products, services or other benefits;
- whether the transaction would impair the independence or judgment of the related person in the performance of his or her duties to us;
- for non-employee directors, whether the transaction would be consistent with Nasdaq's requirements for independent directors;
- whether the transaction is consistent with our Conflict of Interest Policy, which prohibits related persons and others from having a financial interest in any competitor, customer, vendor or supplier of ours;
- the related person's role in arranging the transaction;
- the potential for the transaction to be viewed as representing or leading to an actual or apparent conflict of interest; and
- any other factors that our Corporate Governance Committee deems appropriate.

Our Code of Business Conduct, which sets forth legal and ethical guidelines for all of our directors and employees, states that directors, executive officers and employees must avoid relationships or activities that might impair their ability to make objective and fair decisions while acting in their Company roles.

Other than as noted below, there are no relationships or transactions with related persons that are required to be disclosed in this Proxy Statement under SEC rules.

Dr. Sandrock has a daughter employed by us in a non-executive position outside of the Research & Development organization who received approximately \$220,000 in total compensation in 2020. Consistent with our Related Person Transaction Policy as described above, our Corporate Governance Committee reviewed this matter.

On January 5, 2021, we entered into an exclusive license agreement (the License Agreement) with Sana. Dr. Mulligan currently serves as the Head of SanaX, the research arm of Sana, and Executive Vice Chairman of Sana. Under the License Agreement, we granted Sana an exclusive sublicense (except as to Biogen) of certain riboswitch-based technology licensed to us by Baylor College of Medicine (the Baylor Technology). We have a non-exclusive license to any improvements made by Sana to the Baylor Technology for use by us in our core and emerging growth areas (the Biogen Field). We have a right of first refusal should Sana decide to seek a collaboration for any program in the Biogen Field. Sana will pay us a royalty in the low single digits on net sales of any products developed under the License Agreement (the Sana Products) and will share half of the patent maintenance costs related to the Baylor Technology. The License Agreement will continue until the later of (a) such time as all of Sana's payment obligations related to all Sana Products expire and (b) the expiration of the royalty terms, as defined in the License Agreement, for all Sana Products. Consistent with our Related Person Transaction Policy as described above, our Corporate Governance Committee reviewed this matter.



# 9 Additional Information (continued)

## EQUITY COMPENSATION PLAN INFORMATION

The following table provides information as of December 31, 2020, about:

- the number of shares of common stock subject to issuance upon vesting of RSUs, MSUs and PSUs under plans adopted and assumed by us (assuming target performance); and
- the number of shares of common stock available for future issuance under our active plans: our 2017 Omnibus Equity Plan, our Non-Employee Directors Equity Plan and our 2015 Employee Stock Purchase Plan.

Plan Category	Number of Securities to be Issued Upon Exercise of Outstanding Options and Rights (a)	Weighted-average Exercise Price of Outstanding Options and Rights (b)	Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in column(a)) <sup>(1)</sup> (c)
Equity compensation plans approved by stockholders	1,492,565	—	18,100,439
Equity compensation plans not approved by stockholders	—	—	—
<b>Total</b>	<b>1,492,565</b>	<b>—</b>	<b>18,100,439</b>

(1) Of these shares, (a) 12,116,477 remain available for future issuance under our 2017 Omnibus Equity Plan, (b) 665,955 remain available for future issuance under our Non-Employee Directors Equity Plan and (c) 5,318,007 remain available under our 2015 Employee Stock Purchase Plan. In addition to shares issuable upon the exercise of options or rights, the shares under our 2017 Omnibus Equity Plan and our Non-Employee Directors Equity Plan may also be issued other than upon such exercise.



# 9 Additional Information (continued)

## MISCELLANEOUS

### Stockholder Proposals

Stockholder proposals submitted pursuant to Exchange Act Rule 14a-8 and intended to be presented at our 2022 annual meeting of stockholders must be received by our Secretary no later than December 24, 2021, to be eligible for inclusion in our proxy statement and form of proxy relating to that meeting.

A stockholder proposal submitted outside the processes of Rule 14a-8 and not for inclusion in our proxy statement for the 2022 annual meeting of stockholders will be ineligible for presentation at the meeting unless the stockholder gives timely notice of the proposal in writing to our Secretary at our principal executive offices and otherwise complies with the provisions of our Bylaws. To be timely, our Bylaws provide that we must have received the stockholder's notice no later than March 4, 2022, and no earlier than February 2, 2022. However, if the date of the 2022 annual meeting of stockholders is more than 30 days before or more than 60 days after the first anniversary of the Annual Meeting, we must receive the stockholder's notice not earlier than the close of business on the 120<sup>th</sup> day before the 2022 annual meeting of stockholders and not later than the close of business on the later of (1) the 90<sup>th</sup> day before the 2022 annual meeting of stockholders and (2) the 10<sup>th</sup> day following the day on which public announcement of the date of the 2022 annual meeting of stockholders is first made.

All stockholder proposals for our 2022 annual meeting of stockholders should be sent to our Secretary, Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142.

### Other Stockholder Communications

Generally, stockholders who have questions or concerns should contact our Investor Relations department at (781) 464-2442. However, stockholders who wish to communicate directly with our Board of Directors, or any individual director, should direct questions in writing to our Secretary, Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142. Communications addressed in this manner will be forwarded directly to our Board of Directors or named individual director(s).

### Incorporation by Reference

Notwithstanding anything to the contrary set forth in any of our previous filings under the securities laws that might incorporate future filings, including this Proxy Statement, in whole or in part, the Compensation Committee Report, the Audit Committee Report, the content of [www.biogen.com](http://www.biogen.com), including the charters of the committees of our Board of Directors, Corporate Governance Principles, Related Person Transaction Policy, Conflicts of Interest Policy, Code of Business Conduct, Certificate of Incorporation and Bylaws, included or referenced in this Proxy Statement shall not be incorporated by reference into any such filings.

### Copies of Annual Meeting Materials

Some banks, brokers and other nominee record holders may be participating in the practice of householding proxy statements and annual reports. This means that, unless you have instructed otherwise, only one copy of this Proxy Statement, Annual Report or Notice of Internet Availability of Proxy Materials, as applicable, may have been sent to multiple stockholders in your household. **We will promptly deliver a separate copy of any of these documents without charge to you if you write or call Investor Relations, Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142, (781) 464-2442.** If you want to receive separate copies of our proxy statement, annual report or Notice of Internet Availability of Proxy Materials, as applicable, in the future, or if you are receiving multiple copies and would like to receive only one copy for your household, you should contact your bank, broker or other nominee record holder, or you may contact us at the above address or phone number.

### Manner and Cost of Proxy Solicitation

Biogen pays the cost of soliciting proxies. In addition to solicitation by mail, our directors, officers and employees may contact you in person, by telephone or by email or other electronic means. None of our directors, officers or employees will receive additional compensation for soliciting you. We will reimburse brokerage houses, banks, custodians and other nominees and fiduciaries for out-of-pocket expenses incurred in forwarding our proxy solicitation materials to, and obtaining instructions relating to such materials from, beneficial owners of our common stock. Georgeson LLC, New York, New York, has been retained to assist us in the solicitation of proxies at a fee estimated not to exceed \$12,650.



# APPENDIX A

## GAAP to Non-GAAP Reconciliation

### Diluted Earnings Per Share and Net Income Attributable to Biogen Inc. (unaudited, \$ in millions, except per share amounts)

	For the Twelve Months Ended	
	December 31, 2020	December 31, 2019
GAAP earnings per share – Diluted	\$24.80	\$31.42
Adjustments to GAAP net income attributable to Biogen Inc. (as detailed below)	8.90	2.15
Non-GAAP earnings per share – Diluted	\$33.70	\$33.57

	For the Twelve Months Ended	
	December 31, 2020*	December 31, 2019
GAAP net income attributable to Biogen Inc.	\$4,000.6	\$5,888.5
Adjustments:		
Acquisition and divestiture related costs:		
Amortization of acquired intangible assets <sup>A</sup>	464.8	489.9
Acquired in-process research and development	75.0	—
(Gain) loss on fair value remeasurement of contingent consideration <sup>A</sup>	(86.3)	(63.7)
Loss on divestiture of Hillerød, Denmark manufacturing operations <sup>B</sup>	(92.5)	55.3
Net distribution to noncontrolling interests	0.3	—
Stock option expense	—	26.2
Acquisition-related transaction and integration costs	19.5	27.9
Accelerated share-based compensation expense	—	6.7
Subtotal: Acquisition and divestiture related costs	380.8	542.3
Restructuring, business transformation and other cost saving initiatives:		
2017 corporate strategy implementation	—	3.5
Restructuring charges	—	1.5
Other cost saving initiatives	2.8	—
Subtotal: Restructuring, business transformation and other cost saving initiatives	2.8	5.0
(Gain) loss on equity security investments	(693.9)	(200.2)
Sangamo upfront payment and premium paid on the purchase of Sangamo common stock <sup>C</sup>	208.2	—
Denali upfront payment and premium paid on the purchase of Denali common stock <sup>D</sup>	601.3	—
Sage upfront payment and premium paid on the purchase of Sage common stock <sup>E</sup>	1,084.0	—
Premium paid on early debt redemption	9.4	—
Valuation allowance associated with deferred tax assets <sup>F</sup>	90.3	—
Income tax effect related to reconciling items	(287.9)	31.3
Swiss tax reform <sup>G</sup>	—	(54.3)
Amortization included in Equity in loss of investee, net of tax	40.0	78.2
Non-GAAP net income attributable to Biogen Inc.	\$5,435.6	\$6,290.8

\* Beginning in the third quarter of 2020 material upfront payments associated with significant collaboration and licensing arrangements are excluded from Non-GAAP R&D expense in order to better reflect the Company's core operating performance. Full year Non-GAAP results reflect this change as the \$125.0 million upfront payment related to the collaboration with Sangamo Therapeutics, Inc. in the second quarter of 2020 has been excluded from Non-GAAP R&D expense.

## Appendix A (continued)

## Free Cash Flow Reconciliation

(unaudited, \$ in millions)

	For the Twelve Months Ended December 31, 2020
Net cash provided by operating activities	\$ 4,229.8
Net cash used in investing activities	(608.6)
Net cash used in financing activities	(5,272.7)
Net increase (decrease) in cash and cash equivalents	\$ (1,651.5)
Net cash provided by operating activities	\$ 4,229.8
Purchases of property, plant and equipment (Capital Expenditures)	(424.8)
Free Cash Flow <sup>^</sup>	\$ 3,805.0

<sup>^</sup> Free cash flow is defined as net cash flow from operations less capital expenditures.

A Amortization and impairment of acquired intangible assets for the twelve months ended December 31, 2020, reflects the impact of the impairment charges related to timrepigene emparvovec (BIIB111), which was obtained as part of the Nightstar Therapeutics plc acquisition, and cinpanemab (BIIB054) as well as a \$19.3 million impairment charge related to one of our in-process research and development (IPR&D) intangible assets. During the fourth quarter of 2020 we experienced third-party manufacturing delays for BIIB111 and determined that forecasted costs associated with advancing the program through development and commercialization will exceed our original estimates. We reassessed the fair value of the program based on these changes in assumptions and determined that the program was partially impaired. We recognized an impairment charge of approximately \$115.0 million during the fourth quarter of 2020.

In February 2021 we announced that we discontinued development of BIIB054 in Parkinson's disease as our Phase 2 SPARK study did not meet its primary or secondary endpoints. Although we made this determination in February 2021, it was based on conditions that existed as of December 31, 2020. As a result, we recognized an impairment charge of approximately \$75.4 million during the fourth quarter of 2020 to reduce the fair value of the related IPR&D intangible asset to zero. We also adjusted the value of our contingent consideration obligation related to BIIB054 resulting in a gain of \$51.0 million in the fourth quarter of 2020.

Amortization and impairment of acquired intangible assets for the twelve months ended December 31, 2019, reflects the impact of a \$215.9 million impairment charge related to certain IPR&D assets associated with the Phase 2b study of BG00011 (STX-100) for the potential treatment of idiopathic pulmonary fibrosis, which was discontinued during the third quarter of 2019. We also adjusted the value of our contingent consideration obligations related to BG00011 resulting in a gain of \$61.2 million in the third quarter.

B In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hillerød, Denmark to FUJIFILM Corporation. Upon the closing of this transaction, we received approximately \$881.9 million in cash, which may be adjusted based on other contractual terms, which are discussed below.

In connection with this transaction we recognized a total net loss of approximately \$164.4 million in our consolidated statements of income. This loss included a pre-tax loss of \$95.5 million, which was recorded in loss on divestiture of Hillerød, Denmark manufacturing operations. The loss recognized was based on exchange rates and business conditions on the closing date of this transaction, and included costs to sell our Hillerød, Denmark manufacturing operations of approximately \$11.2 million and our estimate of the fair value of an adverse commitment of approximately \$114.0 million associated with the guarantee of future minimum batch production at the Hillerød facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. We also recorded a tax expense of \$68.9 million related to this transaction. During the fourth quarter of 2019 we recorded a \$40.2 million reduction in our estimate of the future minimum batch commitment utilizing our current manufacturing forecast, which reflects the impact of forecasted batches of aducanumab, an investigational treatment for Alzheimer's disease, resulting in a reduction in the pre-tax loss on divestiture from \$95.5 million to \$55.3 million.

During the fourth quarter of 2020 we reduced our estimate of the fair value of the adverse commitment by approximately \$62.0 million based on our current manufacturing forecasts. Additionally, we recorded a reduction to our pre-tax loss of approximately \$30.5 million due to a refund of interest paid associated with a tax matter. As of December 31, 2020, the cumulative loss on the divestiture of the Hillerød, Denmark manufacturing operations was \$33.2 million.

In addition, we may earn certain contingent payments based on future manufacturing activities at the Hillerød facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. Consistent with our assessment as of the transaction date, we currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.

## Appendix A (continued)

- C In February 2020 we entered into a collaboration and license agreement with Sangamo Therapeutics, Inc. (Sangamo) to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson's disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. In connection with the closing of this transaction in April 2020 we purchased \$225.0 million of Sangamo common stock, or approximately 24 million shares at \$9.21 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of approximately \$83.2 million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of \$125.0 million that was recorded as research and development expense.
- D In August 2020 we entered into a collaboration and license agreement with Denali Therapeutics Inc. (Denali) to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich kinase 2 (LRRK2) for Parkinson's disease. As part of this collaboration, we purchased approximately \$465.0 million of Denali common stock in September 2020, or approximately 13 million shares at \$34.94 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately \$41.3 million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of \$560.0 million that was recorded as research and development expense.
- E In November 2020 we entered into a global collaboration and license agreement with Sage Therapeutics, Inc. (Sage) to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder, postpartum depression and other psychiatric disorders and BIIB124 (SAGE-324) for the potential treatment of essential tremor and other neurological disorders. In connection of the closing of this transaction in December 2020 we purchased \$650.0 million of Sage common stock, or approximately 6.2 million shares at \$104.14 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our consolidated balance sheets to reflect the initial fair value of the Sage common stock acquired and a charge of approximately \$209.0 million to research and development expense in our consolidated statements of income to reflect the premium paid for the Sage common stock. We also made an upfront payment of \$875.0 million that was recorded as research and development expense.
- F Income tax expense for the twelve months ended December 31, 2020, included \$90.3 million in income tax expense related to a net valuation allowance against certain deferred tax assets, due to the decisions of the U.S. District Court of the Northern District of West Virginia and the U.S. District Court of the District of Delaware that the asserted claims of our U.S. patent No. 8,399,514, which cover the treatment of multiple sclerosis with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label, are invalid.
- G During the third quarter of 2019 a new taxing regime in the country and certain cantons of Switzerland was enacted, which we refer to as Swiss Tax Reform. As a result of the impact of Swiss Tax Reform, we recorded an income tax benefit of approximately \$54.3 million resulting from a remeasurement of our deferred tax assets and liabilities in the twelve months ended December 31, 2019.

## Use of Non-GAAP Financial Measures

We supplement our GAAP consolidated financial statements and GAAP financial measures with other financial measures, such as adjusted net income, adjusted diluted earnings per share and free cash flow, which is defined as net cash flow from operations less capital expenditure. We believe that these and other Non-GAAP financial measures provide additional insight into the ongoing economics of our business and reflect how we manage our business internally, set operational goals and form the basis of our management incentive programs. Non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

Our "Non-GAAP net income attributable to Biogen Inc." and "Non-GAAP earnings per share – Diluted" financial measures exclude the following items from "GAAP net income attributable to Biogen Inc." and "GAAP earnings per share – Diluted":

1. *Acquisitions, divestitures and significant collaboration and licensing arrangements*

We exclude transaction, integration and certain other costs related to the acquisition and divestiture of businesses, the acquisitions of assets, significant collaboration and licensing arrangements and items associated with the initial consolidation or deconsolidation of variable interest entities. These adjustments include, but are not limited to, upfront payments in significant collaborations and licensing arrangements, charges for in-process research and development and certain milestones, the amortization and impairment of intangible assets, charges or credits from the fair value remeasurement of our contingent consideration obligations and losses on assets and liabilities held for sale.



**Appendix A** (continued)**2. Restructuring, business transformation and other cost saving initiatives**

We exclude costs associated with our execution of certain strategies and initiatives to streamline operations, achieve targeted cost reductions, rationalize manufacturing facilities or refocus research and development activities. These costs may include employee separation costs, retention bonuses, facility closing and exit costs, asset impairment charges or additional depreciation when the expected useful life of certain assets have been shortened due to changes in anticipated usage and other costs or credits that management believes do not have a direct correlation to our ongoing or future business operations.

**3. (Gain) loss on equity security investments**

We exclude unrealized and realized gains and losses and discounts or premiums on our equity security investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.

**4. Other items**

We evaluate other items of income and expense on an individual basis and consider both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to our ongoing business operations and (iii) whether or not we expect it to occur as part of our normal business on a regular basis. We also include an adjustment to reflect the related tax effect of all reconciling items within our reconciliation of our GAAP to Non-GAAP net income attributable to Biogen Inc. and earnings per share – diluted.



# APPENDIX B

## Certificate of Amendment of Amended and Restated Certificate of Incorporation, as amended

**CERTIFICATE OF AMENDMENT  
TO THE  
CERTIFICATE OF INCORPORATION  
OF  
BIOGEN INC.**

Pursuant to Section 242 of the General  
Corporation Law of the State of Delaware

Biogen Inc. (hereinafter referred to as the “Corporation”), a corporation duly organized and existing under the Delaware General Corporation Law (the “DGCL”), does hereby certify as follows:

**FIRST:** That at a meeting of the Board of Directors of the Corporation on April 7, 2021, resolutions were duly adopted setting forth a proposed amendment to Article XII of the Certificate of Incorporation of said corporation, declaring said amendment to be advisable and directing that the proposed amendment be considered at the next annual meeting of the stockholders. As amended pursuant to such resolutions, Article XII of the Certificate of Incorporation shall be as follows:

*ARTICLE XII*

(a) Exclusive Forum. Unless the Board of Directors or one of its committees otherwise consents to the selection of an alternate forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action brought on behalf of the Corporation and (ii) any direct action brought by a stockholder against the Corporation or any of its directors or officers alleging a violation of the Delaware General Corporation Law, the corporation’s certificate of incorporation or bylaws or breach of fiduciary duties or other violation of Delaware decisional law relating to the internal affairs of the corporation; in each case excluding actions in which the Court of Chancery of the State of Delaware concludes that an indispensable party is not subject to the jurisdiction of the Delaware courts and can be subject to the jurisdiction of another court within the United States.

(b) Federal Forum. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Any person or entity purchasing or otherwise acquiring any interest in any security of the Corporation shall be deemed to have notice of and consented to this provision.

**SECOND:** The foregoing amendment was duly adopted in accordance with Section 242 of the DGCL.

**THIRD:** The effective date of the amendment shall be June , 2021.

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be duly executed in its name this day of June, 2021.

BIOGEN INC.

By: \_\_\_\_\_  
Name:  
Title:







BIOGEN INC.  
225 BINNEY STREET  
CAMBRIDGE, MA 02142

**VOTE BY INTERNET**

*Before The Meeting* - Go to [www.proxyvote.com](http://www.proxyvote.com)

Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.

*During The Meeting* - Go to [www.virtualshareholdermeeting.com/BIIB2021](http://www.virtualshareholdermeeting.com/BIIB2021)

You may attend the Meeting via the Internet and vote during the Meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions.

**VOTE BY PHONE - 1-800-690-6903**

Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the day before the meeting date. Have your proxy card in hand when you call and then follow the instructions.

**VOTE BY MAIL**

Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:

D48340-P53535

KEEP THIS PORTION FOR YOUR RECORDS  
DETACH AND RETURN THIS PORTION ONLY

**THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.**

**BIOGEN INC.**

**The Board recommends a vote FOR the following proposals:**

1. Election of Directors. To elect the thirteen director nominees numbered 1a through 1m to serve for a one-year term extending until the 2022 annual meeting of stockholders and their successors are duly elected and qualified.

	For	Against	Abstain
1a. Alexander J. Denner	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1b. Caroline D. Dorsa	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1c. Maria C. Freire	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1d. William A. Hawkins	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1e. William D. Jones	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1f. Nancy L. Learning	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1g. Jesus B. Mantas	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1h. Richard C. Mulligan	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1i. Stelios Papadopoulos	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1j. Brian S. Posner	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1k. Eric K. Rowinsky	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

	For	Against	Abstain
1l. Stephen A. Sherwin	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1m. Michel Vounatsos	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2021.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Say on Pay - To approve an advisory vote on executive compensation.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. To approve an amendment to Biogen's Amended and Restated Certificate of Incorporation, as amended, to add a federal forum selection provision.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**The Board recommends a vote AGAINST the following proposals:**

	For	Against	Abstain
5. Stockholder proposal requesting a report on Biogen's lobbying activities.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Stockholder proposal requesting a report on Biogen's gender pay gap.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer.

Signature [PLEASE SIGN WITHIN BOX]	Date

Signature (Joint Owners)	Date

**Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:**

The 2021 Notice and Proxy Statement and 2020 Annual Report with Form 10-K are available at: [www.proxyvote.com](http://www.proxyvote.com).

D48341-P53535

**BIOGEN INC.  
Annual Meeting of Stockholders  
June 2, 2021, 9:00 a.m. Eastern Time  
This proxy is solicited by the Board of Directors**

The undersigned hereby appoints Michel Vounatsos, Michael R. McDonnell and Susan H. Alexander, and each of them (with full power to act alone), as proxies of the undersigned with all the powers the undersigned would possess if present during the 2021 Annual Meeting, and with full power of substitution in each of them to appear, represent and vote all shares of common stock of Biogen Inc. which the undersigned would be entitled to vote at the 2021 Annual Meeting of Stockholders, to be held online at [www.virtualshareholdermeeting.com/BIIB2021](http://www.virtualshareholdermeeting.com/BIIB2021) on Wednesday, June 2, 2021, at 9:00 a.m. Eastern Time, and at any adjournment or postponement thereof.

**The shares represented by this proxy will be voted as directed herein. If no direction is indicated, such shares will be voted FOR the election of all of the director nominees listed in Proposal 1, FOR Proposals 2, 3 and 4 and AGAINST Proposals 5 and 6. As to any other matter that may be properly brought before the meeting or any adjournment or postponement thereof, proxy holders will vote in accordance with their best judgment.**

Continued and to be signed on reverse side